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Abstract 
Ganoderma spp. is regarded as a supreme Chinese traditional medicine and 
commonly called lingzhi. Water extract of G. tsugae mycelia was found here to show 
potential protective effects from the adverse effects of a persistent organopollutant, 
p,p '-DDE. Water extract of G. tsugae mycelia had relatively higher contents of 
bioactive terpenes and polysaccharides when compared with 12 commercial lingzhi 
spore products. The terpene fraction of G. tsugae extract competed with E2 in 
binding estrogen receptors ERa and ERp in vitro. Besides, water extract activated 
androgen receptor element (ARE)-promoter in the transgenic yeast. Breast cancer 
cell line MCF-7 expressing ERa, ERp and androgen receptor (AR) was used as an 
endocrine model system in this study. Water extract at low doses (< 0.5 mg/ml) 
stimulated MCF-7 proliferation but induced apoptosis in high concentrations (1 
mg/ml) in estrogen-depleted medium (CD-MEM). Also, it showed abilities to 
up-regulate ARE- and estrogen receptor element (ERE)-genes of the ER and AR 
pathways in MCF-7 in CD-MEM as determined by real-time PCR. 
High concentrations of p’p '-DDE have been reported throughout the world especially 
Asia owing to the historical use of pesticide DDT and current use of pesticide dicofol. 
This organopollutant showed weak affinity to ERa ( E C 5 0 is 4.1x10"^ M) but high 
affinity to ERp ( E C 5 0 is 4.4x10"^ M) in vitro as with the G tsugae terpenes. At cell 
level, p,p '-DDE stimulated MCF-7 proliferation and had synergistic effect with 
17[3-estradiol (E2), the natural female hormone, in CD-MEM but reversed the 
inhibition of dihytrotestosterone (DHT), the natural male hormone, in estrogen-rich 
medium (RPMI 1640)，exemplifying as a xenoestrogen and an anti-androgen. 
Applying DNA microarray to study the human signal transduction pathways in 
MCF-7 cancer cells, the expression profile of p’p '-DDE treated sample was different 
from those treated with E2 or DHT. Several pathways namely: TGF(3, stress / p38 & 
JNK, hypoxia, DNA damage / p53 and Wnt pathways might be affected by p’p '-DDE, 
ii 
indicating its multiple potential action sites. Also, p，p，-DDE increased the expression 
of ER-regulated genes in MCF-7 in CD-MEM as with E2 but to lesser extent. By 
single cell gel electrophoresis, the physiological dose (10 |iM) of p,p '-DDE caused 
DNA damage without increasing apoptosis. This might lead to increasing risk of 
breast cancer. 
At cell level, water extract of G tsugae mycelia at doses lower than 1 mg/ml 
suppressed the proliferation of MCF-7 induced by p’p，-DDE or E2 in CD-MEM. In 
microarray study, this extract had opposite regulative effects on almost half of the 
tested highly expressed genes of the signal transduction pathways regulated by 
p,p '-DDE. These genes included those relative to hormone actions, tumorigenesis 
and DNA damage. G tsugae extract reduced the effects of p，p -DDE on ER- and 
AR-regulated genes in CD-MEM. Also, 0.5 mg/ml of G tsugae extract decreased 
DNA damage caused by p，p '-DDE. 
In summary, both water extract of G. tsugae mycelia and p，p，-DDE had effects on 
cell proliferation, DNA damage and cell death of MCF-7. Hormone-related genes 
and several signal transduction pathways were also affected by both of them. G. 
tsugae extract showed the abilities to reduce those adverse effects of xenobiotic 
p’p -DDE, demonstrating the potential of G. tsugae as a valuable functional food that 
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Chapter 1 Introduction 
1 Introduction 
LI Ganoderma spp. 
1.1.1 Introduction of Ganoderma spp. 
The genus Ganoderma was established by a Finnish botanist, P. Karsten, in 1881 
(Ryvarden 1991). More than 120 species have been reported in the world since then, 
and the majority was found in China (Mao and Lin, 2001). Classification of 
Ganoderma is shown in Table 1.1 (Chang and Miles, 2004). 
Table 1.1 Classification of Ganoderma (Chang and Miles, 2004). 







Zhi was cited in the Shen Nong's Herbal Classic (widely considered as the oldest 
book on Chinese herbal medicine and the foundation of traditional Chinese medicine) 
for enhancing 'vital energy' and promoting 'longevity', and this 'mushroom of 
longevity' has been deemed as the most exalted medicine in ancient China. For a 
long time it has been prescribed for the treatment of chronic hepatopathy, 
hypertension, bronchitis, arthritis, neurasthenia, neoplasm, and tumorigenic diseases 
in China and other countries of Asia (Arisawa et al. 1986; Shiao et al.，1994; Mizuno, 
1996). Some zhi species were interpreted as belonging to the Ganoderma lucidum 
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species complex; Red zhi is G. lucidum or G. tsugae, purple zhi is G. sinensis while 
yellow zhi may be young fruiting bodies of G. tsugae. Recent researches focused on 
the mechanisms of the medicinal effects of Ganoderma spp., such as anti-viral 
(Mothana et al., 2003; El Dine et al.，2008), anti-bacterial (Moradali et al.，2006), 
anti-inflammatory (Kendrick, 1985; Lin et al., 2006), anti-hepatoxic (Shieh et al. 
2001), anti-mutagenic (Lakshmi et al., 2006), neuro-modulatory (Cheung et al., 2000; 
Zhang et al., 2006a; Chen et al., 2007b), cardiac protection (Lasukova et al., 2008), 
anti-tumor, anti-oxidative and immuno-modulatory activities (Chen et al., 2006). 
Different extracts and components from Ganoderma spp. were studied for their 
bioactivities. Two major categories of bioactive components in Ganoderma spp. are 
polysaccharides and terpenes (Paterson, 2006). Polysaccharides are polymers made 
up of monosaccharides joined together by glycosidic bonds, representing a 
structurally diverse class of biological macromolecules with a wide-range of 
physicochemical properties. The major bioactive Ganoderma polysaccharides 
species is branched P-1-3 and (3-1-6-D glucan. The structure is (3-1-3 D-glucopyronan 
with 1-15 units of |3-l-6 monoglucosyl side chains (Paterson, 2006). Terpenes are 
derived structurally from units of isoprene linked together "head to tail" to form 
linear chains or they may be arranged in rings. They are comprised of four groups: 
the (a) volatile mono- and sesquiterpenes (essential oils) (CIO and CI5), (b) less 
volatile diterpenes (C20), (c) involatile triterpenoids and sterols (C30), and (d) the 
carotenoid pigments (C40). Most investigations on Ganoderma concern triterpenoids 
(triterpenes) (Zhou et al., 2006a). Triterpenes structurally are highly oxidized 
lanostanes. Numerous triterpenes have been isolated from G. lucidum (Chen and Yu, 
1990; Kim and Kim, 1999; Luo and Lin, 2002). Some triterpenes were also detected 
in G. tsugae, G. concinna and G. pfeiffer (Su et al., 2000; Gonzalez et al., 2002; 
Mothana et al., 2003). Besides, bioactivities and action mechanisms of crude extracts 
other than pure components also draw lots of attention. The combination of natural 
ingredients to achieve synergistic benefits is one of the basic theories of Traditional 
Chinese Medicine (TCM), called formulae, a unique medical system assisting the 
2 
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ancient Chinese in dealing with diseases (Wang et al., 2008a). Increasing evidence 
demonstrates that, in treating illnesses, including cancer (Chabner and Roberts, 2005) 
and HIV/AIDS (Perelson et al., 1997), treatment regimens containing multiple drugs 
with distinct but related mechanisms can usually amplify the therapeutic efficacies of 
each agent, leading to maximal therapeutic efficacy with minimal adverse effects. It 
is believed that, multiple components could hit multiple targets and exert synergistic 
therapeutic efficacies. However the complexity of TCM makes it difficult to identify 
the essential compounds and explain the precise mechanisms (Wang et al., 2008a). 
Thus studies on crude extracts and pure components give essential evidences to 
reveal the multiple functions of Ganoderma spp. 
1.1.2 Bioactivities of Ganoderma spp. 
The effects of Ganoderma spp. on tumors were widely investigated. Different 
extracts or components from Ganoderma spp. have been shown to suppress tumors 
in vivo. Oral administration of the broken spore preparations, spore germlings 
preparation and spore oils of G. lucidum significantly inhibited the growth of mouse 
sarcoma S-180 cell in vivo (Liu et al., 2002b). Injection of the extracellular 
biopolymer produced by G. applanatum mycelia inhibited the growth of solid tumor 
induced by Sarcoma-180 tumor cells (Jeong et al., 2008). Similar results were shown 
with semi-purified water-soluble and extracellular polysaccharides produced by G. 
tsugae mycelia (Peng et al., 2003，2005). Celiac injection of ganoderic acid T from G. 
lucidum mycelia dramatically suppressed the growth of human solid tumor induced 
by highly metastatic lung cancer cell line, 95-D, in athymic mice (Tang et al., 2006). 
In vitro studies revealed the multiple anti-cancer effects of extracts and bioactive 
components of Ganoderma spp, including inhibition of proliferation, induction of 
cell cycle arrest and apoptosis, enhancement of oxidative stress and DNA damage, 
suppression of telomerase activity and increase in differentiation. Crude water extract, 
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alcohol extract, polysaccharides or triterpenes from basidiomes (basidiocarps, 
fruitbodies, fruiting bodies), mycelia or spore of Ganoderma spp. could inhibit 
growth and trigger apoptosis of different cancer cells, including leukemia cells, 
urothelial cancer cells, hepatoma carcinoma cells, stomach cancer cell, lung cancer 
cells and breast cancer cells (Hu et a l , 2002; Lin et al.，2003; Miiller et al., 2006; 
Kim et al., 2007; Hsu, et al., 2008; Yuen et al., 2008). Ganoderma spp. extracts were 
proved to inhibit proliferation and induce G2/M or GO/Gl cell cycle arrest of several 
cancer cells (Hu et a l , 2002; Lu, et a l , 2004; Jiang et al., 2004a, 2004b & 2006; 
Miiller et al., 2006). Upstream events were reduction of Erk expression, 
up-regulation of p21/Wafl and down-regulation of cyclin Dl , cyclin B and Cdc2. 
Ganoderma spp. extracts also promoted apoptosis in these cancer cells with Bcl-2 
down-regulation, Bax translocation, mitochondrial cytochrome c release and 
caspase-3 activation, while no cytotoxic effect was observed in normal peripheral 
blood mononuclear cells (Hu et al., 2002; Lu, et al., 2004; Jiang et al” 2004a, 2004b 
& 2006; Xie et a l , 2006; Kim et al., 2007). Bcl-2, Bcl-xl and Bax expression might 
be regulated by Akt/NF-kB signaling in the treatment of Ganoderma spp. extracts 
(Jiang et al., 2004a, 2004b & 2006). Polysaccharides isolated from G. lucidum 
exhibited greater inhibitory effect than crude extracts on cell proliferation, while the 
expression of Erk was reduced in the presence of G. lucidum polysaccharide (Xie et 
al., 2006). Triterpene-enriched fraction from G. lucidum also induced prolonged 
G2/M cell cycle phase and strong growth inhibition on human hepatoma Huh-7 cells 
with a rapid decrease in the activity of cell growth regulative protein, PKC, and the 
activation of JNK and p38 MAP kinases (Lin et al., 2003). Lucidenic acids and 
ganoderic acids isolated from G. lucidum caused similar effects on HL-60 (Hsu et al., 
2008; Jiang et al., 2008). Ganoderic acid X from the same species inhibited the 
activities of topoisomerases I and Ila, inhibited DNA synthesis, activated ERK and 
JNK mitogen-activated protein kinases, and induced cell apoptosis on HuH-7 cells in 
vitro (Li et al., 2005). Ganoderiol F, a triterpene from G. amboinense, induced 
growth arrest on HepG2, but exerted less effect on hepatoma Hep3B cells and 
normal lung fibroblast MRC5 cells, and no effect on peripheral blood mononuclear 
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cells (Chang et al” 2006). Lewis lung carcinoma, LLC, was also inhibited by 
triterpenes from G. lucidum (Min et al., 2000; Gao et al., 2002). Highly metastatic 
lung cancer cell line, 95-D, showed a reduction of mitochondrial membrane potential 
(A\(/m) and release of cytochrome c, stimulation of the caspase-3 activity involved in 
apoptosis, increase of protein p53, decrease of ratio of Bcl-2/Bax with Bax 
up-regulation but less change of expression of Bcl-2 with arrestment in Gl/GO phase 
by ganoderic acid T of G. lucidum mycelia (Tang et al., 2006). The combination of a 
chemotherapeutic agent, doxorubicin (DOX), with triterpenes from G. lucidum 
resulted in a synergistic cytotoxicity on HeLa cells through enhanced oxidative stress, 
DNA damage and apoptosis (Yue et a l , 2008). A proteomic study indicated that 
triterpenes from G. lucidum regulated expression of 14 proteins, which play 
important roles in cell proliferation, cell cycle, apoptosis, and oxidative stress (Yue et 
al., 2008). Besides, extracts separated from the culture broth of G. lucidum mycelia 
increased the differentiation ratio of HL-60 cells up to 58% after four days of 
cultivation, compared to 18% in the case of no sample supplementation (Chung et al., 
2001). At the same time, telomerase activity, whose activation is a critical step in 
cellular immortalization and oncogenesis, was inhibited in this bladder cancer cell 
model by extracts from fruiting bodies and spores (Yuen et al., 2008). Liao et al. 
(2006) also found the immunomodulatory protein, FlP-gts, of G. tsugae suppressed 
telomerase activity due to the down-regulation of the telomerase catalytic subunit via 
c-myc-responsive element-dependent and nuclear export mechanisms which might 
be mediated by intracellular calcium release induced by endoplasmic reticulum stress 
in A549 human lung adenocarcinoma cells (Liao et al., 2006 & 2007). 
Metastasis is the spread of a cancer from one organ to another non-adjacent organ. 
Malignant tumor cells can "break away", "leak", or "spill" from a primary tumor, 
enter lymphatic and blood vessels, circulate through the bloodstream, and settle 
down to grow within normal tissues elsewhere in the body. G, lucidum was proved to 
inhibit metastasis in vitro in different cancer cell models. Two pathways have been 
discussed. One was proved in malignant breast cancer cell MDA-MB-231 and 
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prostate cancer cell PC3 (Sliva et al.，2002 & 2003). Water extracts from G. lucidum 
spore and fruiting body powder suppressed constitutive expression of active 
transcription factors AP-1 and NF-KB, which inhibited downstream expression of 
urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) (Sliva et al., 
2002 & 2003). Since uPA stimulated cell migration through interaction with uPAR, 
suppression of their expression drastically reduced tumor invasiveness (Andreasen et 
al., 1997). Breast and prostate carcinoma cell adhesion and integrin expression were 
greatly reduced by different preparations of G. lucidum spores (Sliva et al., 2002 & 
2003; Wu et al., 2006). Yet the polysaccharide preparation exerted the most effects 
(Wu et al., 2006). Ganoderic acid A and H of G. lucidum also suppressed cell 
proliferation, colony formation, adhesion, migration and invasion of MDA-MB-231 
as with water extract (Jiang et al., 2008). These activities of ganoderic acids are 
linked to the hydroxylation in the position 7 and 15 (ganoderic acid A) and 3 
(ganoderic acid H) in their triterpene lanostane structures (Jiang et al., 2008). The 
other pathway was reported on premalignant human urothelial cell HUC-PC. Both 
ethanol and water extracts from fruiting body and spore of G. lucidum induced actin 
polymerization, which in turn inhibited carcinogen 4-aminobiphenyl induced 
migration (Yuen et al., 2008). 
Angiogenesis，the formation of blood vessels by capillaries sprouting from 
pre-existing vessels, is important for normal physiological processes such as 
embryogenesis, growth, and wound healing, as well as pathological processes such 
as tumor growth and metastasis. One of the potential therapeutic strategies for the 
treatment of cancer is the inhibition of angiogenesis (Chan 2009). Alcohol extracts 
from fruiting body of G. lucidum showed anti-angiogenic effects in different models 
(Song et al., 2004). Water extract of G. lucidum inhibited capillary morphogenesis of 
the human aortic endothelial cells (Stanley et al., 2005). Polysaccharides peptide 
from G. lucidum inhibited the growth of vascular endothelial cells too (Cao and Lin, 
2006). Angiogenesis is a complex multistep process involving close orchestration of 
endothelial cells, extracellular matrix, and angiogenic factors (Chan 2009). Cancer 
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cells produce angiogenic factors such as vascular endothelial growth factor (VEGF) 
and transforming growth factor-pi (TGF-pl) (Khosravi et al.，2009). Expression of 
VEGF and TGF-pi is controlled by two distinct families of transcriptions factors 
AP-1 and N F - K B (Stanley et al., 2 0 0 5 ) . Water extract from G. lucidum inhibited 
phosphorylation of Erkl/2, Akt kinase and constitutively active AP-1 and N F - K B 
(Sliva et al., 2002 & 2003; Stanley et al., 2005; Jiang et a l , 2008). Consequently 
secretion of VEGF and TGF-pl was reduced and finally growth of vascular 
endothelial cells was inhibited (Song et a l , 2004; Stanley et al., 2005; Cao and Lin, 
2006). 
Beside the direct phenomena of uncontrolled cell proliferation, angiogensis and 
metastasis in cancer, multidrug resistance (MDR), a major cause of cancer treatment 
failure, is a phenomenon whereby cancer cells develop resistance to a wide variety of 
chemotherapeutic drugs (Perez-Tomas, 2006; O'Connor, 2007). MDR has been 
associated with the overexpression of 2 transmembrane transporters, namely: 
P-glycoprotein (P-gp) and MDR-associated protein (MRP), which act as pumps to 
remove toxic drugs from tumor cells (O'Connor, 2007). Polysaccharides from 
fruiting body of G. lucidum reversed MDR in K562/ADM cells to doxorubicin while 
MDR-1 and MRPl transcription was down-regulated (Li et al., 2008b). 
Immune system is a collection of mechanisms within an organism that protects 
against diseases by identifying and killing pathogens and tumor cells. 
Polysaccharides extracted from G. lucidum had the ability to increase the cytokine 
production in vitro and in vivo probably through toll-like receptor 4 (TLR4) or 
activated neutrophil through protein kinase C (PKC) and p38 mitogen-activated 
protein kinase (MAPK) (Wang et al., 1997; Hsu et al., 2002 & 2003; Lin et al., 2006; 
Zhu et al., 2007; Li et al., 2008a). Polysaccharides from fresh fruiting bodies of G. 
lucidum potentiated cytokine production by human monocytes-macrophages and T 
lymphocytes in vitro (Wang et al., 1997). Polysaccharide preparation increased the 
release of interleukin (IL)-lp, tumor necrosis factor (TNF)-a, and IL-6 from 
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macrophage and interferon (IFN)-Y from T lymphocytes (Wang et al., 1997). The 
cytokine-containing mononuclear cell-conditioned media contain these cytokines 
were found to suppress the proliferation and clonogenicity of both the HL-60 and the 
U937 leukemic cell lines, and induce apoptosis (Wang et al., 1997). Since 
polysaccharides alone had no such effects even at a higher dose, and untreated 
mononuclear cell-conditioned media did not suppress leukemic cell growth, the 
anti-tumor activity was derived from the elevated levels of cytokines by G. lucidum 
polysaccharides (Wang et al., 1997). Not only the polysaccharide extracts from G. 
lucidum, but those from other four Ganoderma species, namely: G. tsugae, G. 
oerstedii, G resinaceum and G subamboinens, significantly stimulated phagocytosis 
and nitric oxide production by RAW 264.7 macrophage cell line in vitro (Chen et al., 
2007a). They also up-regulated mouse splenocyte proliferation in the absence of 
mitogen Con A, while they down regulated the proliferation in the presence of Con A 
(Chen et al., 2007a; Ji et al., 2007). Toll-like receptor 4 (TLR4) and membrane 
immunoglobulin (Ig) were required for polysaccharide-induced B cell proliferation, 
and TLR4 was also involved in polysaccharide-mediated macrophage activation. 
Thus, TLR4 may be the immune receptor for polysaccharides of G. lucidum (Shao et 
al., 2004). In splenic mononuclear cells, polysaccharides extracted from G. lucidum 
spores stimulated proliferation, cytokine production and increases in the expression 
of myosin regulatory light chain 2-A, Rho GDP dissociation inhibitor beta, 
T-cell-specific GTPase, phosphatidylinositol transfer protein a, and decreases in the 
expression of apoptosis-associated speck-like protein containing a CARD, 14-3-3 tau, 
p-actin，tubulin a 2, copine I，and y-actin (Ma et al., 2008). In neutrophil, 
polysaccharides of G. lucidum inhibited spontaneously Fas-enhanced apoptosis, and 
enhance phagocytosis and chemotaxis in vitro (Hsu et al., 2002 & 2003). Exposure 
of neutrophils to polysaccharides for 24h caused increases in PKC, p38 MAPK, Hck, 
and Lyn activities, which were reduced by wortmannin (phosphatidylinositol 
3-kinase, PI3K inhibitor), pyrazolpyrimidine 2 (Srcfamily tyrosine kinase inhibitor), 
Ro318220 (PKC inhibitor), and SB203580 (p38 MAPK inhibitor), but not by 
PD98059 (mitogen-activated protein/ERK kinase inhibitor) (Hsu et a l , 2003). In vivo 
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studies proved again the immune effects of polysaccharides from G lucidum (Lin et 
al., 2006; Zhu et al., 2007; Li et al., 2008a). In immunosuppressed mice, low-dose 
polysaccharide accelerated recovery of bone marrow cells, red blood cells and white 
blood cells, as well as splenic natural killer cells and natural killer T cells, and 
enhanced T and B cell proliferation response, cytotoxic T lymphocyte activity, as 
well as NK cell and lymphokine activated killer cell activity (Zhu et al., 2007). 
Furthermore, it promoted phagocytosis and cytotoxicity of macrophages without side 
effect (Zhu et al., 2007). The serum IFN-y levels in mice bearing S-180 solid tumor 
increased in all polysaccharide-treated groups but not in the control group and the 
tumor weight decreased significantly (Li et al., 2008a). Water extracts from G. tsugae 
also proved to modulate the macrophage responses and the production of IL-2 and 
IL-4 in vivo in mice (Lin et al., 2006). 
Oxidative damage to DNA is likely to be a cause of cancer (Galaris et al., 2008). 
Reactive oxygen species such as the hydroxyl radical (H0-), superoxide radical ((V.) 
and H2O2, are inevitably produced in vivo during this process, which result in aging, 
cell death and tissue damage (Halliwell and Gutterdge, 1999). Antioxidant 
supplements, or foods containing antioxidants, may be used to help human body 
reduce oxidative damage (Yang et al. 2002). Ganoderma spp. are one source of 
anti-oxidant agents. Methanolic extracts and water extracts from two species, G. 
lucidum and G. tsugae, showed anti-oxidant abilities in several in vitro assays (Mau 
et al., 2005a, b; Ajith and Janardhanan, 2007). G. lucidum polysaccharides prevented 
membrane damage in rat liver mitochondria, as well as lipid peroxidation, protein 
oxidation, depletion of protein thiols and inactivation of the anti-oxidant enzymes, 
which were induced by the free radicals generated during "/-irradiation (Li et al., 
2007). These abilities of G. lucidum polysaccharides in inhibiting irradiation-induced 
oxidative injury were proved to be more effective than a-tocopherol (Vitamin E) (Li 
et al., 2007). Many naturally occurring compounds with antioxidant activities are 
known to protect cellular components from oxidative damage and prevent diseases 
(Gescher et al., 1998; Ren et al., 2003; Clark and You, 2006). Water-soluble 
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polysaccharides from Ganoderma protected human proximal tubular epithelial cells 
from human serum albumin (HSA)-induced oxidative DNA damage and cytotoxicity 
in human proximal tubular epithelial cells with amelioration of the increased release 
of IL-8 and soluble intercellular adhesion molecules-1 (sICAM-1) (Lai et al., 2006). 
The prior oral administration of dried methanolic extract of the fruiting bodies of G. 
lucidum markedly inhibited mutagenicity induced by a priority persistent 
organopollutant benzo[a]pyrene (B[fl]P) (Lakshmi et al., 2006). This extract 
prevented the increase of serum glutamate oxaloacetate transaminase (SGOT), serum 
glutamate pyruvate transaminase (SGPT), alkaline phosphtase ALP activities and 
lipid peroxidation consequent to B[fl]P challenge, and enhanced the levels of reduced 
glutathione (GSH) and activities of glutathione peroxidase (GPx), 
glutathione-5'-transferase (GST), superoxide dismutase (SOD), and catalase (CAT). 
This piece of evidence suggests that G. lucidum extract restored antioxidant defense 
and prevented hepatic damage consequent to the challenge by B[a]P (Lakshmi et al., 
2006). 
Besides, Ganoderma spp. have shown the potential to regulate endocrine system, 
which might be a new strategy to prevent hormone-related cancer and other diseases 
(Jiang et al., 2006; Liu et al., 2006a, b; Zaidman et al., 2007). Ethyl acetate extract of 
G. lucidum decreased androgen receptor transcriptional activity, suppressed levels of 
secreted prostate-specific antigen, and suppressed androgen receptor protein level in 
LNCaP prostate cancer cells (Zaidman et al., 2007). Mechanism studies showed that 
the crude ethyl acetate extract and active fraction GLF4 of G. lucidum disrupted 
androgen receptor function via competition with the natural ligand 
dihydrotestosterone (DHT) and suppression of androgen receptor/androgen response 
element complex formation (Zaidman et al., 2007). The water extract of G. lucidum 
also down-regulated the expression of ERa in MCF-7 cells but did not affect the 
expression of ERp in MCF-7 and MDA-MB-231 cells in DMEM with 10% fetal 
bovine serum (FBS) (Jiang et al., 2006). In addition, G. lucidum inhibited 
estrogen-dependent as well as constitutive transactivation activity of ER through 
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estrogen response element (ERE) in a reporter gene assay (Jiang et al., 2006). 
1.1.3 Endocrine system and breast cancer 
The endocrine system is an integrated system of glands which produce and secrete 
extracellular signaling molecules known as hormones (Benassayag et al., 2002). 
Hormones regulate and coordinate physiological and metabolic functions by acting 
on receptors located on or in target cells (Spener, 2002). A hormone exhibits 
specificity which is a sort of lock and key mechanism (Cooper and Kavlock, 1997). 
In this study, effects of two steroid hormones and their analogs were discussed. One 
is 17p-estradiol (E2). It represents the major estrogen called female hormone in 
humans. During the reproductive years, most 17P-estradiol in women is produced by 
the granulosa cells of the ovaries by the aromatization of androstenedione (produced 
in the theca folliculi cells) to estrone, followed by conversion of estrone to estradiol 
by 17p-hydroxysteroid reductase. Smaller amounts of estradiol are also produced by 
the adrenal cortex, and (in men), by the testes (Pentikainen et al., 2006). The other is 
5a-dihydrotestosterone (DHT), one of male hormones called androgen. It is a 
biologically active metabolite of the hormone testosterone, formed primarily in the 
prostate gland, testes, hair follicles, and adrenal glands by the enzyme 5a-reductase 
by means of reducing the 4,5 double-bond of testosterone (Swerdloff and Wang, 
1998). 
1.1.3.1 Estrogen 
Estrogens are polycyclic molecules that are rigid and asymmetrical (Figure 1.1). 
Specific 2-D structural features of estrogen are important for potency include a 
unsaturated A-ring, a D-ring, substitution by a hydroxy group in the 7-a- and /or 
11-P-positions, and a hydrophobic backbone (Benassayag et al., 2002). Estrogens 
11 
Chapter 1 Introduction 
influence the growth, differentiation and functioning of many target tissues. These 
include tissues of the male and female reproductive systems such as mammary gland, 
uterus, ovary, testis, and prostate. Estrogens also play an important role in bone 
maintenance and in the cardiovascular system, where estrogens have certain 
cardioprotective effects (Clark et al., 1992). Estrogens are retained with high affinity 
and specificity in target cells by binding proteins termed the estrogen receptors (ER) 
(Murdoch and Gorski, 1991; Lauritzen, 2000). 
Figure 1.1 2D and 3D skeletons of 17p-estradiol (E2). 
1.1.3.2 Estrogen receptors 
Estrogen actions are mediated by binding to specific receptors (ERs), which act as 
ligand-inducible transcription factors. There are two forms of the ER, a (Green et al., 
1986a, b) and (3 (Kuiper et al., 1996, Mosselman et a l , 1996; Norflee et al., 2000; 
Razandi et al., 1999) in human. ERs belong to nuclear receptor superfamily of 
steroid and thyroid hormones, vitamin D，retinoids and prostanoids (Wahli and 
Martinez, 1991; Beato et al., 1995; Mangelsdorf et al., 1995). ER a gene is located at 
chromosome 6 of 6q25.1 (Menasce et al., 1993). It extends over more than 140 kb 
which contains eight exons and encodes a protein of 595 amino acids with a 
predicted molecular weight of 66,182 dalton (Pari, 2000). N-terminal A/B contains a 
ligand-independent transactivation function, AF-1, which is required for maximal ER 
function (Tora et al., 1989). Region C which is characterized by a helix-loop-helix 
structure stabilized by two zinc atoms contains the DNA-binding domain which 
determines the specificity of target gene activation (Kumar et al., 1986; Green and 
Chambon, 1987; Webster et al., 1988; Ylikomi et al., 1992; Pierrat et al., 1994). A 
second ER gene was identified in 1996. It is located in chromosome 14 of 14q22-24 
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and designated ER p where as the classical ER gene was termed ER a (Kuiper et al., 
1996; Mosselman et al., 1996). ER a and ER p share a common and basic 
three-domain structure with a N-terminal domain (A/B domain) which is highly 
immunogenic and comprises sites for interaction with proteins involved in 
transcriptional activation (Enmark and Gustafsson, 1999). Also, it possesses a central 
DNA-binding domain C and ligand-binding domain E/F domain. The highest degree 
of homology between ER a and ER p is in the DNA-binding domain with 95% 
identity of amino acid sequence. On the other hand the homologies of A/B and E/F 
domains are less than 20% and 60% respectively (Kuiper et a l , 1996). ER a and ER 
P binds to estradiol with high affinity and specificity. They both activate transcription 
of reporter genes containing estrogen response elements in a hormone-dependent 
manner (Kuiper et al., 1996; Tremblay et al., 1997; Barkhem et al., 1998). 
The classical view of the mechanism of an estrogen action is that its effects are 
mediated through binding to the nuclear ER(s), which then bind to estrogen response 
elements (ERE) in nuclear DNA to cause transcriptional activation of 
estrogen-responsive genes (Enmark and Gustafsson, 1999). Firstly, estrogen binds to 
ligand-binding domain in region E, and dissociation of heat shock proteins would be 
induced followed by the formation of stable ER homodimers (Gordon and Notides, 
1988; Kumar and Chambon, 1988; Linstedt et al., 1986; Smith and Toft, 1993). 
Secondly, the hormone-activated ER dimmer interacts through the DNA-binding 
domain with regulatory DNA enhancer sequences, and a common ER-binding DNA 
sequence was identified in the 5' regions of several estrogen-inducible target genes 
(Seiler-Tuyns et al., 1986; Martinez and Wahli, 1989). This estrogen-inducible target 
DNA sequence is called an estrogen response element (ERE) and is characterized by 
a 13-base pair palindrome with 5-bp stems separated by a 3-bp spacer and a 
consensus sequence of GGTCAnnnTGACC (Klein-Hitpass et al., 1986; Klock et al., 
1987). Finally, the E2-ER-ERE complex is postulated to promote the dissociation or 
inactivation of corepressor proteins and the recruitment of coactivator proteins to 
interact with AF-2 domain (Horwitz et a l , 1996). This protein-DNA complex 
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contains the nucleus of a preinitiation complex to which RNA polymerase II and 
other basal transcription factors can bind efficiently to activate high levels of gene 
transcription (Bagchi et al., 1992; Ptashne, 1988). 
Besides, the mitochondrial genome also contains ERE-like sequences (Sekeris, 1990; 
Demonacos et al., 1996). Several studies have reported detection of estrogen binding 
to mitochondria and the presence of estrogen-binding proteins (EBPs) within 
mitochondria (Grossman et al” 1989，Moats and Ramirez, 2000，Monje and Boland, 
2001, Monje et al., 2001). Monje and colleagues (Monje and Boland, 2001，Monje et 
al., 2001) demonstrated the presence of both ERa and ERp in mitochondria of rabbit 
uterine and ovarian tissues. Estrogen treatment also increased the transcript levels of 
several mitochondrial DNA (mtDNA)-encoded genes for mitochondrial respiratory 
chain (MRC) proteins and MRC activity in rat hepatocytes and human Hep G2 cells 
(Chen et al., 1998). Later, Chen et al. (1998) found that ERa and ERp are present in 
mitochondria of human breast cancer MCF-7 cells, located within the MCF-7 cell 
mitochondrial matrix, and that the mitochondrial ERa and ERp account for 10 and 
18% of total cellular ERa and ERp in E2-treated MCF-7 cells, respectively. It was 
also found that E2 significantly enhanced the amounts of mitochondrial ERa and 
ERp in a time- and concentration-dependent manner and that these effects are 
accompanied by a significant increase in the transcript levels of mtDNA-encoded 
genes, i.e., cytochrome c oxidase subunits I and II (Chen et al., 1998). These 
E2-mediated effects were inhibited by the pure ER antagonist, ICI-182780, 
indicating the involvement of ERs (Chen et al., 2004). This mechanism explains the 
temporally delayed effects of E2 because it requires a series of macromolecular 
syntheses and protein localizations to produce responses over time periods of several 
hours to days. 
Estrogens and their analogues also exert a variety of short-term effects (seen in 
seconds to minutes) on their target organs. For example, estradiol (E2) rapidly affects 
monovalent and divalent cation transport, glucose uptake, and water imbibitions in 
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the rat uterus (Szego, 1978). In neurons and GH3 pituitary tumor cells, estrogens can 
elicit changes in electrical activity within minutes (Benbow, 1975; Adamson and 
Woodland, 1977; Schorderet-Slatkine, 1977; Kelly et al., 1977; Nabekura et a l , 
1986). A fast action of estrogen mediates calcium mobilization in granulosa cells 
(Morley et al., 1992) and osteoblasts (Lieberherr et al., 1993). Rapid electrical 
responses to estrogens also occur in several areas of the brain and other tissues (Dufy 
et al., 1976; Kelly et al., 1977; Nabekura et al., 1986; Smith et a l , 1989; Chen et al., 
1991; Wong and Moss, 1992; Lieberherr et al., 1993; Kelly et al., 1997). Several 
groups have provided evidence for the binding of a labeled steroid to the 
membrane-associated site (Pietras and Szego, 1977，1980; Bressibn et al., 1986). An 
estrogen binding site at the plasma membrane of pancreatic p cells has been 
described (Nadal et al., 1998). Once 17b-estradiol binds to this site, cGMP increases, 
activating protein kinase G, which phosphorylates ATP-dependent potassium 
channels (KATP), depolarizing the plasma membrane, and enhancing intracellular 
Ca2+ concentration ([Ca ]i) signals. As a consequence, insulin secretion is increased 
(Nadal et al., 1998; Ropero et al., 1999). 
1.1.3.3 Estrogen responsive genes 
1.1.3.3.1 pS2 
Trefoil factor 1 (pS2, TFFl，or BCEI, D21S21, pNR- 2，and HPS2) on chromosome 
21q22.3, is first identified in the MCF-7 human breast cancer cell line (Masiakowski 
et al., 1982). pS2 mRNA expression level is a prevalently used indicator of 
estrogenicity, and the translation product of pS2 mRNA is also induced in MCF-7 
cell in response to estrogen, which makes it one of the models to study 
estrogen-regulated gene expression (Jakowlew et al., 1984; Kim et al., 2000). The 
protein is a peptide of 60 amino acids consistently detected in the superficial and 
foveolar epithelia of gastric mucosa (Luqmani et al., 1989). pS2 expression has also 
been observed in normal breast ducts (Hahnel et al., 1993), where it may have a 
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physiological role similar to its function in the homeostasis and repair of 
gastrointestinal mucosa. The relationship between pS2 and human cancer has arisen 
after the finding that this trefoil peptide is the most abundant estrogen-induced 
messenger RNA in MCF-7 breast cancer cells (Jakowlew et al., 1984). Nevertheless, 
pS2 expression in a variety of other carcinomas, such as lung, pancreas, prostate, 
bladder, medullary carcinoma of the thyroid, mucinous carcinoma of the skin, 
endometrium, ovary and cervix, suggests a wider biological role of this peptide in the 
complex process of tumor progression. Two general patterns have emerged from the 
clinical studies: pS2 tends to be absent or reduced in tumors from organs in which 
healthy subjects express high levels of pS2 (i.e. stomach) (Luqmahi et al., 1989)，and 
it is overexpressed in tumors from organs in which healthy subjects express nil or 
low levels of pS2 (Corte et al., 2006). In breast cancer, pS2 expression is positively 
associated with estrogen receptor (ER) positive tumors, and inversely related with 
histological grade (Besse et al., 1994; Soubeyran et al., 1995). Furthermore, most 
studies conclude that tumoral expression of pS2 is associated with a better prognosis 
(Rio and Chambon, 1990; Gion et al., 1993; Foekens et al., 1993; Besse et al., 1994; 
Soubeyran et al., 1995), and is also a predictive factor for positive response to 
endocrine therapy in breast cancer patients (Rio and Chambon, 1990; Soubeyran et 
al., 1996; Elledge et al., 2000). 
pS2 in breast cancer may act by several mechanisms. Firstly the growth-inhibitory 
activity of pS2 has already been reported; mice lacking pS2 showed enhanced 
tumorogenesis in gastric mucosa (Lefebvre et al., 1996), and pS2 induced growth 
inhibition in the human AGS gastric adenocarcinoma cell line (Calnan et al., 1999). 
Thus, from these in vivo and in vitro data, a tumor suppressor function has been 
proposed for pS2. Secondly pS2 protects cells from chemical or bad-induced 
apoptosis, hinting a dual anti-proliferative and anti-apoptotic role of pS2 
(Bossenmeyer-Pourie et al., 2002). UV irradiation and benzalkonium chloride (BAK) 
activate caspase-dependent pathways to chromatin nuclear condensation (Huron et al., 
2006). pS2 negatively interferes with these pathways at two levels. The peptide 
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delays caspase-8 activation at the level of the death-inducing signalling complex 
(DISC), upstream of the mitochondrial events. It also activates N F - K B and promotes 
the expression of the caspase inhibitor XIAP (X-linked Inhibitor of Apoptosis 
Protein), which delays caspase-9 and caspase-3 activation by cytochrome c released 
from mitochondria (Huron et al., 2008). In ulcerative and acute inflammatory bowel 
diseases such as Crohn's disease, duodenal peptic ulcer, or hemorrhagic rectocolitis, 
pS2 is ectopically expressed along the entire human gastrointestinal tract, and pS2 is 
also observed in cells of regenerating tissues surrounding areas of damage, 
suggesting that pS2 might be involved in the repair process and the maintenance of 
mucosal integrity (Rio et al., 1991; Wright et al., 1993). In this context, transgenic 
mice overexpressing human pS2 in the jejunum have a lower rate of induced 
ulceration in this part of the gastrointestinal tract, showing that pS2 exerts a 
protective effect (Playford et al., 1996). Thirdly pS2 could stimulate cell migration, 
which is directly related with tumoral aggressiveness. One in vitro study has shown 
that transfection of human pS2 cDNA has morphologic effects on the murine 
adenocarcinoma cell line 410.4 whose phenotype was comparable to the hepatocyte 
growth factor, a positive control, and in which the dispersed growth pattern in 
three-dimensional collagen gel was enhanced (Williams et al., 1996). Also, stable 
expression of pS2 promotes invasiveness of human colonic HCT8/S11 cells and their 
cell scattering (Emami et al., 2001). Therefore, tumor expression of pS2 has been 
associated with a favorable prognosis in breast cancer, while estrogens stimulate the 
motility of breast cancer cells via the induction of pS2. Thus hormonal therapies may 
require the reduction in the expression of pS2 leading to inhibition of the migration 
of breast tumor cells (Prest et al., 2002). 
pS2 was initially isolated from the estrogen receptor-positive MCF7 breast 
carcinoma cell line (Jakowlew et al., 1984). In estrogen-treated MCF7 cells, pS2 
expression is directly controlled at the transcriptional level via an ERE in the pS2 
promoter (Prest et al., 2002). Thus, pS2 was found to be a marker of anti-estrogenic 
treatment in advanced stages of breast cancer (Soubeyran et al.，1996; Elledge et a l , 
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2000). In another study on 1031 patients with invasive breast cancer, a low but 
significant predictive value was shown on tumoral pS2 levels in patients who 
received tamoxifen as a single adjuvant systemic therapy (Corte et al., 2006). 
However, there are discordant results on its predictive value on hormonotherapy in 
advanced disease (Luqmani et al., 1993) as well as with regard to adjuvant 
hormonotherapy (Spyratos et al. 1994; Soubeyran et al., 1996). 
Nevertheless, several clinical and experimental data suggest an estrogen-independent 
mechanism of pS2 expression by breast carcinomas (Crosier et al., 2001). The 
expression of pS2 is markedly higher in the estrogen-independent tumors which 
progress rapidly in the screening intervals and bear lower expression levels of 
estrogen receptor (Crosier et al., 2001). Thus, ER-independent mechanisms, such as 
DNA methylating changes at CpG sites within the promoter/enhancer region, are 
involved in the control of pS2 in healthy as well as tumor cells (Martin et al., 1997; 
Metivier et al., 2008). In addition, the pS2 gene has an upstream promoter enhancer 
region that is responsive to stimulation by estrogen, but also to plasminogen activator, 
FOS, and JUN oncoproteins, phorbol ester tetra-acetate and epidermal growth factor 
(Nunez et al., 1989). Taken together, the expression and function of pS2 in breast 
carcinomas are complex with estrogen regulation via ER control and cross-talk by 
other modulators especially those of ER-independent ones. 
1.1.3.3.2 Progesterone receptor 
Progesterone receptor (PGR), located on chromosome Ilq22-q23, is another member 
of the nuclear/intracellular receptor superfamily of ligand dependent transcription 
factors (Tsai and Malley, 1994; Leonhardt et a l , 2003). Estrogen binding to ER is 
regarded as a ligand. Isoforms of nuclear progesterone receptors are known namely 
PGR-A (94 kDA) and PGR-B (116 kDa). They are the receptors of an ovarian steroid, 
progesterone, which plays a major role in regulating female reproductive events. 
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These events include ovulation, luteinization, the maintenance of luteal structure and 
function, development of uterine and mammary gland, implantation, sustenance of 
pregnancy and neurobehavioural expression associated with sexual responsiveness 
(Clarke and Sutherland, 1990; Lydon et al., 1995). PGR-A and PGR-B are translated 
from the same gene, but initiated at different promoters indicating differential 
transcriptional control, and consequently, PGR-A lacks 164 amino acids from the 
N-terminal of PGR-B (Hanekamp et al., 2003). Kastner et al. (1990) have defined 
these two promoters in the PGR gene, promoter B from -711 to +31 and promoter A 
from +464 to+/1105. 
At pregnancy, activation of PGRs results in extensive epithelial proliferation, 
increased dichotomous side branching and differentiation of milk-filled alveolar 
lobules that fill the interductal spaces by late pregnancy (Conneely et al., 2003). At 
weaning, removal of the suckling stimulus results in involution of the lobular 
alveolar system through apoptosis and matrix-degrading, proteinase-mediated 
remodeling to ultimately resemble the general architecture of the prepregnant 
mammary gland and complete the developmental cycle (Conneely et al., 2003). 
Recent studies have shown that PGR-A is responsible for calcitonin expression and 
production of a metalloproteinase involved in follicular rupture (Richer et al., 2002) 
and PGR-B is required for the normal cell proliferation, differentiation of the 
mammary epithelium, and histidine decarboxylase expression (Mulac-Jericevic et al., 
2000; Conneely et al., 2001). Ablation of PGRs expression in mice resulted in a 
significantly reduced incidence of mammary tumor growth in response to carcinogen 
challenge (Lydon et al., 1999). This demonstrates a crucial role of PGRs as obligate 
mediators of the intracellular signaling pathways for the initiation of mammary 
tumors induced by the carcinogen (Lydon et al., 1999). PGR-A and PGR-B are found 
in equimolar amounts in normal breast but their ratios are altered in advanced disease; 
Patients having PGR-A rich tumors have much faster disease recurrence than those 
with PGR-B specific tumors and have poor survival rates (Anderson, 2002; Jacobsen 
et al” 2004). Thus, PGRs are considered to be good prognostic markers of breast 
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cancers irrespective of the patient's progestational status (Jacobsen et al., 2004). 
Similar to ERs, PGRs act as nuclear transcription factors. In general, PGR-B is a 
stronger transcriptional activator, while PGR-A can function as a ligand-dependent 
repressor of other steroid hormone receptors including PGR-B and ER (Vegeto et al., 
1993). Also, regardless of the transcriptional levels of PGRs, PGR-B but not PGR-A 
shows interaction with the SH3 domain of tyrosine kinase Src and downstream 
region of MAPK (Erk-l/-2) for activation (Boonyaratanakomkit et al., 2008). 
Activated MAPK regulates selected target genes such as cyclin D1 (CCNDl) that 
lack direct PGR binding response elements (PREs). Since CCNDl.plays a key role in 
Gl-S cell cycle progression, it explains the substantial (70%) increase in the 
percentage of cells in G2M+S phase induced by progestin through PGR in T47D 
breast cancer cells (Boonyaratanakomkit et al., 2008). T47-D breast cancer cells also 
display enhanced horizontal migration and invasion of three-dimensional matrices in 
the presence of progesterone and synthetic progestin medroxyprogesterone acetate 
(MPA) (Fu et al., 2008). In the presence of progesterones, PGR-A interacts with the 
G protein Gan, while MP A drives PGR to interact with tyrosine kinase c-Src and 
activate phosphatidylinositol-3 kinase, leading to the activation of RhoA/ROCK-2 
cascade (Fu et al., 2008). The extra-cellular small GTPase RhoA/ Rho-associated 
kinase (ROCK-2) cascade mediates progesterone- and MPA-induced moesin 
activation, cell migration and invasion (Fu et al., 2008). Exposure to the 
progesterones triggers a rapid remodeling of the actin cytoskeleton and the formation 
of membrane ruffles required for cell movement, via the rapid phosphorylation of the 
actin-regulatory protein moesin (Fu et al., 2008). However, depending on the cell 
type, hormonal environment, growth conditions and developmental stage, 
progesterone can either stimulate cell proliferation, or inhibit growth and promote 
cell differentiation (Mangelsdorf et al., 1995; Li and O'Malley, 2003; Edwards, 
2005). 
In breast cancer, both PGR-A and PGR-B are up-regulated by E2 (Nardulli et al.， 
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1988; Wei et al., 1988; Vienonen et al., 2002). This E2-induced increase in PGR 
expression is dependent upon the expression of ER. When mice fail to express ERa, 
PGR levels fall to 60% of normal levels, and PGR mRNA cannot be induced by 
estrogen treatment (Hewitt and Korach, 2000). In HeLa cells transfected with PGR-B, 
PGR-B promoter activity was enhanced by ERa, but not by ERp (Flototto et al., 
2004). Similar results were also obtained in BT20 and Ishikawa cells (Flototto et al., 
2004). Interestingly, neither promoters of PGR contain an ERE (Kastner et al., 1990; 
Misrahi et al., 1988). Promoter A, however, contains an ERE half-site located 
upstream of two Spl sites (Kastner et al, 1990). ERa enhances specific Spl binding 
to the Spl sites as well as binding to the ERE half-site for activation (Petz and 
Nardulli, 2000; Schultz et al., 2003). With the comparison of ERa variants lacking 
transactivation functional domain AFl or AF2 and wild-type ERa, it was found that 
AFl but not AF2 of ERa is essential for activating the PGR-B promoter. Inability of 
ERp to mediate up-regulation of the PGR-B promoter was probably due to its lack of 
this AFl activity (Flototto et al., 2004). 
1.1.3.4 Androgen 
Androgens, which were first discovered in 1936，stimulate or control the 
development and maintenance of masculine characteristics in vertebrates by binding 
to androgen receptors. They are also the precursor of all estrogens. The primary and 
most well-known androgen is testosterone (Figure 1.2). Testosterone (T) could be 
converted into E2 by aromatase in breast cancer cells, such as MCF-7 (Maggiolini et 
al., 2001). It could also be converted into 5a-dihydrotestosterone (DHT), which 
cannot be aromatized by 5a-reductase to reduce the 4,5 double-bond primarily in the 
prostate gland, testes, hair follicles, and adrenal glands (Figure 1.3, Swerdloff and 
Wang, 1998). DHT is 3 times more potent than testosterone (Swerdloff and Wang, 
1998). Androgens play a key role in the formation of testes and spermatogenesis in 
male animals (Lombardo et al., 2005). Recent results indicated that androgens 
inhibited adipogenic differentiation in 3T3-L1 cells by AR-mediated nuclear 
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translocation, activation of Wnt signaling and downstream down-regulation of 
CCAAT/enhancer binding protein-a and and peroxisome proliferator-activated 
receptor-y2 protein all of which normally support adipocyte function (Singh et a l , 
2006). Androgens promote the enlargement of skeletal muscle cells and probably act 
in a coordinated manner to enhance muscle function by acting on several cell types 
in skeletal muscle tissue (Sinha-Hikim et al., 2006). Androgen levels are also relative 
to the human aggression and libido (Giammanco et al., 2005). 
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Figure 1.3. 2D skeletal of 5a-dihydrotestosterone (DHT). 
In women, the primary androgens are testosterone (T) synthesized in the ovaries and 
adrenal glands, and androstenedione and dehydroepiandrostenedione synthesized 
primarily in the adrenals. Androgens play key roles in regulating the functions of 
vital organs in women, including the reproductive tract, bone, kidneys and muscle, 
and can act indirectly as prohormones of estradiol or directly by binding to the 
androgen receptor. There is a decline in serum T levels with increasing age, as 
ovarian production reduces (Labrie et al., 2003), although tissue levels of androgens 
are potentially maintained, as both normal and cancerous breast tissues have the 
requisite steroid biosynthetic enzymes to produce androgens and estrogens from 
adrenal precursors (Martel et al., 1994; Labrie, 2003; Labrie et al., 2003). While little 
22 
Chapter 1 Introduction 
research has been performed on the role of androgen action in the normal breast, it is 
known that excess androgen level (e.g. in congenital adrenal hyperplasia or with use 
of anabolic steroids) suppresses breast development (Labrie et al., 2003). Androgens 
have a predominantly inhibitory effect on the growth of breast cancer cells, both in 
vitro and in vivo (Dauvois et al., 1991; De Launoit et al., 1991; Hackenberg et al., 
1991; Birrell et al., 1995; Ortmann et al., 2002; Greeve et a l , 2004). This inhibitory 
effect is mediated by the androgen receptor (AR) and is potentially due to induction 
of apoptosis (Kandouz et al., 1999; Lapointe et al., 1999). 
1.1.3.5 Androgen receptor 
Androgen receptor (AR) gene, located on chromosome Xqll .2-ql2, is more than 90 
kb long and codes for a protein that has 3 major functional domains: the N-terminal 
domain, DNA-binding domain, and androgen-binding domain (Pasquali, 2006; Hare 
et al., 2009). The protein functions as a steroid-hormone activated transcription factor. 
Binding of DHT results in a distinct conformational arrangement of the ligand 
binding domain (LBD), and the formation of a conserved cleft, termed AF2, which is 
critical for interaction with accessory proteins that ultimately determine the program 
of AR-directed nuclear events (Sack et al., 2001). The AR is expressed in -70-90% 
of primary breast tumors, a higher frequency than either estrogen or progesterone 
receptors (70-80% and 50-70%, respectively), and in 75% of metastatic breast cancer 
deposits (Lea et al., 1989; Hall et al., 1996; Kuenen-Boumeester et al., 1996; Honma 
et al., 2003; Moinfar et al, 2003; Riva et a l , 2005). Expression of AR in breast 
tumors has been associated with increased patient survival (Langer et al., 1990; 
Agoff, 2003; Schippinger et al” 2006), although a correlation between AR 
expression and tumor grade and stage was not found in another study (Anim et al., 
2005). There is emerging evidence that the androgen signaling pathway plays a 
critical protective role in breast cancer growth (Langer et al., 1990; Birrell et al., 
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1998; Brys, 2000; Liao and Dickson, 2002). Recent studies suggest that in addition 
to the direct AR-mediated genomic actions of androgens, androgens inhibit the 
growth of breast cancer cells by opposing the growth-stimulatory effects of 
estrogen-mediated ERa activation (Greeve et al., 2004). DHT decreases expression 
of ERa mRNA and protein in breast cancer cells (Poulin et al., 1989), and AR 
inhibits ERa but not ERp activity, potentially via direct binding to ERa 
(Panet-Raymond et al., 2000). In vivo administration of estradiol by ovariectomized 
rhesus monkeys induced breast epithelial cell proliferation, but coadministration of 
E2 and testosterone (T) prevented this increase in proliferation (Zhou et al., 2000). 
Furthermore, the coadministration of mixed sex hormones suppressed the E2 
mediated induction of Myc (Zhou et a l , 2000). Thus, the interaction between 
androgen and estrogen signaling may play a critical role in controlling cellular 
proliferation and maintaining tissue homeostasis in the breast (Szelei et al., 1997; 
Birrell et al., 2007). 
1.1.3.6 Androgen responsive genes 
1.1.3.6.1 Transmembrane prostate androgen-induced RNA 
Transmembrane prostate androgen-induced RNA (TMEPAI, or PMEPAl, STAGl), 
locates on chromosome 20ql3. The open reading frame of TMEPAI was 
characterized as a 759-bp nucleotide sequence coding for a 252-amino-acid protein 
(Xu et al., 2000). The analysis of TMEPAI protein sequence indicated the existence 
of a type lb transmembrane domain between residues 9 and 25 (Xu et al., 2000), and 
motifs that suggest that it may bind Src homology 3- and tryptophan tryptophan 
domain-containing proteins (Rae et al., 2001). Analysis of multiple normal human 
tissues with northern blots revealed the highest level of TMEPAI expression in 
prostate tissue followed by uterus (Xu et al., 2000; Rae et al., 2001). The expression 
of TMEPAI in prostate carcinoma cells, 22RV1 and LNCaP, was induced by 
androgen in a time- and dose-specific manner (Xu et al., 2000; Hartel et al., 2004). 
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Increased expression of androgen responsive genes in the "hormone-refractory" 
CWR22R variant of the CWR22, a human prostate cancer transplantable nude mouse 
xenograft, suggests the activation of AR-mediated cell signaling in relapsed CWR22 
tumors following castration (Xu et al., 2000). Evaluation of TMEPAI expression in 
androgen-dependent/independent tumors of the CWR22 xenograft model revealed 
that TMEPAI was overexpressed in three of four androgen-independent tumor tissues 
(Xu et al.，2000). These observations define TMEPAI as an androgen-regulated gene 
exhibiting abundant expression in prostate tissue. Thus, TMEPAI has potential to 
serve as an androgen signaling read-out biomarker in prostate tissue to identify novel 
targets in therapy of hormone-refractory prostate cancer (Xu et al., 2000; Hartel et al., 
2004). 
Besides prostate cancer cells, TMEPAI also overexpressed in renal cell carcinoma, 
stomach adenocarcinomas, rectal adenocarcinomasbreast and ovarian cancer cell 
lines and breast primary tumors (Rae et a l , 2001; Giannini et al., 2003). Chemical 
inhibition of the EGFR pathway impairs TMEPAI expression in EGFR amplified 
breast cancer cells (Giannini et al., 2003). Thus it is likely that TMEPAI 
overexpression in many breast cancer cell lines, and primary tumors may be a 
consequence of the constitutive activation of the EOF pathway. In addition, the 
transcript of TMEPAI was also shown to be induced by transforming growth factor 
beta (TGF-P) (Itoh et al., 2003; Brunschwig et al., 2003; Levy and Hill; 2005). 
Although the biological function of TMEPAI has not been fully understood, ERG 1.2, 
the mouse homolog of TMEPAI, is a cell-cycle-regulated gene with a sudden peak 
expression when quiescent cells were stimulated to enter the cell cycle and a quick 
decline before cells enter S phase (Giannini et al., 2003). TMEPAI has also been 
reported to be involved in p53-mediated apoptosis (Anazawa et al., 2004) and cell 
growth inhibition (Brunschwig et al., 2003). Besides, TMEPAI is an immediate-early 
response gene for TGF-P signaling and negatively regulates TGF-p signaling in 
mammalian cells (Itoh et al., 2007). 
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1.1.3.6.2 Uridine diphosphate glucose dehydrogenase 
Uridine diphosphate glucose dehydrogenase (UDPGDH) gene, located on 
chromosome 4pl5.1, encodes UDPGDH that converts UDP-glucose to 
UDP-glucuronate (Spicer et al., 1998). UDP-glucuronate is the substrate for the 
numerous glucuronosyl transferases, which act on the synthesis of 
glycosaminoglycans and glucuronidation reaction of xeno- and endobiotics, such as 
bilirubin, drugs, and steroid hormones (Burchell and Coughtrie, 1989; Tephly and 
Burchell, 1990). Autoradiography revealed two UDPGDH transcripts were present in 
most tissues, and the highest expressing tissues were liver and prostate (Spicer et al., 
1998). Besides, UDPGDH transcripts are also ubiquitously expressed in human 
breast cancer cells (Lapointe and Labrie, 1999). The expression of this gene is 
up-regulated by TGF-|3 and down-regulated by hypoxia in several cell lines 
(Bontemps et al., 2003). In ZR-75-1 cells, UDPGDH transcript was induced rapidly 
by DHT (Lapointe and Labrie, 1999). The increase in UDPGDH messenger RNA 
was completely prevented by coincubation with the pure antiandrogen 
hydroxyflutamide, but not by cycloheximide, an inhibitor of protein synthesis, 
indicating that UDPGDH is directly regulated by the androgen receptor (Lapointe 
and Labrie, 1999). Up-regulation of UDPGDH expression by androgens might play 
an important role in the control of sex steroid inactivation via glucuronidation in 
breast cancer cells (Lapointe and Labrie, 1999). 
1.1.3.7 Breast cancer 
Breast cancer is the most common cancer in women (Parkin et al., 2001), which 
caused 548,000 deaths in 2007 all around the world (World Health Organization; 
Fact sheet N° 297, July 2008). Risk factors for the disease include high plasma 
estrogen level (Missmer et al., 2004), high levels of expression of estrogen receptors 
(ERs) in mammary tissue (Khan et al., 2000; Kurebayashi et al., 2000), and high 
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breast density as revealed by mammography screening (Boyd et al., 1982). The 
administration of antiestrogens constitutes the most useful treatment for 
hormone-dependent breast cancer (Wallgren et al., 1985) and was shown to be 
effective in preventing breast cancer in clinical trials (Fisher et al., 1998). In view of 
the pivotal role of estrogens in the pathogenesis of breast cancer, current therapies in 
postmenopausal women aim to either block its interaction with the estrogen receptor 
(ER), by the use of an antiestrogen such as tamoxifen or an ER downregulator, or 
inhibit the conversion of androstenedione to estrone with an aromatase inhibitor (e.g., 
letrozole, anastrozole, exemestane) (Cole et al., 1971; Smith and Dowsett, 2003). ER 
a and p are expressed in malignant tissue with concentrations different from those 
found in the corresponding normal tissue. Breast cancer can be characterized by a 
high level of ER a expression (Suo et al., 2001). Researches of ER-positive breast 
cancer cell lines revealed that E2 increased the rate of cell proliferation by two 
mechanisms, i.e. by recruiting noncycling cells from GO state into cell cycle and by 
shortening the overall cell cycle time due to a reduction in length of G1 phase (Hou 
et al., 1996). Treating MCF-7 cells with an antiestrogen leads to growth arrest with a 
reduction in proportion of cells in S phase (Taylor et al., 1983; Wakeling et al., 1989). 
Decrease in cell proliferation rate can be negated by simultaneous or subsequent 
addition of E2 (Sutherland et al., 1983). This further supports that the 
anti-proliferation of antiestrogens acts by competitive inhibition of the 
estrogen-induced mitogenic signaling (Sutherland et al., 1983). Also, androgens (e.g., 
fluoxymesterone) historically have been used as hormonal therapy for advanced 
breast cancer, demonstrating an efficacy comparable to that of tamoxifen (Tormey et 
al., 1983, Ingle et al., 1991). Clinical observations indicate that androgens or 
androgenic compounds can have beneficial effects on inhibiting breast cancer growth 
in women (Labrie et a l , 1992). 
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1,2 Endocrine Disruption of p,p'-DZ>£ 
1.2.1 Introduction of p,p' -DDE 
p,p'-DDE, l，l-dichloro-2,2-bis(p-chlorophenyl)ethylene (Figure 1.4), is the main 
stable oxidative degradative metabolite of DDT, which was discovered in 1939 by 
Paul Miiller as a very effective insecticide (Khera and Clegg, 1969). DDT quickly 
became the most widely used pesticide in the world. However, in the 1960's, it was 
discovered that DDT cause birth defects in animals and humans (Khera and Clegg, 
1969). DDT is now banned in many countries, but it is still used in some developing 
regions to prevent malaria and other tropical diseases by killing mosquitoes and other 
disease-carrying insects. 
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Figure 1.4 Comparison of the 2D skeletal of p,p'-DDE (A), E2 (B), DHT (C) and 
progesterone (D). 
In North-Eastem Brazil, one of the poorest regions, 50% of the population lived in 
favelas, and pest mosquito and rodent problems were serious. Thus, DDT and other 
insecticides were widely sprayed by the local inhabitants in agriculture. As a result, 
the incidence of genital malformations in male newborns was as high as 
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94/10000/year in this region (Sampaio et al., 2005). These newborn patients with 
genital malformations were apt to have parents' exposure to pesticides (Jeandel et al., 
2005). In DDT resistant strain of malaria vector Anopheles gambiae’ p’p '-DDT was 
converted into p,p，-DDE by glutathione S-transferases (GSTs) (Figure 1.5 in Wang 
et al., 2008b). However, few epidemiological studies have examined whether 
cytochrome P450 (CYP) or GST was associated with adverse outcomes in 
populations occupationally-exposed to DDT and DDE (Eaton, 2000). Nevertheless, 
the environmental fate of DDT to DDE and isomers make the total DDT residues 
(SDDT; toxic DDT and its degradative metabolites) still as a priority pollutant urging 
for immediate remediation (USEPA). 
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Figure 1.5 Putative elimination reaction mechanism to convert p,p '-DDT into 
The P-hydrogen (the hydrogen linked to Cp) in DDT is in bold. The -S" 
group of activated ionic GSH (GS') launches a nucleophilic attack against the DDT 
P-hydrogen, which eliminates a HCl from p,p '-DDT and yields the final product 
p’p，-DDE (Wang et al., 2008b). 
1.2.2 p,p，-Z)D五 in environments 
p,p '-DDE is very resistant to spontaneous degradation in the environment. High 
concentrations of p，p，-DDE residue were detected in surface water, soil and sediment 
in many different regions, although DDT has been banned for over 20 years (Table 
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1.2). In Dutch standard, the intervention value in groundwater of total DDTs is 0.01 
iag/1 while for China, concentration of total DDTs should be lower than 1.0 |ig/l in 
groundwater for drinking, commercial and irrigation water for protecting the human 
health (Environmental Protection Department, 1994; State Environmental Protection 
Administration of China, 1995). Although they are not for surface water, the 
determined concentrations of p,p '-DDE were much higher than the intervention 
value of total DDTs (Table 1.2). Also, the value for soil is 4.0 mg/kg in Dutch 
standard and 0.5 mg/kg for agricultural soil in Chinese standard (Environmental 
Protection Department, 1994; State Environmental Protection Administration of 
China, 1995). In Table 1.2, most soil samples collected from different parts of China 
exceeded the 0.5 mg/kg agricultural soil reference, and some samples from other 
countries also exceeded the intervention value of the Dutch standard. 
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Table 1.2 p,p '-DDE residues in different environments. 




Surface water from Qiantang River of Zhejiang ND-93.4 Zhou et al. (2006b) 
Surface water from lakes and rivers of Yunnan 
90-1860 Yang et al. (2007) 
plateau 
Surface water from Selangor River, Malaysia 12.2-270.7* Leong et al. (2007) 
Surface water from Tonghui River of Beijing 3.71-207.9 Zhang et al. (2004) 
Soils (ng/g) 
Soils from the outskirts of Beijing 0.05-832.37 Zhu et al. (2005) 
Soils from Pearl River Delta 0.14-231 Li et al. (2006) 
Surface soils in the whole regioin of Tianjin 0.05-348.6 Gong et al. (2004) 
Horticultural soils from New Zealand 5-12900 Gaw et al. (2006) 
Soils from Hong Kong 90-1730 Zhang et al. (2006b) 
Soils from Texas-Mexico border ND-60 Miersma et al. (2003) 
Agricultural soils of Alabama 0.2-112 Hamer et al. (1999) 
Agricultural and garden soils in the US Com 
ND-1600 Aigner et al. (1998) 
Belt 
Sediments (ng/g dry wU 
Sediments from Qiantang River of Zhejiang ND-40.07 Zhou et al. (2006b) 
Sediments from Tonghui River of Beijing 0.11-3.78 Zhang et al. (2004) 
Sediments from estuaries in China 0.95-16.93 Yuan et al. (2001) 
Richardson and 
Surfacial sediments from Hong Kong ND-1.51 
Zheng (1999) 
•Total DDIs; ND: Not Detected. 
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1.2.3 p，p ’ -DDE in human body 
p,p '-DDE can be uptaken by both plants and animals. White and his colleagues 
reported that different plants including crops and vegetables absorbed p，p，-DDE with 
root bioconcentration factors from 0.41 to 16.0 (White, 2002; White et al., 2005). 
Fresh water fishes and marine fishes collected from markets in Hong Kong had 
detectable p’p '-DDE with concentrations from 0.68 to 244 ng/g wet weight (Cheung 
et al., 2007). Through diet, p,p -DDE is accumulated in human fatty tissue; 
p’p，-DDE could be detected highly frequently in human serum, .milk or placenta 
samples. p’p -DDE had a higher concentration on average than other organochlorine 
pesticides in human tissues (Torres et al., 2006). The levels of p,p '-DDE in human 
breast milk and serum are commonly used to reflect the body burden and degree of 
exposure over time in the general population. In many studies, a decreasing trend in 
p,p -DDE concentration was observed in the human breast milk from Swedish 
women from 1972 to 1997 (Figure 1.6) (Noren and Meironyte, 2000). However, in 
China, p’p，-DDE concentration in human breast milk was still as high as 2850 ng/g 
fat in Guangzhou, 2480 ng/g fat in Hong Kong, 2000 ng/g fat in Dalian and 1720 
ng/g fat in Beijing, which were much higher than those of some other developed 
countries, such as Canada, Japan (Wong et al., 2005). This was probably due to the 
presence of DDT as impurity in some pesticides used in China now (Huang et al., 
2000). 
Due to its fat-solubility the biological half life of p’p，-DDE in human was estimated 
to be 8 years based on serum concentrations (Axmon and Rignell-Hydbom, 2006). 
However, a study showed that the main reason leading to the reduction of p,p '-DDE 
concentration in women is thought to be lactation, through which p,p '-DDE is 
delivered to their babies (Soliman et al., 2003). 
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Figure 1.6 Concentrations of p,p '-DDE in Swedish human milk (ng/g) in 1967-1997 
(Noren and Meironyte, 2000). 
1.2.4 p,p,-DDE and reproductive system 
In most studies, researchers tried to make a relationship between organochlorine 
pesticides and abnormalities of reproductive system in human, using case-control 
approaches. High occupational exposure to DDT in three groups of male malaria 
control workers, whose average serum p，p-DDE concentrations were as high as 50, 
82，and 298 |ag/g fat, respectively, increased risk of birth defects when compared 
with low exposure with average serum p 'p-DDE concentrations lower than 39.68 
Hg/g fat (Salazar-Garcia, et al., 2004). Significant difference of p,p '-DDE 
concentrations was found in seminal plasma between fertile and infertile men, as 
7.24+0.46 and 20.29+2.13 |ig/l, respectively, and an elevation in the fructose level 
along with decrease in the y-glutamyl transpeptidase and acid phosphatase activities 
was found in those infertile men (Pant et al.，2004 &2007). Also, p,p '-DDE was 
reported to associate thyroid hormone level changes in men (Meeker et al., 2007). 
However, in other studies on men, no or weak relationship was found between the 
p,p -DDE and thyroid hormone levels, sex hormone levels (Turyk et al., 2006; 
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Dalvie et al., 2004a), seminal markers (Elzanaty et al” 2006), infertility (Dalvie et a l , 
2004a) or sperm quality (Dalvie et al., 2004b). This may be owing to the relatively 
lower p,p -DDE concentrations in these studies, between 50 to 1000 ng/g lipid. In 
female, DDE concentration in serum was much higher in breast cancer patients 
irrespective of age, diet, and geographic distribution, and was at 862+0.154 jig/l and 
47+0.018 |ag/l in patient and control groups, respectively (Mathur et al., 2002; 
Charlier et al., 2003). However, other studies do not support this association 
(Helzlsouer et al., 1999; Wolff et al., 2000; Laden et al., 2001). An increase of fetal 
loss was also reported to be related to the increased concentration of p’p，-DDE, when 
the concentration is up to 60 |ag/l in serum (Torres-Arreola et al., 2003). An 
insignificant increased risk of preterm birth in relation to serum p,p '-DDE levels was 
observed when the p,p '-DDE was between 111.6-228.8 ng/g lipid (Torres-Arreola et 
al., 2003). Lopez-Cervantes et al. (2004) concluded that the contradictory results on 
the relationship between p,p '-DDE and breast cancer risk stem from different 
methodologies adopted in 22 studies. The meta-analysis using DerSimonian and 
Laird's method for random effects models on these 22 studies suggest to discard the 
putative relationship between p,p '-DDE and breast cancer risk. Nevertheless, the 
exposure to SDDT during certain periods of human development might be critical for 
breast cancer risk (Lopez-Cervantes et al., 2004). In a case-control study on 
endometrial cancer patients with the average concentration of 517 ng p,p '-DDE/g 
lipid and that in control with 393 ng/g lipid, Hardell et al. (2004) applied an odds 
ratio to measure the association between endometrial cancer, and the serum 
concentration of p’p '-DDE. For the group with the concentration of p’p，-DDE lower 
than median and never use of estrogen replacement therapy, the ratio was 1.0. The 
group with the concentration of p,p '-DDE lower than median and ever use of 
estrogen replacement therapy was 0.8 (95% confidential interval (CI): 0.2-3.3). The 
group with the concentration of p,p '-DDE higher than median and never use of 
estrogen replacement therapy was 1.6 (95% CI: 0.5-4.8). And the group with the 
concentration of p’p，-DDE higher than median and ever use of estrogen replacement 
therapy was 2.3 (95% CI: 0.6-8.6) (Hardell et al., 2004). Thus, the results indicated 
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an interaction between p’p '-DDE and estrogen replacement drugs in the etiology of 
endometrial cancer (Hardell et al., 2004). In another study, the serum concentrations 
of p,p '-DDE in patients with endometriosis are significantly higher than control 
women, as 770 ng/g fat and 310 ng/g fat, respectively (Quaranta et al., 2006). Also, 
higher concentration of p,p '-DDE is found in women with spontaneous abortion 
(Korrick et al., 2001). Exposure of mothers to DDT and its main metabolite 
p,p'-DDE increased time to pregnancy and decreased fertility in the daughters (Cohn 
et a l , 2003). These evidence supports that medium to high levels of p,p '-DDE are 
responsible at least partially for reproductive anomaly when p,p '-DDE is found in 
high concentrations in both male and female tissues. 
J.2.5 Endocrine disruptor 
In recent years, researchers have voiced concerns about endocrine disruption. 
Accumulating evidence has suggested that many environmental chemicals can alter 
reproduction, growth, and survival by changing the normal function of the endocrine 
system. A new scientific term, endocrine disruptor, entered the scientific lexicon to 
describe these "hormone-like" chemicals that interfere with hormonal signals of an 
organism (Colbom et al., 1993). However, the complexity of the endocrine system 
obstructs the identification of the specific mechanisms through which endocrine 
disrupters elicit their responses. For example, in reproductive system, endocrine 
disrupters may act on different levels, depending on the entire hormone dynamic 
pathway. The secretion of gonadotropin is the first target that may be affected by 
endocrine disrupters. An in vivo study on rat showed that bisphenol A, an estrogenic 
plasticizer, significantly decrease luteinizing hormone (LH) concentration in serum 
(Gharravi et al., 2006). Male workers exposed to bisphenol A diglycidyl ether had 
higher urinary bisphenol A and lower plasma follicle-stimulating hormone (FSH) 
concentration than controls (Hanaoka et al., 2002). Endocrine disrupters can also 
interfere estrogen synthesis by altering the expression and activity of aromatase, 
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which catalyzes the conversion of testosterone to estradiol (Sakimura et al., 2002; 
Taupeau et al., 2003). Hormone transportation and activation may be disrupted too. 
Estrogen sulfotransferase (EST), which transforms estradiol into estradiol sulfate 
before transporting to its target cells through the blood, acts as a molecular switch in 
estrogen target tissues to regulate local estrogen activity (Song, 2001). Hydroxylated 
metabolites of polychlorinated biphenyls (OH-PCB) were reported to be inhibitors of 
EST in in vitro study (Kester et al., 2000). On target cells, endocrine dismptors may 
compete with hormone in binding to receptors on their target cells, acting as an 
agonist that enhances the hormone function or antagonist that inhibits the hormone 
function (Howell, 2006; Bolego et al., 2006). Finally, the signal pathways activated 
by hormones may be disrupted through cross-talk with other pathways which 
respond to endocrine dismptors (Oesterreich et al., 2001). 
Among all endocrine dismptors, xenoestrogen draws most attention. They are 
synthetic compounds that have estrogenic activities, or call estrogenicity, including 
plasticizers, surfactants, constituents of detergents, pesticides, and a variety of other 
chemicals (Soto et al., 1991 & 1995; Smith et al., 1992; Jobling et al., 1995). They 
imitate or enhance the effect of estrogens, and then disrupt the reproductive system. 
These are thought to be the environmental factors/ pollutants that cause the 
increasing human breast cancer risk and decreasing sperm count over the last four 
decades in industrialized countries (Mendez et al., 2003; Lopez-Cervantes et al., 
2004). Vertebrates synthesise steroids via a pathway that involves the sequential 
degradation of cholesterol to progestins, then androgens (e.g. testosterone) and 
finally estrogens (e.g. 17(3-estradiol) (Hanukoglu 1992). This pathway is found in 
both sexes, and circulating plasma concentrations of sex steroids are representative 
of the relative conversion of androgens to estrogens (Hanukoglu 1992). Females 
have elevated plasma estrogens compared with androgens, whereas males have the 
opposite ratio (Hanukoglu 1992). It is the ratio of androgens to estrogens that creates 
a male versus female hormonal milieu (Hanukoglu 1992). In both sexes, androgens 
elicit an antiestrogen effect (Shilling and Williams, 2000). In the presence of DHT, 
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MCF-7 proliferation is inhibited regardless the concentration of E2, which constantly 
induces the proliferation of MCF-7 (Ando et al., 2002). Cell cycle analysis showed 
an increase in number of cells in GO/Gl phase, and androgen receptor expression 
was increased after DHT treatment in another estrogen-receptor and 
androgen-receptor positive breast cancer cell lines, CAMA-1 (Ando et al., 2002). 
Similar results were obtained in an androgen receptor overexpression MCF-7 (Szelei 
et al., 1997) and ZR-75-1 (Poulin et al., 1988). 
Antiandrogens are a group of hormone receptor antagonist compounds which are 
capable of preventing or inhibiting the biologic effects of androgens. Abnormalities 
in male sexual development may be mediated at the level of the androgen receptor 
(Kelce and Wilson, 1997). Even though the serum androgen in female is low, and the 
mechanism to cross-talk to estrogen pathway is unclear, it is essential to regulate the 
female hormone function. The environmental antiandrogens identified exhibit low to 
moderate affinity for AR and act as type I antagonists by preventing AR DNA 
binding (Wong, 1995). These effects may diminish when the serum androgen 
concentration increases (Kelce et al., 1997). So it seems that the presence of a potent 
antiandrogen can create an 'estrogenic environment', thus producing symptoms 
indicative of estrogen exposure. 
1.2.6 Action mechanism of p，p，-DDE on endocrine system 
p,p -DDE has been well accepted as a potent androgen antagonist. It acted as an 
androgen receptor antagonist both in vivo and in vitro (Kelce et al., 1995 & 1997). 
Kelce et al. (1995) found the I C 5 0 of p,p -DDE in androgen receptor competition 
binding assay was 5 |LIM. In Freyberger and Ahr's study, p,p '-DDE had a I C 5 0 of 1.7 
in competition against synthetic androgen R1881 binding to androgen receptor 
(Freyberger and Ahr, 2004). In transient human androgen receptor (hAR) reporter 
gene assay using HepG2 human hepatoma cells and African monkey kidney cell line 
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CV-\,p,p'-DDE inhibited AR-mediated transcriptional activity induced by DHT in a 
concentration-dependent manner (Maness et al., 1998; Xu et al., 2006), and showed 
inability to activate androgen receptor in a yeast reporter gene system at the 
concentration from 100 nM to 1 mM (Gaido et a l , 1997). In vivo, p,p '-DDE was 
shown to decrease testicular weight, seminal vesicle weight, prostate weight, sperm 
count, reduce immunohistochemical staining of AR in epididymal nuclei, induce a 
testosterone-repressed prostatic message (i.e. TRPM-2), and repress a 
testosterone-induced prostatic message (i.e., prostatein subunit C3) in adult rats 
(Kelce et al., 1995 & 1997; Gray et al., 2001; Yamasak et al., 2003). It also delayed 
the reproductive development in pubertal male rats, although the serum concentration 
of testosterone did not change (Kelce et al., 1995). 
Besides, observed perturbations of reproductive functions, including constant estrus, 
lack of ovulation, and uterotrophic response in immature rats are probably induced 
by organochlorine pesticides through binding and activation of the estrogen receptor 
(ER) (Kupfer and Bulger, 1980). Since the risk factors for breast cancer include high 
plasma estrogen levels (Missmer et al., 2004) and high levels of expression of 
estrogen receptors (ERs) in mammary tissue (Kurebayashi et al., 2000; Khan et al., 
2000), the estrogen-like property of p,p '-DDE also draws lots of attention. However, 
the effects of p,p '-DDE on ER pathway is obscure. It had the ability to induce 
proliferation of estrogen-dependent human breast cancer cells in estrogen-depleted 
media and showed additive effects with human endogenous estrogen 17p-estradiol 
(E2). Specific inhibitors of the estrogen receptor, ICI 182,780, completely inhibited 
this effect (Soto et al., 1995; Rasmussen et al” 2003). Also, p,p '-DDE induced the 
expression of endogenous estrogen-upregulated genes, such as pS2 and al-ACT, and 
suppressed the expression of endogenous estrogen-downregulated genes, such as 
MAO-A and TGF|33 (J0rgensen et al” 2000). In vivo study on male mice showed that 
p’p '-DDE induced transfected estrogen-receptor-promoted luciferase activity in most 
estrogen receptor-expressed tissues (Penza et al., 2004). These all indicate that 
p’p '-DDE activates the ER pathway. 
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However, p’p '-DDE shows weak binding affinity to estrogen receptors (Kelce et al., 
1995; Kuiper et al., 1998). In two transformed yeast expression-reporter systems, 
only o,/?'-DDE showed the ability to activate the transformed human estrogen 
receptor, but not p,p '-DDE (Chen et al., 1997). These evidence did not support the 
hypothesis that p,p -DDE activated ER pathway directly through ER and estrogen 
responsive genes with ERE-promoter. Thus Aube et al. (2008) suggested that the 
antiandrogen property of p,p -DDE may contribute to its estrogen-like effect in 
breast cancer cell model. In CAMA-1 breast cancer cells expressing both estrogen 
receptor (ER) a and androgen receptor (AR), whose proliferation was increased by 
estrogens but decreased by androgen, p,/>'-DDE can markedly increase the 
proliferation of CAMA-1 cells in the presence of physiological concentrations of 
estrogens and androgens, but not in the absence of sex steroids in the cell culture 
medium (Aube et al., 2008). Yet this hypothesis cannot fully explain the significantly 
increased proliferation of wild-type MCF-7, which bore lower expression of AR than 
those transfected ones, by p’p '-DDE under the condition of steroids depletion and the 
activation of transfected estrogen-receptor-promoted luciferase activity in most 
estrogen receptor-expressed tissues in vivo (Soto et al., 1995; Rasmussen et al., 2003; 
Penza et a l , 2004). 
1.2.7 Apoptosis 
In E-screen, estrogenic compounds increase the proliferation of MCF-7. However, 
apoptosis, which is one of the main types of programmed cell death, is another 
process that may affect the cell number in such an assay system. The B-cell 
lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and p53 are proteins reported 
to involve in apoptosis (Cory and Adams, 2002; Vousden and Lu, 2002). Bcl-2 and 
Bax are the prototypes for a family of mammalian genes, Bcl-2 gene family, and the 
proteins they produce. They govern mitochondrial outer membrane permeabilization 
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(MOMP) and can be either pro-apoptotic (such as Bax) or anti-apoptotic (such as 
Bcl-2) (Cory and Adams, 2002). BAX is believed to interact with, and induce the 
opening of the mitochondrial voltage-dependent anion channel (VDAC) (Oltval et al., 
1993). Alternatively, growing evidence suggests that activated Bax proteins form an 
oligomeric pore, the mitochondrial apoptosis-induced channel (MAC) in the outer 
membrane (Oltval et al., 1993). This results in the release of cytochrome c and other 
pro-apoptotic factors from the mitochondria, leading to activation of caspases (Oltval 
et al., 1993). In contrast, Bcl-2 would block apoptosis, possibly through inhibition of 
Bax, when it inhibits plasma membrane blebbing, nuclear condensation and DNA 
endonucleolytic cleavage all of which are classical characteristics of programmed 
cell death after its overexpression (Hockenbery et al., 1990; Zamzami et al., 1998). 
p53, a tumor suppressor gene located on the short arm of chromosome 17, is an 
important component of cellular machinery which responds to genotoxic stresses 
particularly DNA damage (MacDonald and Ford, 1997). Double-stranded breaks 
formed by y-irradiation and DNA-repair intermediates formed by UV irradiation of 
DNA damage raise p53 levels (Cui et al., 2007). p53 protein is primarily located in 
nucleus but can be detected in cytoplasm in G1 cells and cells after DNA synthesis 
(Vousden and Lu, 2002). It maintains genomic integrity by arresting the cell cycle or 
by inducing apoptosis (Ko and Prives, 1996; Levine, 1997). Up-regulation of Bax is 
one of the events whereby p53 induces apoptosis. Bax gene is known to be 
transcriptionally regulated by p53 during induction of apoptosis (Miyashita and Reed, 
1995). p53 may mediate down-regulation of Bcl-2 by binding to silent Bcl-2 (Haldar 
et al., 1994). Estrogen was found to be able to up-regulate Bcl-2 expression in 
MCF-7 cells, and inhibits apoptosis in mammary gland and breast cancer cell MCF-7 
which expresses functional estrogen receptor by an increase of Bcl-2 mRNA level 
(Kyprianou et a l , 1991; Teixeira et al., 1995，Perillo et al., 2000). However, the 
effect of p’p，-DDE on apoptotic genes has not been investigated. 
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1.3 Food therapy against endocrine disruption 
1.3.1 Food therapy and functional food 
Food therapy is a practice of healing using natural foods instead of medications. 
“Medicine and food are of the same sauce", the Yellow Emperor's Classic of Internal 
Medicine says (Neijing, 300 BC). Chinese food therapy is a modality of traditional 
Chinese medicine. As early as Chinese discovered fanning and agriculture, they 
discovered the medicinal properties of food, and food has been studied and analyzed 
for its medicinal effects on people. Throughout Chinese history, people used their 
own resources to find cures because most people could not afford being sick. This 
knowledge enables people to use food as the first line of defense to ward off common 
sicknesses and diseases. This is why preventive healthcare is so popular in China. It 
is particularly popular among Cantonese people who enjoy slow-cooked soups. Food 
therapy items are usually slowly cooked in water for couple of hours as a type of hot 
water extraction. A mixture of ingredients is dissolved into a soup, which is believed 
to benefit the balance of human body and prevent diseases; The traditional Chinese 
medicine is usually prepared in ‘chai’ (tea or more accurately as hot water extract). 
This kind of soups is also used to strengthen the body against diseases, improve body 
health, treat diseases and/or help recovery from a suffering after medical treatments. 
Some recipes are believed to provide nutrients, resources including energy as well as 
activating the immune systems with the maintenance or regain of homeostasis. 
In this view, these foods not only supply the basic nutrition, but also have a 
health-promoting and disease-preventing property. The term "functional foods" was 
first introduced in Japan in the mid-1980s and refers to processed foods containing 
ingredients that aid specific body functions, in addition to being nutritious. Currently, 
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there is no universally accepted definition for functional foods. A variety of terms 
have also appeared world-wide such as nutraceuticals, medifoods, vitafoods and the 
more traditional dietary supplements and fortified foods. However, the term 
"functional foods" has become the predominant one even though several 
organizations have attempted to differentiate this emerging food category. Health 
Canada, for instance, defines a functional food as "similar in appearance to a 
conventional food, consumed as part of the usual diet, with demonstrated 
physiological benefits, and/or to reduce the risk of chronic diseases beyond basic 
nutritional functions" and a nutraceutical as "a product isolated or purified from 
foods that is generally sold in medicinal forms not usually associated with foods 
(Health Canada website: http://hc-sc.gc.ca). The Institute of Medicine of the U.S. 
National Academy of Sciences has defined functional foods as those that 'encompass 
potentially healthful products," including "any modified food or food ingredient that 
may provide a health benefit beyond the traditional nutrients it contains" (Hasler, 
1996). In Korea, functional foods are defined as dietary supplement whose purpose is 
to supplement the normal diet and have to be marketed in measured doses, such as 
pills (Kim et al, 2006). In a word, functional foods are generally considered as those 
foods which are intended to be consumed as part of the normal diet and that contain 
biologically active components which offer the potential of enhanced health or 
reduced risk of disease. Examples of functional foods include foods that contain 
specific minerals, vitamins, fatty acids or dietary fibre, foods with added biologically 
active substances such as phytochemicals or other antioxidants and probiotics that 
have live beneficial. According to this definition, unmodified whole foods such as 
fruits and vegetables represent the simplest form of a functional food. For example, 
broccoli, carrots, or tomatoes would be considered functional foods because they are 
rich in such physiologically active components as sulforaphane, P-carotene, and 
lycopene, respectively. In Hong Kong, China and USA, 'dietary supplements' which 
are of legal status, are used to include the products which are edible and provide 
health benefits while these products are consumed as supplementary to the normal 
diet. 
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People are faced with a number of major health challenges arising from aging and 
lifestyle diseases. A recent report estimates a saving of 20% per year to health care 
expenditures through consumption of functional foods (Hasler, 1996; Holub, 2002). 
Thus, the world market for functional foods and beverages is growing steadily each 
year, with annual growth rate estimates varying between 8% and 14% (Verbeke et al., 
2007). This trend is likely to continue since the effects of lifestyle diseases create 
greater demand for food products targeting health and wellness (Verbeke et al., 2007). 
As a result, developing countries have started to emerge as active ingredients 
exporters to cater for the increasing demand in the developed countries (Williams et 
al., 2006). Moreover, demand for functional foods within the developing countries is 
also growing. For instance, India, with its strong tradition of eating healthy foods, 
ranks among the top ten nations in buying functional foods and the market is 
expected to continually expand (Ismail, 2006). 
Do the functional foods really benefit human health? Epidemiological, experimental 
and clinical studies have shown some evidence. Certain types of food, such as fruit, 
vegetable and green tea, can affect a variety of body functions and provide health 
benefits. Fruit and vegetable intake is associated with low risk of breast cancer in a 
group of Norwegian women (Engeset et a l , 2009), low risk of colorectal adenomas 
(Wu et al., 2009) and also other cancers (Takachi et al, 2007, Nothlings et al., 2007a). 
Other diseases, such as cardiovascular disease, are also reported to be associated with 
low consumption of fruit and vegetable (Liu et al., 2000; Takachi et al, 2007). 
Specific food components, such as antioxidants (Bjelakovic et al., 2007), vitamins 
(Perez-Lopez, 2007), fatty acids (Arendash et a l , 2007) and flavanoids (Lin et al” 
2007; Nothlings et al” 2007b), which are considered to benefit in the prevention of 
cancers, cardiovascular diseases, diabetes, bone diseases, obesity and other diseases, 
also draw lots of attention. However, although some researches supported the 
positive effect of functional foods, the others did not (Arendash et al., 2007; Vrieling 
et al., 2009; Thiebaut et al., 2009). A recent study called for a careful reconsideration 
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of fortification programs, since adding folic acid to the diet may benefit some 
consumers but cause damage to others (Kim, 2007). The absence of unequivocal 
evidence supporting diet-disease relationships poses a challenge for the public to 
place their faith in nutritional messages. 
Thus, foods designated as "functional" and ascribed specific health benefits should 
receive scientific scrutiny before specific health claims are permitted. In countries 
with a rich cultural tradition of belief in the health-enhancing properties of various 
foods and food components, many foods are associated with specific health claims 
but may not have scientific documentation to parallel the long-standing experience 
with these foods, especially for the eastern functional food. There is clearly a 
difference between the Western perspective on functional foods and the Eastern 
perspective. In the West, functional foods are viewed as revolution and represent a 
fast growing segment of the food industry. Food companies, drug companies, 
chemical companies and boutique companies arising from grass-roots research and 
development efforts are all racing to bring functional foods to market. In the Eastern 
countries, in contrast, functional foods have been a part of the culture for centuries. 
In Traditional Chinese Medicine, foods that have medicinal effects have been 
documented since at least 1000 BC. Communication of Chinese medicine and 
pharmacology to India and Vietnam took place as early as the Han Dynasty (before 
AD 24) (Dai and Luo, 1996). The Chinese foods have both preventive and 
therapeutic effects and are an integral part of health maintenance. This philosophy is 
now being increasingly recognized around the world (Shi, 2005). In China, there are 
an estimated 3000 varieties of so-called functional food products in the market, and 
the total annual sales of such foods amount to about US$6 billion (Report on 
Functional Foods, November 2007, Food and Agriculture Organization of the United 
Nations (FAO)). Most of the functional foods in China are based on Traditional 
Chinese Medicine (Table 1.3, Dai and Luo, 1996). However, in most cases, the 
experimental evidence for the safety and efficacy, the active compounds and the 
action mechanisms of these foods are weak (Dai and Luo, 1996). Understanding the 
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functions of Chinese functional foods, which were defined by Traditional Chinese 
Medicine, with Western medicine theories, needs a connective theory between them. 
Even though Chinese researches have put lots of efforts on it (Wang et al., 2008a), it 
is still a long way to go. 
H 
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Table 1.3 Examples of foods used in the prevention and treatment of diseases in 
Traditional Chinese Medicine and pharmacology (Dai and Luo, 1996). 
Foods of animal origin 
Honey Musk Hippocampus 
Polyrhachis vidua Roger Edible fat of milk Turtle, softshelled 
Chevr., egg shell of mantis Placenta hominis Chicken 
Oyster Human milk Black bone chicken 
Shell of abalone Mussel Deer embryo and placenta 
Carp Bomhyx mori Bezoar 
Shell of tortoise Martians dermestoides Mutton 
Snake Stichopus japanicus Human saliva 
Swallow's nest Pearl Yogurt (cow or horse) 
Deer hom antler Sea clam 
Foods of plant origin 
Ganoderma Lotus root Pollen 
Auhcularia Mung bean Glycine max 
Lily Cornus officinalis Black sesame 
Allium macrostemon Juglans regpia Euryale ferox Salisb. 
Yam Peach Hylotelephium erythrostictum 
Morus alba Pea Prunus persica 
Almond Coriander Panax quinquefolium 
Chinese jujubee Kiwi fruit Water chestnut 
Apocynum venetum Portulaca oleracea 
Job' tears Benincasa hispida Castanea 
Garlic Rhubarb Banana 
Haw Poria cocos Buckwheat 
Grapes Lentinus Calabash 
Lotus seed pine nut Broad bean 
Cinnamomum cassia Presi Allium tuberosum Tea 
Polygonum multiflorum Dendrobium nobile Celery 
Panax ginseng Alpinia oxyphylla Wheat 
Trapa bispinosa Cannabis sativa Com 
Litchi Sphora japonica Shepherd's purse 
Sonchius oleraceus Ziziphus spinosa Euphoria longan 
Persimmon Cordyceps Lycium barbarumi 
Watermelon Ginger 
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1.3.2 Ganoderma as a Functional food 
The functions of Ganoderma spp. as medicine have been introduced in section 1.1.2. 
Ganoderma spp. are also a famous functional food. Lots of commercial products 
including spores, fruiting bodies, mycelia, and mixtures of them packed as capsules 
or tea bags are sold in stores. The most common method to cook Ganoderma spp. is 
to boil dry pieces of fruiting bodies and other supplement foods in water with slow 
fire for several hours, even though some people also make tea with hot water or 
make wine with rice wine. The Chinese believe that different recipes for Ganoderma 
spp. cooking can make different soups that give different benefits to human health. 
For example, Ganoderma spp. cooked with pettitoes can smooth skin, reduce 
wrinkles and prevent aging. When cooked with pork and baishu (rhizoma 
Atractylodis Macrocephalae), Ganoderma can protect liver. When prepared with 
chicken, the ‘chai’ helps to recover from disease or surgery, and cooked with pigeon 
can cure insomnia, and so on (Cultivation and Medicinal Use of Ling-Chih Herb, 
1976). It seems that Ganoderma spp. not only have medical functions on multiple 
diseases but also serve as functional food in daily life. The advantages include not 
only their multiple functions, but also the low adverse effect to human health, which 
are both proved in Chinese medicine with lingzhi as a superior category for daily 
consumption (Cultivation and Medicinal Use of Ling-Chih Herb, 1976). That is why 
it can be taken daily as food, which is not like the other medicines with more or less 
toxicity. Thus, prevention of diseases by Ganoderma spp. becomes possible under 
the guideline of Chinese medicine and the evidence in the modem medicine. 
1.3.3 Cancer prevention by dietary agents 
Substantial attention has been given to primary cancer prevention in daily life. 
Dietary factors are thought to contribute to as much as one-third of the factors 
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influencing the development of cancer (Ovesna et al., 2004). And it is estimated that 
nearly one-third of all cancer deaths in the United States might be prevented through 
appropriate dietary modification (Khan et al., 2008). Thus cancer prevention by 
dietary agents is worth more attention. Dietary agents can act at various stages of 
tumor development, including inhibition of tumorigenesis, inhibition of tumor 
promotion, induction of cell differentiation, and inhibition of invasion and metastasis 
without causing any toxicity (Khan et al., 2008; Ovesna et al., 2004). Those dietary 
agents, including antioxidants, catechins, polyphenols, stilbenoids, lignans, and 
triterpenes, mostly come from dietary vegetables, Chinese medicines, olive oil, fruits, 
green tea, and so on (Zhou, 1991; Ovesna et al., 2004; Seeram et al., 2008; Sotiroudis 
and Kyrtopoulos, 2008; Khan et al., 2008; Syed et al., 2008). Various dietary 
antioxidants have proved as effective agents for cancer prevention by reducing 
oxidative stress which has been implicated in the development of many diseases, 
including cancer (Khan et al., 2008). In general, other compounds prevent cancer 
mainly through causing cell cycle arrest, inducing apoptosis, inhibition of invasion, 
angiogenesis, and metastasis (Syed et al., 2008). Moreover, these dietary agents also 
benefit the prevention of hormone-relative diseases including cancer of the sex 
organs through hormone-related pathways, such as inhibition of 5a-reductase, which 
transforms testosterone into a more effective form DHT, in prostate cancer (Liu et al., 
2006a & b; Syed et al., 2008). 
1.3.4 Hormone therapy 
Hormone therapy is very common in aging and hormone-related cancer. With aging, 
the hormone level in both women and men are reducing to such extent that 
osteoporosis may be resulted. A supplementary low dose of estrogen, progesterone 
and testosterone may prevent discomfort caused by diminished circulating hormones, 
such as hot flashes, irregular menstruation, fat redistribution, etc. (Boothby et al., 
2004). Hormone therapy is one of the major medical treatments for hormone-related 
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cancers, such as breast cancer, endometrial cancer and prostate cancer. It manipulates 
the endocrine system through exogenous administration of specific hormones to 
inhibit the production or activity of such hormones, which can cause the cease of 
certain cancer growth and furthermore cancer cell death. For hormone-related 
cancers, hormone therapy has several targets. Aromatase inhibitors, such as letrozole 
and anastrozole, are used for breast cancer in postmenopausal women. At menopause, 
estrogen production in the ovaries stops, but other tissues continue to produce 
estrogen by aromatase from androgens. Thus aromatase inhibitors can keep the 
estrogen at an extremely low level, which inhibits the growth of estrogen-responsive 
cancers (Brodie et al., 2009). Analogs of gonadotropin-releasing hormone (GnRH), 
such as leuprolide and goserelin, can be used to suppress the production of estrogen 
and progesterone from the female ovaries or suppress the production of testosterone 
from the male testes through a negative feedback effect (Schally, 2008). 
Antiandrogens, such as fluamide and bicalutamide, bind and inhibit the androgen 
receptor, blocking the growth- and survival-promoting effects of testosterone on 
certain prostate cancers (Matthews, 2007). Selective estrogen receptor modulators 
(SERMs)，such as tamoxifen, are another class of hormonal therapy agents which act 
as antagonists of the estrogen receptor and are used primarily for the treatment and 
chemoprevention of breast cancer. In history, androgens also used as hormone 
therapy agents for breast cancer. Poulin et al. (1989) proposed a beneficial effect of 
androgen therapy due to a reduction in ER levels, and Ingle et al. (1991) suggested 
that treatment with tamoxifen and the androgen fluoxymesterone provided a survival 
advantage over tamoxifen alone. However, the side effects of these synthetic 
hormones include hot flashes, osteoporosis, fatigue, sexual dysfunction, anemia, and 
so on (Matthews, 2007), have drawn as much concern as their medical value. For 
example, in menopause women, low estrogen level may cause osteoporosis. To 
prevent breast cancer, estrogen level can be lowered by aromatase inhibitors, analogs 
of gonadotropin-releasing hormone or SERMs, which unfortunately may increase the 
risk of osteoporosis. Sometimes, synthetic hormone is modified to reduce side effects, 
such as raloxifene, which is designed against tamoxifen to prevent osteoporosis as 
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well as reduce the incidence of breast cancer in postmenopausal women, since it has 
estrogenic actions on bone and antiestrogenic actions on the uterus and breast (Vogel 
et al., 2006). However, patients are easy to get problems from overdose in hormone 
therapy before they know the optimal doses for them (Greil et al., 2009). Thus, 
although the efficacy of synthetic hormones makes them popular in medical cancer 
treatments, it may not be a good choice to apply them in the prevention of 
hormone-related cancers for normal people. 
1.3.5 Hormone-related properties of Ganoderma spp.. 
Two major groups of active components of Ganoderma spp. are polysaccharides 
and triterpenes (Paterson, 2006). The anticancer effects of polysaccharides have been 
intensively explained due to the antioxidation and immunomodulation properties 
(Wang et al., 1997; Lai et al., 2006). Also the effects of triterpenes were mainly 
described as cancer cell cycle arrest and induction of cancer cell apoptosis (Min et al., 
2000; Gao et al., 2002; Lin et al., 2003; Li et al., 2005; Chang et al., 2006; Tang et al., 
2006; Hsu, et al., 2008; Jiang et al., 2008; Yue et al., 2008). However, among these 
numerous studies, the hormone properties of Ganoderma extracts were occasionally 
reported. Zaidman et al. (2007 & 2008) found that acetate extract of G. lucidum can 
reduce DHT-induced androgen receptor transcription in cancer cell models. 
Triterpenes isolated from G lucidum were reported to inhibit 5a-reductase, which is 
one of the pharmacological strategies for the hormone treatment of prostate cancer 
(Liu et al., 2006a & b). Antiandrogen property of triterpene, ganoderol B, from G 
lucidum is also proved by its binding to AR and suppression of AR pathways in vitro 
and in vivo (Liu, et al., 2007). On the contrary, a clinical study showed that 
Ganoderma spore preparation notably elevated the blood androgen level in aging 
males with partial androgen deficiency, without the side effects of synthetic androgen 
on the cardiovascular system (Peng et a l , 2006). It seems that the hormone effects of 
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Ganoderma are ambiguous and really dependent on the sample preparation and the 
tested model. Also, even though the hormone-like components of Ganoderma is 
considered to be triterpenes, these are a mixture of different compounds which may 
exert different hormone effects individually and in combination. 
1.4 The aim of the study 
This study aim to further investigate the effects of Ganoderma extracts and 
p,p -DDE on hormone-relative pathways, and test the feasibility of the hot-water 
extract of G. tsugae prepared from the vegetative mycelial stage to reverse the 
adverse effects of p,p -DDE in the breast cancer cell model. The project objectives 
include 1) analysing and comparing the properties of two cultivated Ganoderma 
species; 2) examining the hormonal capacities of selected Ganoderma sample using 
steroid receptor assays and the ERa-, ERP- and AR-positive breast cancer cell, 
MCF-7, in steroid-depleted environment as a model; 3) investigating the endocrine 
disrupting effects of p,p -DDE were also studied with the same assays and cell model; 
4) comparing the combination treatment by both water extract and p,p '-DDE with 
their individual effects in the analysis of breast cancer cell proliferation, 
hormone-relative gene expression, cell cycle, and DNA damage; 5) measuring the 
overall differential profiles of transduction signaling of MCF-7 under the treatments 
of water extract of GT2, p,p，-DDE and two natural hormone as positive control using 
microarray assay. The results may give a new view to understand the prevention or 
cure effect of Ganoderma spp. on breast cancer, as well as its potential to regulate 
the human endocrine system. It is also hoped to elucidate the relationships among 
p,p '-DDE, receptors, genes and breast cancer cell proliferation. Whether the water 
extract is able to reverse the adverse effects of p,p '-DDE in the breast cancer cell 
model is wished to reveal in the combination treatments. 
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2 Materials and methods 
2,1 Ganoderma samples 
Ganoderma tsugae strain GT 2 (GT2) was a conventional hybrid between a Japanese 
cultivar and a Chinese parent from province Hebei, China, and G. lucidum strain 
TPW (GLTPW) was a wild isolate from Tai Pang Wan, province Guangdong, China. 
Commercial lingzhi spore products were collected from markets in Hong Kong 
(Table 2.1). 
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Table 2.1 Commercial Ganoderma (lingzhi) spore products used in the present study. 
Code Commercial Product 
Broken spore products 
1 2036 Ganoderma Sporo-Pollen 
2 Natural Square Lingzhi Spore-Pollen 
3 Yee Yan Tong Ganoderma Sporo-pollen 
4 Herbs Ganoderma Spore-Pollen (Fully Wall-broken) 
5 Royal Medic Broken Ganoderma Spore 
6 Organic Wayon Ganoderma Lucidum Spore Capsule 
7 Arashi Kuni Dual-Brokerage Ganoderma Spores 
Lingzhi Master Completely Sporoderm-Broken Germinating Spore of 
8 
Ganoderma 
Wai Yuen Tong Celestial Herb Ganoderma Lucidum Spores (Completely 
10 
Wall-Broken) 
11 Eu Yan Sang Extra Strength Lingzhi Cracked Spores 
12 NutriGreen Lingzhi Formula 
13 Suzhong No.l Ganoderma Lucidum* 
01 Health Bank Lingzhi Spores 100% Shell Broken 
02 Vita-CM Pure Lingzhi Spores 
03 Opal Health Ganoderma Sporo-Pollen (Fully Wall-broken) 
04 Cupal Lingzhi Spore 
05 Suzhong No.l Lucidum* 
Lingzhi spore oil products 
9 DBS Ganoderma Spore Lipid 
31 Lingzhi Master Ganoderma Spore Bioactive Lipid 
32 2036 G Spore Lipids DHA 
33 Yee Yan Tong Ganoderma Spore Lipids 
* Sample No. 05 is from the same sample brand as No. 13 but different year. 
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2.2 Artificial cultivation of Ganoderma spp 
Strains GT2 and GLTPW were maintained in potato dextrose agar (PDA, CM 
514092, International Laboratory USA, San Bruno, CA, USA) plates at 28�C in 
darkness. Mycelia were submerged fermented in fermentator (Bench-Top Fermentor 
B. Braun Model BiostatB Basic, B. Braun Biotech, Melsungen, Germany) with a 
working volume of 5 liters. Mushroom complete medium (CM) consisted of 0.05% 
MgS04.7H20 (302，Ajax Chemicals, Auburn, Australia), 0.046% KH2PO4 (391, Ajax 
Chemicals, Auburn, Australia), 0.1% K2HPO4 (7758-11-4, Fluka & Riedel-de Haen, 
Seelze, Germany), 0.2% bacteriological peptone (MC 24, Lab M, Bury, UK), 0.2% 
yeast extract powder (MC 1, Lab M, Bury, UK) and 2% g D-glucose (Prod 101174Y, 
BDH, Poole, UK) was used (Raper and Miles, 1958). The working conditions were: 
temperature, 28 °C; agitation speed, 200 rpm and the inoculum rate, 80 ml/1 and air 
flow rate 2 1/min. Mycelia were harvested after 5 day incubation, washed with 
distilled water, freeze dried and stored in a drying cabinet. Fruit bodies were cultured 
in the mushroom cultivation complex, Department of Biology, The Chinese 
University of Hong Kong (CUHK). Compost for fruiting consisted of 60% sawdust, 
20% milled coconut fibre, 14% wheat bran, 5% sucrose and 1% lime (Luk, 2005). 
Sawdust, milled coconut fibre, wheat bran, sucrose (agricultural grade) and lime 
were from markets in Hong Kong, China. Mycelial running was carried out with an 
incubator (TV80UL, S/N 223031, Memmert, Schwabach, Germany) at 2 8 � C in 
darkness. The compost bag was then transferred to a fruiting environmental chamber 
in the mushroom cultivation complex in CUHK after it was completely colonized. 
Basidiomes were induced by a photoperiod of 12 h light 12 h dark, incubation at 28 
and relative humidity of 85%. 
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2,3 Molecular identification of Ganoderma spp. 
The identities of the species were confirmed by analyses of nuclear ribosomal DNA 
repeat (ITS 1, 5.8S and ITS2) and mitochondrial small subunit of ribosomal DNA 
(Mt-SSU-rDNA) (Cheung, 2001). Primers were ITSl: TCCTCCGCTTATTG 
ATATGC and ITS2: GGAAGTAAAAGTCGTAACAAGG for ITS (White et a l , 
1990; Chiu et a l , 1996), MSI: CAGCAGTCAAGAATATTAGTCAATG and MS2: 
GCGGATTATCGAATTAAATAAC for Mt-SSU-rDNA (White et al., 1990; Cheung, 
2001). 
2.3.1 Extraction of genomic DNA 
Genomic DNAs of Ganoderma samples were extracted using DNA extraction kit of 
NucleoSpin® Plant (740570250, Macherey & Nagel, Diiren, Germany) and protocol 
was provided by supplier. About 100 mg of each sample were weighed. Then 200 |il 
cell lysis buffer CI were added. The samples were homogenized and vortex mixed 
briefly. The mixture was incubated at 60°C for 30 minutes followed by centrifugation 
at 14,000 X g for 5 minutes. The clear lysate was collected, and 300 |il buffer C4 
premixed with 200 |il ethanol was added to each sample. Then the mixture was 
loaded to a new tube with NucleoSpin® Filter column and was brought to 
centrifugation for 1 minute at 14,000 x g. The flow-through was discarded. This step 
was repeated until all the lysate has passed through the column. Then, 400 \i\ buffer 
CW was added to the column followed by centrifugation for 1 minute at 14,000 x g. 
Flow-through was discarded. Next, 700 |il buffer C5 was added to the column and 
centrifuged for 1 minute at 14,000 x g and flow-through was discarded. Another 200 
buffer C5 was added to the column again, and the whole tube was brought for 
centrifugation at 14,000 x g for 2 minutes in order to remove buffer C5 completely 
and dry the residue on the silica membrane of the column. The column was then 
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placed into a new 1.5 ml centrifuge tube and 100 yd elution buffer CE, which was 
preheated to 70 was transferred onto the membrane of the column. The tube was 
incubated at room temperature for 5 minutes. After the incubation, the tube was 
centrifuged for 1 minute at 14,000 x g for elution of the DNA. 
2.3.2 Gene-specific polymerase chain reaction (PCR) 
A 10 jil of reaction mixture containing IX Reaction Buffer, 3.5 mM MgCb, 0.25U 
Taq DNA polymerase (Thermoprime Plus, 10342-020, Invitrogen, Carlsbad. CA, 
USA), 0.2 mM each dNTP (99216-99219, Invitrogen, Carlsbad. CA, USA), 0.5 ^M 
each primer, about 300 ng DNA and ultra pure water were prepared. The thermal 
program for ITS consisted of 94�C for 2 min, 36 cycles of 95�C for 1 min, 56�C for 1 
min and 72°C for 2 min, followed by 72°C for 10 min with the use of thermal cycler 
(PTC-IOOTM，16921, MJ Research, Inc., Watertown, MA, USA) (Chiu et al., 1996; 
White et al., 1990). The thermal program for Mt-SSU-rDNA consisted of 94°C for 2 
min, 39 cycles of 95�C for 2 min, 58�C for 1 min and 72�C for 2 min, followed by 
72°C for 10 min (Cheung, 2001). 
2.33 Gel electrophoresis 
1.5% agarose gel was set. 1.5 g of agarose (15510-027, Invitrogen, Carlsbad. CA, 
USA) dissolved in 100 ml of Ix TAE buffer (0912 406, Amresco, Hong Kong), Then, 
1 of each PCR sample was mixed with 1 loading buffer (30% Glycerol, 0.25% 
Bromophenol Blue, 0.25% Xylene Cyanole, #R0611，Fermentas, Glen Bumie, MD, 
US). Samples were loaded into wells of the solidified gel. 1 jjj of DNA size marker 
(GeneRuler™ lOObp DNA Ladder Plus ready-to-use, #SM0321, Fermentas, Glen 
Bumie, MD, US) mixed with 1 |j,l loading buffer was run in parallel. They were 
allowed to run at llOV for 30 minutes. DNA was visualized using ethidium bromide 
staining. Gel image was captured using a gel documentation system (Gel Doc EQ 
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System, 170-8060, Bio-Rad, Segrate, Italy). 
2.3.4 Purification of PCR amplified product for sequencing 
PCR product band from ethidium bromide-stained agarose gel was excised using a 
razor blade under 310 nm UV exposure. Then DNA eluted from agarose gel was 
purified using GENECLEAN® SPIN Kit (1101-600, Q-Bio gene, Montreal, Canada). 
400 of the suspended GENECLEAN® SPIN GLASSMILK for adsorbing DNA 
was transferred to GENECLEAN® SPIN Filter. Then the excised agarose block was 
cut and put into the spin filter, and the setup was incubated at 55°C for 5 min with 
inversion at 1 minute interval. The spin filter was brought to centrifugation at 14,000 
X g for 1 min. Flow-through was discarded and 500 |il of NEW Wash from the kit 
were added to the filter, then centrifuged for another 30 seconds and flow-through 
was discarded again. The pellet was dried after spinning for 2 more minutes at 
14,000 X g. The filter was then transferred to a fresh catch tube. Then 8 |a,l elution 
solution was added to the filter, and the tube was gently shaken. In order to elute out 
the DNA, the tube was spun for 30 seconds and another 4 p.1 elution solution was 
added to improve the recovery efficiency. Afterwards it was spun down for 30 
seconds again, and the filter was then discarded and purified DNA was collected. 
Products were resolved by 1.5% agarose gel electrophoresis, and images were 
captured using the gel documentation system. 
2.3.5 Cycle-sequencing 
A cycle sequencing mixture consisting of 1 jil ITS3 primer (CATCGATGAAG 
AACGCAGC, a primer between ITSl and ITS2, White et al., 1990; Cookson et al., 
2000; Lai, 2008), 4 i^l dRhodamine Terminator (a set of dye terminators, four ddNTP 
labelled with different dyes, 403042, Applied Biosystems, Foster City, CA, USA) 
57 
Chapter 2 Materials and methods 
and purified DNA template was adjusted to a final volume of 10 by ultra pure 
water. The thermal profile was: 25 cycles of DNA denaturation at 96°C for 15 s, 
annealing at 50°C for 5 s and extension at 60°C for 4 min by a thermal cycler 
PTC-IOOTM. 
2.3.6 Sequencing 
The cycle-sequencing products were precipitated by 26 |al of 95% ethanol with 3 M 
sodium acetate (pH 5.2) (S-8625, Sigma-Aldrich, St. Louis, MO, USA) in 0.6 ml 
PGR tube in ice for 15 minutes. Then the mixture was centrifuged at 14,000 x g for 
25 minutes. The supernatant was discarded after centrifugation. The pellet was 
washed with 200 |j,l 70% ethanol. The mixture was then vortex mixed and 
centrifuged at 14,000 x g for 20 minutes. Supernatant was discarded again, and the 
pellet was vacuum dried for 2 minutes. Then 12 |il Hi-Dye Formamide (4311320, 
Applied Biosystems, Foster City, CA, USA) were added to each tube to dissolve the 
pellet. The pellet was resuspended by vortex mixing, followed by spinning down. 
The mixture was then denatured at 95�C for 2 minutes using thermal cycler 
PTC-IOOTM. After the denaturing step, the tubes were placed in ice immediately 
for 5 minutes to prevent fusion of DNA strands. The mixture was centrifuged, and 
the supernatant was pipetted out into a plate for ABI Prism 3100 Genetic Analyser 
(Applied Biosystems, Foster City, CA, USA). DNA was sequenced by ABI Prism 
3100 Genetic Analyser. 
2.3.7 Sequence analysis 
The sequence generated by the ABI Prism 3100 Genetic Analyser was processed by 
the software Sequencing Analysis version 3.0 (Applied Biosystems, Foster City, CA, 
USA). ITS2 fragments of GT2 and GLTPW were aligned by free web-based program 
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ClustalW (http://www.ebi.ac.ukyTools/clustalw2/index.htmn. 
2,4 Chemical analyses of Ganoderma spp 
Fresh mycelia were washed by distilled water twice, freeze-dried and crushed into 
fine powders. Fruit bodies were freeze-dried and ground into fine powders by 
sterilized mortar and pestle in liquid nitrogen. Water extracts were prepared by 
incubating 0.1 g sample in 1 ml ultra pure water at 121°C and 1 kPa pressure. Water 
extracts of commercial lingzhi spore powder samples were extracted by incubating 
0.1 g sample in 1 ml ultra pure water at 3 7 � C with shaking for 4 h. Spore oil and 
other oil samples were extracted by incubating 0.1 g samples in 1 ml 5 mM 
hydroxypropyl-p-cyclodextrin (56332, Fluka & Riedel-de Haen, Seelze, Germany) at 
3 7 � C with shaking for 4 h. 
2.4.1 Polysaccharide preparations 
Total water-soluble polysaccharides in water extracts were determined. Water-
soluble alcohol-insoluble polysaccharides were precipitated from water extracts by 
96% ethanol (prepared by 100% ethanol, HPLC, ETOOl52500, Scharlau, Sentmenat, 
Spain) and centrifuged at 14,000 x g for 15 min (Luk, 2005). Pellet was dried and 
redissolved in ultra pure water. Polysaccharide contents were determined by anthrone 
method (Loewus, 1952). One ml of anthrone solution (0.1 g anthrone (10740, Fluka 
& Riedel-de Haen, Seelze, Germany) dissolved in 100 ml 76% H2SO4 (10276，BDH, 
Poole, UK)) was added to 0.1 ml samples. The solution was heated at 100�C for 15 
min for acid hydrolysis. The mixture was cooled to room temperature, and the 
absorbance was measured at 620 nm. Polysaccharide was expressed as 
D-glucose-equivalent units using a series of D-glucose solution as standard. 
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2.4.2 Terpene profile 
0.1 g mycelia, fruit bodies or spore samples were saponified with 0.5 ml saturated 
aqueous KOH (P564060, Fisher Scientific, Loughborough, UK). Then 8 ml of 100% 
ethanol were added to each sample in a screw-capped tube followed by incubation 
with rotation at 10 rpm at 85°C for 30 minutes. The unsaponificable matter was 
extracted with 20 ml hexane (15249, BDH, Poole, UK). Then the solutions were 
diluted with 12 ml water and shaken at 200 rpm for 1 h. The hexane extracts were 
collected and rotary dried. The dried extracts were weighed, resuspended in 1 ml 
diethyl ether (HPCL grade, A3509S, LAB-SCAN, Ireland) and analysed by 
GC-MSD (GC, 6890N, MSD, 5973N, Aligent Technologies, Inc., Santa Clara, CA, 
USA). Samples were injected at 62.5 kN m'^ by Hewlett Packard (HP) 7673 
automatic injector into a HP 6890 series gas chromatograph (Hewlett Packard, 
Atlanta, GA, USA) connected to a mass selective detector. A HP-5 MS column of 5% 
phenyl methyl silicone (0.25 mm x 30 m x 25 |im film thickness, Aligent 
Technologies, Inc., Santa Clara, CA, USA) was used, and putative identification of 
the terpenes was analyzed by matching the mass spectra of the resolved peaks with 
the stored spectra in the library (NIST 98.1). The carrier gas was helium at flow rate 
50 ml/min. GC operating conditions started at 150°C and held for 5 min, and then 
increased to 300°C at 5 � C /min and held for 10 min. 
2.4.3 Fatty acid profile 
The fatty acid profiles were identified by MIDI Sherlock Microbial Identification 
System (Sasser, 1990). Sixteen mg of each sample was mixed with 1 ml Reagent 1 
(150 g/L NaOH (1310-73-2，Fluka & Riedel-de Haen, Seelze, Germany) in 50% 
methanol (10158，BDH, Poole, UK)), vortex mixed for 5-10 s and incubated at 
100�C in a water bath for 5 min. Samples were cooled slightly and vortex mixed for 
5-10 s again, then continually incubated at 100°C for 25 min. After cooling to room 
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temperature by running tap water, 2 ml Reagent 2 (6.00 N HCl (HI68，Mallinckrodt, 
St. Louis, MO, USA) : methanol = 13:11) were added into each sample, vortex 
mixed for 5-10 s and incubated at 80°C for 10 min. Then 1.25 ml Reagent 3 (hexane: 
methyl tert-butyl ether (65293, Fluka & Riedel-de Haen, Seelze, Germany) = 1:1) 
was added into each sample after cooling to room temperature by running tap water. 
Solutions were mixed end-over-end for 10 min. The top phase of each solution was 
transferred to a new tube. 3 ml of Reagent 4 (12 g/L NaOH) were added and mixed 
end-over-end for 5 min. Upper organic phase was diluted by 2 fold by Reagent 3 for 
GT2 and GLTPW samples. 10 ul was injected to MIDI GC Sherlock System 
(HP6890 Series Gas Chromatograph, MIDI Inc., Newark, DE, USA). Identification 
of the methyl esters of the fatty acids in a sample was by matching the retention 
times with a fatty acid standard mix (Calibration Standard Kit for the Microbial 
Identification System, 1200-A, MIDI Inc., Wilmington, DE, USA). The carrier gas 
flow rate was 0.4 ml/min. The oven temperature profile was started at 170°C, 
increased to 260°C at 5 � C /min, and then increase to 310�C at 40�C /min and held for 
1.5 min. 
2,5 Anti-oxidation activities 
2.5.1 Superoxide radical scavenging assay 
Measurements of scavenging activities against superoxide anions of samples were 
done based on the PMS-NADH system (Fried, 1975). 0.5 ml of 156 }iM nitroblue 
tetrazolium (NBT, N6876, Sigma-Aldrich, St. Louis, MO, USA), 0.5 ml of 468 \iM 
p-nicotinamide adenine dinucleotide (reduced form, NADH, N1511, Sigma-Aldrich, 
St. Louis, MO, USA) and 50 [d of water extract of each sample were mixed. The 
reaction started by adding 50 |il of 60 i^M phenazin methosulfate (PMS, P-9625, 
Sigma-Aldrich, St. Louis, MO, USA) to the mixture. The reaction mixture was 
incubated at 25°C for 5 min, and the absorbance was measured at 560 nm. Three 
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replicates were performed for each sample. Vitamin C (A0278, Sigma-Aldrich, St. 
Louis, MO, USA) was used as a standard. The inhibition ratio (%) was calculated 
using the following formula: 
Inhibition ratio (%) = (A-A,)/A * 100% 
Where A was the absorbance of negative control (ultra pure water)，and Ai was the 
absorbance of sample. Superoxide radical scavenging abilities were expressed as 
vitamin-C-equivalent units. 
2.5.2 DPPH radical scavenging assay 
Twenty five i^l of 0.5 mM solution of 2,2-diphenyl-l-picrylhydrazyl (DPPH, D9132, 
Sigma-Aldrich, St. Louis, MO, USA) in ethanol was mixed with 75 \x\ of sample 
solution (Katsube et al., 2004). The mixture was shaken at 700 rpm for 30 min. 
Absorbance was measured at 517 nm. Three replicates were performed for each 
sample. Vitamin E (T3251, Sigma-Aldrich, St. Louis, MO, USA) was used as a 
standard. The inhibition ratio (%) was calculated using the following formula: 
Inhibition ratio (%) = (A-A,)/A * 100% 
Where A was the absorbance of negative control (ultra pure water), Ai was the 
absorbance of sample. DPPH radical scavenging abilities were expressed as 
vitamin-E-equivalent units. 
2.6 Anti-proliferation effect on human breast cancer cells 
Human breast cancer cell line MCF-7 (HTB-22, ATCC, Manassas, VA, USA) was 
maintained in RPMI medium 1640 (23400-021, Gibco BRL, Gaithersburg, MD, 
USA) supplemented with 2 g/L NaHCOs (31437，Fluka & Riedel-de Haen, Seelze, 
Germany) and 10% fetal bovine serum (FBS) (100-500, Gem Cell, West Sacramento, 
CA，USA) in a humidified incubator (Water Jacketed C02 Incubator, Forma Series 
II, HEPA Classl00,Thermo Electron Co., Hong Kong ) at 37�C and 5% CO2. Cells 
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were seeded in 96-well plate at a density of 4x10^ cell/well. The medium was 
replaced after overnight incubation with tested samples in fresh medium. Vehicle 
controls were set by fresh medium with ultra pure water. The cells were harvested in 
96 h. Medium was removed, and 25 0.25% trysin-EDTA (15400-054, Gibco BRL, 
Gaithersburg, MD, USA) was added to each well and incubated for 2 min. Then cells 
in each well were stained by 25 |li1 0.4% trypan blue solution (T8154, Sigma-Aldrich, 
St. Louis, MO, USA). The cell suspension was loaded to the counting chamber of a 
hemocytometer and the unstained cells were counted. Each treatment was performed 
in 3 replicates (Tolnai, 1975). A set of data was shown in mean 土 S.D. 
Anti-proliferation activities were quantified as inhibition effects or proliferation 
effects: 
IE = (Ns/Nn - 1) X 100 
PE=NS/NN X 100 
IE: inhibition effect. PE: proliferation effect. Ns： number of cells in sample treatment; 
NN： number of cell in vehicle control. 
2,7 Hormone-like effects 
2.7.1 E-screen test 
The E-screen assay was modified from Soto et al. (1995) as follows: MCF-7 cells 
were pre-cultured in steroids-depleted medium (CD-MEM) formulated from minimal 
essential medium (MEM, 11900-024, Gibco, Grand Island, NY, USA) supplemented 
with 10% charcoal-dextran treated fetal bovine serum (CD-FBS, SH30068.03, 
Hyclone, Logan, UT, USA), 0.1 mM MEM non-essential amino acid (11140-050, 
Gibco, Grand Island, NY, USA) and 1 mM sodium pyruvate (11360-070, Gibco, 
Grand Island, NY, USA) at 37°C in an atmosphere of 5% CO2 for two days. Then 
MCF-7 cells were seeded into 96-well plates at a density of 4 x 10^ cells per well 
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with fresh CD-MEM overnight. 1% ultra pure water in culture medium or 0.1% 
DMSO without affecting cell population size was studied in parallel as vehicle 
control. Three replicates were performed for a control or treatment test. 0.1% DMSO 
combined with 1% ultra pure water without affecting cell population size was studied 
in parallel as vehicle controls when compared with the treatment of GT2 mycelia 
combined with p’p -DDE. Assay was terminated after 96 hours by removing media 
from the well. Cell number was quantified by trypan blue viability assay as stated 
above (section 2.6). Data were presented as PE calculated as section 2.6 or RPE 
calculated as follows: 
RPE = (NS/NN- 1 )/(NP/NN- 1)*100 
RPE: relative proliferation. Ns： number of cells in sample treatment; Np： number of 
cells in positive control (E2); Nn： number of cell in vehicle control. 
EC50 and its 95% confidence limits were calculated by EPA Probit analysis program 
used for calculating LC/EC values version 1.5 (http://www.epa.gov/eerd/stat2.htmy 
Comparisons between two dose-dependent curves were performed with 
paired-sample T test. 
2.7.2 In vitro estrogen receptors (ERs) competitor binding assays 
Binding affinities of Ganoderma extracts, E2, DHT and p’p，-DDE to ERa and ERp 
were studied by HitHunter Estrogen receptor EFC Chemiluminescent Detection Kit 
(900001902, DiscoveRx, Amersham Biosciences, Buckinghamshire, UK) (Kumar et 
al., 2005). E2 was the positive controls. 10 |iM E2 stock was serially diluted in 
eppendorf tubes using 100% DMSO (D2650, Sigma-Aldrich，St. Louis, MO, USA). 
Terpene extracts were dissolved in 100% DMSO. Water extracts were dissolved in 
ultra pure water. 100% DMSO or ultra pure water was used as negative control for 
terpene extracts or water extracts, respectively. Each sample had three replicates. 
Purified ERa (P2187, Invitrogen, Carlsbad. CA, USA) and ERp (P2466, Invitrogen, 
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Carlsbad. CA, USA) were diluted with assay buffer to 15 nM. For each assay, 30 |xl 
receptor solution was mixed with 20 \i\ ED reagent and 2 |il sample, and the mixture 
was incubated in white or black bottom 96-well plate for 90 min at room temperature. 
For the "No ED" control, 30 |xl receptor solution was mixed with 20 |il assay buffer 
instead of ED reagent and 2 |il more assay buffer instead of sample. After incubation, 
40 |xl substrate mixture (Galacton-«Stor: Emerald-II: CL Substrate = 1:5:19) was 
added into each assay and incubated for 60 min at room temperature. Plate was 
covered with aluminum foil during incubation. The chemiluminescent signal was 
detected by Microplate Reader (Infinite M200, 30015056, Tecan, Mannedorf, 
Switzerland) at 1 s/well. Three replicates were performed for one treatment or control, 
and the data were shown in mean 土 S.D. EC50 and its 95% confidence limits of 
binding to ERa and ERp were calculated by EPA Probit analysis program used for 
calculating LC/EC values version 1.5 (http://www.epa.gov/eerd/stat2.htm). 
2.7.3 Recombinant yeast cell based ER-, AR- and PGR-responsible 
promoter assays 
2.7.3.1 Recombinant yeasts 
Three recombinant yeasts were kindly provided by Dr. Susan M. Ross, senior 
research associate of the Hamner Institute for Health Sciences, Research Triangle 
Park, NC, USA. The S. cerevisae strain BJ3505 [MATa, pep4: HIS3, prbl-Dl, 6R’ 
his3-D200, lys2-801, trpl-DlOl, ura3-52 (canl)], was used for the ERa assay, the 
YPH500 strain (MATa, ura3-52, lys2-801, ade2-101, trpl-D63, his3-D200, Ieu2-Dl) 
was used for the AR assays and PGR assay (Sikorski and Hieter, 1989). Yeast 
transformants used for measuring ERa activity have been described previously 
(Pham et al., 1992). The yeast contains two separate plasmids: (1) an expression 
plasmid which contains the CUPl metallothionein promoter fused to the human ERa 
cDNA, and (2) a reporter plasmid carrying two estrogen response elements upstream 
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of the structural gene for P-galactosidase. In this study protein SPT3 was 
overexpressed in yeast containing AR or PGR. The rationale behind this approach is 
that the mammalian counterparts of this protein, TAF18, when coexpressed with 
steroid receptor in transfected mammalian cells enhance transcriptional efficacy 
without altering potency or specificity (Imhof and McDonnell, 1996). As a result, 
yeast transformants used for measuring AR or PGR activity contain three separate 
plasmids: (1) an expression plasmid which contains the CUPl metallothionein 
promoter fused to the human AR or PGR (Vegeto et al., 1992), (2) a reporter plasmid 
carrying two copies of an androgen or a progesterone responsive element upstream 
of the structural gene for p-galactosidase (Vegeto et al., 1992), and (3) a plasmid 
encoding for SPT3. 
2.7.3.2 Growth medium for recombinant yeasts 
A selection medium for ERa transformed BJ3505 yeast contained 6.7 g/L yeast 
nitrogen base without amino acids (10415-11, BDH, Poole, UK), plus 20 g/L 
D-glucose (Prod 101174Y, BDH, Poole, UK), 60 mg/L leucine (L-8000, 
Sigma-Aldrich, St. Louis, MO, USA), 36 mg/L lysine (4945550H, BDH, Poole, UK) 
and 24 mg/L L-histidine-HCl (810-1062IL, Gibco BRL, Gaithersburg, MD, USA). 
For AR transformed YPH500 yeast, the selection medium containing 6.7 g/L yeast 
nitrogen base without amino acids, plus 20 g/L D-glucose, 36 mg/L L-lysine-HCl, 24 
mg/L uracil (U1128, Sigma-Aldrich, St. Louis, MO, USA), 40 mg/L adenine sulfate 
(800-6002IL, Gibco BRL, Gaithersburg, MD, USA), and 48 mg/L L-tryptophan 
(810-1 llOIL，Gibco BRL, Gaithersburg, MD, USA). For PGR transformed YPH500 
yeast, the selection medium containing 6.7 g/L yeast nitrogen base without amino 
acids, plus 20 g/L D-glucose, 36 mg/L L-lysine-HCl, 40 mg/L adenine sulfate, and 
48 mg/L L-tryptophan. Medium was sterilized by Millipore filtration (0.45 |im in 
diam membrane) and stored in room temperature. 
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2.7.3.3 ER, AR and PGR assays 
Yeast transformants were grown overnight at 30°C with vigorous orbital shaking at 
200 rpm in selective media. Following overnight culture, the yeasts were then 
subcultured in fresh medium and allowed to grow until early-mid-log phase (OD660 
approximately 1.0). Yeasts from early-mid-log phase growth (OD660 approximately 
1.0) were diluted to an OD660 of 0.03 in selective medium plus 50 \iM CUSO4 (C7631, 
Sigma-Aldrich, St. Louis, MO, USA) to induce receptor production. The diluted 
yeast was aliquoted into 50-ml conical screw cap tubes (5 ml/tube, Falcon, BD 
Biosciences, San Jose, CA, USA) to which a test sample was added. An ultra pure 
water (1%) or 0.1% ethanol only control was included in each experiment. 1 nM E2, 
10 nM DHT and 1 nM progesterone as positive controls were performed in every 
experiment for the ER, AR and PGR assays respectively. The yeast cultures were 
incubated overnight at 30°C with vigorous orbital shaking at 200 rpm (Gaido et al., 
1997). 
2.7.3.4 P-Galactosidase assay 
After incubation the yeast culture samples were diluted in the appropriate selective 
medium to an OD660 of 0.25, (3 -Galactosidase assay was performed using the Yeast 
P-Galactosidase Assay Kit (75768, Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer's protocol. 100 jil was added to each well of a 96-well 
plate. OD660 was measured again for each well in plate. Each sample was assayed in 
triplicate. 2X galactosidase Assay Buffer was thawed on ice. An equal volume of 
Y-PER® Reagent was added to make the working solution (WS). Each well required 
100 |il of the WS. After addition, the plate was incubated at room temperature for 30 
min. The well containing medium only (no cells) was used to zero the instrument. 
The P-galactosidase activity was calculated using the following formula: 
p- galactosidase activity = ( 1 0 0 0 x A420) / (t x V x OD660) 
t = time (in minute) of incubation, V = volume of (ml) cell used in the assay. 
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Relative activity was the ratio of total activity of (3-galactosidase in treatment over 
that of vehicle control. 
2.7.4 Real time PCR 
Human breast cancer cells were treated and incubated as stated in sections 2.7.1 with 
CD-MEM in 100 mm diameter tissue culture dishes for 96 h. Cells were harvested by 
scraping from culture dishes and concentrated by centrifugation at 170 x g for 3 min. 
mRNA was isolated by PureLink micro-to-midi total RNA purification system 
(12183-018, Invitrogen, Carlsbad. CA, USA) according to the manufacturer's 
protocol. The yield and purity of the RNA were quantified by spectrophotometry 
(S02334, Spectra Max 250, Gene Co. Ltd, Sunnyvale, CA, USA) with measurement 
of absorbance at 260 nm and 280 nm. Pure RNA has an A260 丨 A280 ratio of 1.5-2.0 in 
water (Manchester, 1995). The concentration of RNA was calculated as: [RNA] in 
|j.g/|j.l = A260 X 0.04 X dilution factor. First-strand cDNA was obtained by Superscript 
First-Strand Synthesis System for RT-PCR (11904-018, Invitrogen, Carlsbad. CA, 
USA) according to the manufacturer's protocol. The real time PCR reaction mixture 
was consisted of: 12.5 \i\ of 2X SYBR Green Master Mix (4309155, Applied 
Biosystems, Foster City, CA, USA), 2.5 |il of each 10 \iM primer, 7 \i\ of autoclaved 
ultra pure water and 0.5 |j,l of diluted cDNA. The primer sets for the target genes are 
listed in Table 2.2. 0.5 |j,l of autoclaved ultra pure water was used instead of cDNA as 
the No Template Control (NTC) to determine the background fluorescence of the 
reagents. The PCR thermal profile was: an initial activation step at 95°C for 10 min 
followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and 
extension at 72°C for 30 s, performed with real time PCR machine (ABI7700， 
Applied Biosystems, Foster City, CA, USA). A dissociation curve was obtained after 
PCR thermal cycles, with a thermal program of 95�C for 15 s, 55�C for 15s, and then 
temperature was increased slowly to 95°C at an increasing rate of 2°C/min. Each 
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treatment had three replicates. Data were analyzed by AACt method (Livak and 
Schmittgen, 2001). Treatments were compared and grouped by one-way ANOVA 
provided in SPSS version 11.5. 
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Table 2.2 A list of the primer sets for the genes under study by real time PCR. 
Gene Primers Ampli References 
5’-GTGGGGCGCCCCAGGCACCA-3’ Schiller et a l , 
P-actin 540 bp 
5’-CTCCTTAATGTCACGCACGATTTC-3, 2006 
5'-CCACCAACCAGTGCACCATT-3' 
ERa 108 bp Latil et a l , 2001 
5'-GGTCTTTTCGTATCCCACCTTTC-3' 
5,-AGAGTCCCTGGTGTGAAGCAAG-3, 
ERP 143 bp Latil et al., 2001 
5'-GACAGCGCAGAAGTGAGCATC-3' 
5,-CCTGGCTTCCGCAACTTACAC-3’ 
AR 168 bp Latil et al., 2001 
5'-GGACTTGTGCATGCGGTACTCA-3' 
5'-CGCGCTCTACCCTGCACTC-3' 
PGR 121 bp Latil et al., 2001 
5'-TGAATCCGGCCTCAGGTAGTT-3' 
5'-CATGGAGAACAAGGTGATCTG-3' 
pS2 356 bp Luk, 2005 
5'-CAGAAGCGTGTCTGAGGTGTC-3' 
5'-GGCAGAACACTCCGCGCTTCTTAG-3' Xu et a l , 2000 
TMEPAI 146 bp 
5'-CAAGCTCTCTTAGCTTGTGCATTC-3' Hartel et al., 
AGGCTCTGAATTTGCCAGAA-3‘ Designed by 
UDPGDH 224 bp 
5’-ATGTGC ACCTTC ATCC ATC A-3 ’ Primer3 * 
5 ‘ -GGTGCC ACCTGTGGTCC ACCTG-3 ‘ Zhang et al., 
Bcl-2 459bp 
5'-CTTCACTTGTGGCCCAGATGG-3' 1999 
5'-CAGCTCTGAGCAGATCATGAAGACA-3 Zhang et al., 
Bax 538bp 
5, -GCCC ATCTTCTTCC AG ATGGTG AGC-3 ‘ 1999 
5 ‘ -CTGAGGTTGGCTCTGACTGTACC A-3 ‘ Zhang et al., 
p53 591 bp 
5，-CTC ATTC AGCTCTCGG AAC ATCTC-3 ’ 1999 
*Primer3: web based primer design software (http://frodo.wi.mit.edu/�. UDPGDH 
mRNA sequence (NM_003359.2) was cited from National Center for Biotechnology 
Information (NCBI, http://www.ncbi.nlm.nih.govA. 
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2.8 Flow cytometry 
Cells were treated and incubated as stated in section 2.7.1 and then harvested. Then 
cells were washed with PBS (0.8% NaCl (30123，BDH, Poole, UK), 0.02% KCl 
(12636, BDH, Poole, UK), 0.02% KH2PO4, 0.115% NaaHPCU (10.3834G, BDH, 
Poole, UK)) twice. Flow cytometry were performed according to the protocol 
modified from Deitch et al. (1982). Cells were fixed in 70% ethanol at -20°C 
overnight, centrifuged and washed by PBS again. Then cells were suspended in 1 ml 
of propidium iodide (PI, P4170, Sigma-Aldrich, St. Louis, MO, USA) solution 
containing 50 mg/1 PI, 0.12% Tris base (604205, Boehringer Mannheim, Indpls.，IN, 
USA) and 700 kU/1 RNase A (R6513, Sigma-Aldrich，St. Louis, MO, USA) and 1 
ml/1 NP-40 (3536696 International Laboratory USA, San Bruno, CA, USA), pH 8.0 
and incubated for half an hour at room temperature. Flow cytometric measurements 
were performed using a Cytomics FC 500 (Beckman Coulter, Fullerton, CA, USA). 
For each measurement, 5,000 single cell events were collected, while cell doublets 
and aggregates were gated out. Cell cycle histograms were analysed using Multicycle 
AV for Windows, DNA Cell Cycle Analysis Software (Phoenix Flow systems, San 
Diego, CA, USA). Based on this programme, only cell cycles with low variation 
coefficient of the GO/Gl peak (CV < 5) and low Reduced Chi-Square (RCS)-values 
(RCS < 3), an indication of how well the model describes the observed data, were 
used for further statistical analysis. Results are presented as mean 土 S.D. of three 
independent samples. 
2.9 Comet assay 
The single cell gel electrophoresis (SCGE) or comet assay was performed to assess 
the degree of DNA strand breakage according to Cerda et al. (1997) and Chiu et al. 
(2000). Slides were precoated by dipping in molten regular agarose (0.5%) 
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(15510-027, Invitrogen, Carlsbad, CA, USA) and then let solidify at room 
temperature. Cells were suspended in 1 ml 1% low-melting-point agarose (50112, 
FMC, Rockland, ME, USA) in PBS. Then the mixture was dropped onto the slide 
and covered with a cover slip at 4°C for 5 min. After solidification, the coverslip was 
peeled off, and the slide were immersed in freshly prepared lysing solution consisting 
of high salts and detergents (2.5 M NaCl, 100 mM NazEDTA (E5134, Sigma-Aldrich, 
St. Louis, MO, USA), 10 mM Tris (604205, Boehringer Mannheim, Indpls., IN, 
USA), pH 10-10.5，1% Triton X-100 (XI00, Sigma-Aldrich, St. Louis, MO, USA) 
and 10% DMSO) at 4°C for at least 1 h to remove the cell membrane. Subsequently, 
the slides were incubated in alkaline buffer (300 mM NaOH, 1 mM NazEDTA, 
pH >13) for 25 min for DNA unwinding. Then the whole system was 
electrophoresed at 25V for 25 min. Neutralizing buffer (0.4 M Tris, pH 7.5) were 
added at 4°C to neutralize the excess alkali for three times and 5 min each. After 
dehydration by immersing the slides in absolute ethanol for 5 min, the slides were 
stained in 2 mg/ml ethidium bromide (EB, E8751, Sigma-Aldrich, St. Louis, MO, 
USA) solution. Nuclei were examined using a fluorescence microscope (Eclipse 
E600, Nikon, Hong Kong) with a green excitation filter 515-560 nm and a barrier 
filter of 590 nm set. The extent of DNA migration was determined with a CCD 
camera and quantified by the image analysis system (Komet version 3.1，Kinetic 
Imaging Ltd., Liverpool, U.K.). On each slide, 30 randomly selected cells were 
measured. These cells were analyzed for DNA damage by measuring the tail length 
( |Lim), which is the distance of DNA migration from the body of the nuclear core; the 
tail moment, which is the product of the tail length and the fraction of total DNA in 
the tail; the Olive Tail Moment, which is calculated from the formula: [(Tail mean -
Head mean)/Tail% DNA]/100; and the Tail Extent Moment, which is measured as 
(Tail length x Tail %DNA/100). 
72 
Chapter 2 Materials and methods 
2,10 DNA microarray 
2.10.1 Total RNA isolation 
350 [i\ of Lysis and Binding Buffer was added to cells in a 1.5-ml RNase-free tube. 
After inserting into a filter column, the tube was centrifuged for 1 min at 11,000 x g. 
After removing the filter column, 350 |il of ethanol (70%) was added to the filtrate, 
and the content was mixed by hand shaking. Then the content (700 jj,l) was pipetted 
to a spin column and centrifuged for 30 s at 8,000 x g. After adding 350 |xl of 
Desalting Buffer onto the spin column and centrifuged again for 60s at 11,000 x g, 
further washing of the pellet was by adding 200 |il of Pre-Wash Buffer onto spin 
column and centrifugation again for 30s at 8,000 x g. The pellet was washed twice 
with 350 |il and 200 |j1 of Washing Buffer by centrifuging for 30s at 8,000 x g and 3 
min at 11,000 x g respectively. For the last step, the spin column was placed into a 
clean RNase-free centrifuge tube and 50 jxl of RNase-free H2O were added to the 
spin column. The tube was incubated at room temperature for 1 min before 
centrifugation for 2 min at full speed. The spin column was discarded and the 
flowthrough containing the purified total RNA was collected and stored at -20°C for 
two to four days or at -80°C for up to six months. RNA content was measured in 
RNase-free 10 mM Tris, pH 8.0 buffer and calculated using equation mentioned in 
section 2.7.4. 
2.10.2 cDNA synthesis 
Components Gl , G3, and H2O were thawed on ice, then mixed and collected at the 
bottom of the tube with a brief spin in a microcentrifuge. They were kept on ice. G2 
and RI components were transferred from -20°C to ice just before use. First, 
Annealing Mixture was prepared for each RNA sample: 0.5 |ig total RNA, 1.0 |il 
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component G1 and RNase-Free H2O to a final volume of 10 mixed in a sterile 
PCR tube. The mixture was incubated at 70°C for 10 min, followed by a brief 
centrifugation to collect the mixture at the bottom of the tube, and then immediately 
placed on ice. Second, the cDNA Synthesis Master Mix was prepared for each 
sample: 4 [d RNase-free H2O, 4 |il 5X cDNA Synthesis Buffer (G3), 1 gl RNase 
Inhibitor (RI) and 1 |il cDNA Synthesis Enzyme Mix (G2) gently mixed with a 
pipette up and down 2 to 3 times followed by a brief centrifugation to collect the 
mixture at the bottom of the tube. Third, 10 jil of cDNA Synthesis Master Mix was 
added to each tube containing 10 jxl of Annealing Mixture with a pipette up and 
down 2 to 3 times followed by a brief centrifugation to collect the mixture at the 
bottom of the tube. Tubes were incubated at 42°C for 50 minutes followed by 75�C 
for 5 minutes and then were cooled to 37°C. Products were centrifuged briefly to 
collect the mixture at the bottom of the tube, and the tube was returned to 37°C for 
addition of the Amplification Master Mix. 
2.10.3 Preparation of labelled cRNA 
Buffer G24 was warmed to room temperature and vortexed to form a homogenous 
suspension. G25 was transferred from -20°C to ice just before use. Amplification 
Master Mix was prepared by mixing 16 i^l 2.5X RNA Polymerase Buffer (G24), 2 jil 
10 mM Biotinylated-UTP, and 2 |il RNA Polymerase Enzyme (G25) with a pipette 
up and down 2 to 3 times followed by a brief centrifugation to collect the mixture at 
the bottom of the tube. 20 |il Amplification Master Mix was added to each tube 
containing 20 |il of cDNA and then incubated for 4 hour at 37°C. 
2.10.4 cRNA purification 
cRNA was purified before quantification. Washing Buffer was diluted by adding 
100% ethanol to the G17 bottle upon first opening the bottle. 60 i^l of RNase-free 
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H2O was added to each cRNA Synthesis reaction tube for a final volume of 100 
The entire mixture was added to a 1.5-ml RNase-free tube with 350 \i\ Lysis & 
Binding Buffer (G6) and 350 of 100% ethanol. The contents were mixed well with 
a pipette up and down 5 to 6 times and immediately loaded onto the center of its own 
Spin Column. Samples were centrifuged for 30 sec at 8,000 x g. Flow-through was 
discarded, and 600 Washing Buffer (G17 with ethanol) was added to each spin 
column followed by centrifugation for 30 s at 8,000 x g. Flow-through was discarded 
again. cRNA was washed again by adding 200 \i\ Washing Buffer (G17 with ethanol) 
to each spin column before centrifugation for 1 min at 11,000 x g. Flow-through was 
discarded. Further centrifugation for 2 min at 11,000 x g was applied to dry the 
column. Each Spin Column was transferred to a fresh Elution Tube. 50 \i\ of room 
temperature RNase-free 10 mM Tris buffer pH 8.0 (G26) was added to the center of 
each spin column, and the tube was centrifuged for 1 min at 8000 x g after incubating 
at room temperature for 2 min. The eluted purified cRNA was kept on ice. The 
cRNA content was measured in RNase-free 10 mM Tris, pH 8.0 buffer and 
calculated as section 2.7.4. 
2.10.5 01 igo GEA rray hybridization 
The array membrane was pre-wetted by adding roughly 5 ml of deionized water to 
the hybridization tube. Hybridization tube was screwed on the cap hand-tight and sat 
inverted for at least 5 minutes. The GEAhyb Hybridization Solution was pre-warmed 
to 60°C, and the bottle was inverted several times to allow complete dissolution of 
the buffer components. Then the deionized water was discarded from the 
hybridization tube. 2 ml of pre-warmed GEAhyb Hybridization Solution were added. 
The tube was vortexed briefly, screwed on hand-tight and then placed into a 
hybridization cylinder. Pre-hybridization was performed by incubating the 
hybridization cylinder in hybridization oven at 60°C for 1 to 2 hours with continuous 
but slow agitation at 5 to 10 rpm. 
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4 }ig of biotin-labeled cRNA target was mixed with 0.75 ml of pre-warmed GEAhyb 
Hybridization Solution to make the Target Hybridization Mix and kept at 60°C. The 
pre-hybridization solution was discarded from the hybridization tube. Then the 
Target Hybridization Mix containing the labeled cRNA target was added to the tube 
and hybridized overnight at 60°C with continuous but slow agitation at 5 to 10 rpm. 
5 ml of both Wash Solution 1 and Wash Solution 2 were prepared for each Oligo 
GEArray being processed. Wash Solution 1 contained 2X SSC and 1 % SDS. Wash 
Solution 2 contained O.IX SSC, 0.5 % SDS. Both Wash Solution 1 and Wash 
Solution 2 were warmed to 60°C before use. The Target Hybridization Mix was 
poured from the hybridization tube into a clean microcentrifuge tube and stored at 
-20°C. 5 ml Wash Solution 1 were added to the hybridization tube, which was 
vortexed briefly and then placed back into hybridization oven. The membrane was 
washed at 60°C with faster agitation at 20 to 30 rpm for 15 minutes. Wash solution 
was discarded. Then 5 ml Wash Solution 2 were added to the hybridization tube. It 
was vortexed briefly and then placed the tube back into hybridization oven again. 
The membrane was washed for exactly 15 minutes at 60°C with 20 to 30 rpm 
agitation. The wash solution was discarded immediately. The cap was placed back on 
the hybridization tube to prevent the membrane from drying. The oven was turned 
off, and the oven, hybridization tubes and cylinders were cooled to room 
temperature. 
2.10.6 Chemiluminescent detection 
The hybridization signal was detected using the Chemiluminescent Detection Kit 
(D-01, SuperArray, Frederick, MD, USA). The Oligo GEArrays were blocked by 
adding 2 ml GEAblocking Solution Q to the hybridization tube followed by brief 
vortex. Incubation was done for 40 min with continuous agitation at 20 to 30 rpm. 
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IX Buffer F was prepared by diluting 5X Buffer F with ddH20. 16 ml of IX Buffer 
F were needed for washing each Oligo GEArray. Another 16 ml of IX Buffer F were 
needed for diluting alkaline phosphatase-conjugated streptavidin (APSA). 2 |il of 
AP-SA was added into 16 ml of IX Buffer F, and tubes were inverted several times 
for analyzing 8 Oligo GE Arrays. The GEAblocking Solution Q was added to the 
tube after incubation. 2 ml diluted AP-SA Buffer were added to each tube which was 
vortexed briefly and incubated for exactly 10 min with continuous but gentle (5-10 
rpm) agitation. AP-SA Buffer was discarded. The membrane was then washed four 
times with 4 ml IX Buffer F for 5 min with gentle agitation. The tube was vortexed 
briefly after each addition of fresh IX Buffer F. The last wash buffer was discarded. 
The membrane was washed twice more by adding 3 ml Buffer G and inverting three 
times after each addition. Buffer G was discarded. 1.0 ml CDP-Star 
chemiluminescent substrate was added to the hybridization tube by aseptic technique. 
The tubes were rotated in the hybridization oven in room temperature for 2 to 5 min. 
Using forceps, the array membrane was taken out of the tube and put on a piece of 
clean, absorbent filter paper to remove excess CDP-Star Solution. The membrane 
was placed into a plastic sheet protector or into a small plastic zip-lock bag, and all 
bubbles were smoothed out. The chemiluminescent array image was captured by an 
imaging station with a high quality, cooled CCD camera (Lumi-Imager F1 
Workstation, Roche Applied Science, Basel, Switzerland). 
2.10.7 Data analysis 
The microarray signals of high expression genes were grouped by Cluster 3.0 
(http://bonsai.ims.u-tokvo.ac.ip/~mdehoon/software/cluster/software.htmV 
Treatments and genes were clustered by Complete Linkage Clustering. Clustering 
result was viewed by Tree View 1.1.3 (http://itreeview.sourceforge.netA. 
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3 Results 
3,1 Analysis of Ganderma spp, 
3.1.1 Mycelia and fruiting bodies 
Two species of Ganoderma were cultured and analysed in this study. Mycelia of GT2 
and GLTPW were harvested from fermentor after 5-day incubation. 10.73 g GT2 and 
7.35 g GLTPW fine powders were obtained after freeze dry. Fruiting bodies of two 
species were collected (Figure 3.1). The total yield was 35.48 g for GT2 and 17.88 g 
for GLTPW from 15 bags each of which contained 500 g compost. 
Figure 3.1 Fruiting bodies of GT2 (left) and GLTPW (right). 
3.7.2 Identification of Ganoderma spp. 
Two Ganoderma species were identify by ITS and Mt-SSU-rDNA. ITS and 
Mt-SSU-rDNA fragments were amplified from GT2 and GLTPW, and resolved in 
Figure 3.2. The length of ITS from GT2 and GLTPW are similar at about 600 bp. 
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Sequences of ITS from both GT2 and GLTPW were different. Sequences are shown 
in Figure 3.3. Base pairs matched were highlighted by asterisks and variable bases 
between GT2 and GLTPW were highlighted by arrows. 96% identity was shown in 
the sequenced region between two species. The sequences of these two strains were 
aligned with the sequences of Hong Kong G. lucidum and the G. tsugae Japanese 
parent in previous articles (Cheung, 2001; Luk, 2006). The lengths of Mt-SSU-rDNA 
from two species are different, about 2800 bp and 600 bp respectively. This result 




1 2 3 4 
Figure 3.2 ITS and Mt-SSU-rDNA fragments from GT2 and GLTPW. 1: ITS of GT2, 
2: ITS of GLTPW, 3: MS of GT2, 4: MS of GLTPW. 
GT2 TGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACCTTGCGCTCCTTGGTA 60 
GLTPW TCTGAATTGC AGAATTC AGTGAATC ATC GAATCTITGAAC GC AC CTTGC GCTC CTTGGTA 60 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GT2 TTC C GAGGAGC ATGC CTGTTTGAGTGTC ATGAAATCTTC AAC CTAC AAGCTnTGTGGTT 120 
GLTPW TTC C GAGGAGC ATGC CTGTITGAGTGTC ATGAAATCTTC AAC CTGC AAGCnTTGTGGIT 120 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GT2 TGTAGGCrrGGACTTGGA&GCrrGTC GGC C GTTATC GGTC GGCTC CTCTTAAATGC ATTA 180 
GLTPW TGTAGGCTTGGACTTGGAGGCTTGTC GGC C GTTCTC GGTC GGCTC CTCTTAAATGCATTA 180 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GT2 GCTTGGTTC CTTGC GGATC GGCTCTC GGTGTGATAATGTCTAC GC C GTGAC C GTGAAGC G 240 
GLTPW GCTTGGTTCCTTGCGGATCGGCTCTCAGTGTGATAATGTCTACGCTGCGACCGTGAAGCG 240 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GT2 nTGGCGAGCTTCTAACCGTCTTAT---AAGACAGCTTTATGACCTCTGACCTCAAATCA 297 
GLTPTJ TTTGGC GAGCTTCTAAC C GTCTC AGTTGGAGAC AACTTTATGAC CTCTGAC CTC AAATC A 300 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
GT2 GGTAGGACTACCCGCTGAACTTAAGCATATCAATAA 333 
GLTPU GGTAGGACTACCCGCTGAACTTAAGCATATCAATAA 336 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 
Figure 3.3 Alignment of ITS2 region of GT2 and GLTPW by ClustalW2. Base pairs 
matched are highlighted by asterisks and different ones are highlighted by arrows. 
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Besides, DNAs of commercial Ganoderma spores were also extracted, and ITS and 
Mt-SSU-rDNA were amplified by PGR. Figure 3.4 shows the PGR results. Not all 
the products could be amplified. However, the amplified samples seemed to have a 
similar length of ITS and Mt-SSU-rDNA to that of GLTPW. DNA of several 
products could not be amplified probably because the sporoderm-broken process 
destroyed their DNAs seriously. 
700bp 一 
^ ^ i g i ^ m i ^ ^ i i i i 6oobp 
^ • m ^ H ^ ^ ^ m i l ^ 6 0 0 b p L o w e r panel 
Figure 3.4 ITS (upper panel) and Mt-SSU-rDNA (lower panel) fragments from 
commercial Ganoderma spores. From left to right in the left column is DNA size 
marker, sample Nos. 1，2，3, 4, 5，6，7，8, 10, 11, 12 and 13. And in the right column 
is DNA size marker, sample Nos. 01, 02, 03, 04 and 05. 
3.1.3 Chemical properties of samples 
Polysaccharides and terpenes were reported to be the major active components that 
contributed to the multiple medical functions of Ganoderma (Section 1.1.2). Thus 
the water-soluble polysaccharides, water-soluble alcohol-insoluble polysaccharides 
and terpenes were extracted from Ganoderma mycelia and fruiting bodies and 
quantified. Fatty acid profile could help to identify the sample species and they are 
another major group of bioactive components in Ganoderma, and reported to be 
mainly unsaturated, which are relative to the stability of cell membrane and 
contributed to anti-oxidation and supplementary to essential fatty acids in human 
body (Chen et al., 2005; Wang et al., 2006). Thus water-soluble polysaccharides, 
water-soluble alcohol-insoluble polysaccharides, terpenes and fatty acids of 
80 
Chapter 3 Results 
Ganoderma mycelia, fruiting bodies and commercial spore samples were extracted 
and quantified. 
The determined polysaccharide contents are shown in Table 3.1 and Table 3.2. 
Mycelia of GT2 contained the highest content of both types of polysaccharides in 
GT2 and GLTPW samples. The water-soluble polysaccharide content of commercial 
spore products varied from (1.5±0.1)o/o to (42.8±0.3)o/o, and the water soluble 
alcohol-insoluble polysaccharides varied from (0.4+0.1)% to (11.8+0.1)%. The 
highest contents among the commercial products were even higher than the mycelia 
of fruitbodies preparation of the 2 Ganoderma species. Commercial sample 03 had 
dextrin as packing agent and thus boosted up the water-soluble polysaccharide 
content (manufacturer, personal communication). Yet its water-soluble 
alcohol-insoluble polysaccharide content was not raised to the same extent (Table 
3.2). 
Terpene content in each sample is also listed in Table 3.1 and Table 3.2. In general, 
terpenes extracted from mycelia and fruiting bodies of GT2 and GLTPW were more 
than those from commercial spore products. Profiles of terpenes were analysed by 
GC-MS. Besides, since water extraction is the most common method for the public 
to obtain the nutrition from Ganoderma products, the terpenes extracted from water 
extracts of GT2 and GLTPW were also analysed. Each sample was analysed twice. 
Data were reproducible, and only one of them is shown in Figure 3.5. Putative 
identification of peaks of terpenes from mycelia of GT2 and its water extract are 
shown in Figure 3.6. The terpene contents from mycelia and fruiting bodies were 
similar in each sample of two species. A large peak of ergosterol was seen in all of 
four samples. It was lost in water extract samples, but some water soluble terpenes 
remained. Figures 3.7 and 3.9 list the terpene profiles of Ganoderma commercial 
spore and spore oil products. Putative identification of peaks of terpenes from spore 
sample is shown in Figure 3.8. The putative terpenes were list in table 4.2 in Chapter 
4. Most spore powder samples had similar terpene profiles to each other, even though 
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they were different from those of mycelia and fruiting bodies. Spore oil samples 
contained the same major peak as powder samples. However, some samples had poor 
contents or contained some additives, such as vitamin E, or even other components 
that could not be extracted from Ganoderma spores, such as cholesterol as showed in 
Figures 3.7 and 3.9. 
Moreover, profiles of fatty acids of GT2, GLTPW and Ganoderma commercial spore 
products were also analysed by MIDI system. Each sample was analysed twice. Data 
were reproducible, and only one of them is shown in Figures 3.10 or 3.11. The total 
contents of saturated fatty acids and unsaturated fatty acids were similar in all 
samples (Figure 3.10). The details about the fatty acid components were list in Table 
4.3. Some minor fatty acids were present in some samples but absent in others, which 
help to identify the two cultural species and spore products (Figure 3.10). In their 
water extract samples, most fatty acids were remained, even though some minor fatty 
acids were lost in water extraction process (Figure 3.10, Table 4.3). Commercial 
spore products had much more complicated fatty acid profiles. Fatty acid profiles 
were depended on the qualities and degree that the spores were broken. 
In summary, most of commercial products of Ganoderma are spores, but their 
chemical properties were various and the chemical determination of these spore 
samples was some time affected by supplemental compounds. The mycelia and 
fruiting body of GT2 and GLTPW contained more terpenes. Among them, mycelia 
of GT2 had highest contents of polysaccharides. 
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Table 3.1 Chemical properties of GT2 and GLTPW. 
Samples WSPS* (%) WSAIPS** (%) Terpene content (%) 
GT2 mycelia 33.2土 1.4 2.4土0.1 8.1±0.1 
GLTPW mycelia 18.9土2.2 2.1±0.2 8.0土0.2 
GT2 fruiting body 9.2土0.8 2.2土0.2 8.1±0.2 
GLTPW fruiting body 7.9土0.9 2.1±0.3 8.2±0.1 
* Water-soluble polysaccharides; ** Water-soluble alcohol-insoluble polysaccharides 
Table 3.2 Chemical properties of commercial Ganoderma spore products. 
Products WSPS* (%) WSAIPS** (%) Terpene content (%) 
1 2.8±0.3 0.9 土 0.0 4.3 土 0.4 
2 4.1 土 0.1 0.4+0.1 4.9±0.4 
3 28.1±3.4 7.4 土 0.4 3.3 土 0.4 
4 16.2±2.3 8.8±0.7 4.2±0.3 
5 4.8 土 0.4 0.6±0.0 3.7 土 0.2 
6 1.5±0.1 0.5±0.0 3.9±0.6 
7 21.2±0.5 11.8 土 0.1 4.5±0.3 
8 3.6 土 0.0 1 . 8 ± 0 . 1 4 . 1 ± 0 . 0 
1 0 1 4 . 2 ± 1 . 6 8.5 土 0.4 3 . 5 ± 0 . 4 
11 17.0 土 1.1 5.2+0.2 3.1 土 0.2 
12 252+2.1 11.2土 1.1 3.9±0.7 
1 3 1 3 . 6 土1.0 9 . 1 + 0 . 7 2 . 5 ± 0 . 5 
0 1 3 . 8 ± 0 . 3 0 . 6 ± 0 . 0 3.6 土 0.6 
02 2.6土 0.0 0.5 土 0.0 3.1 土 0.1 
03 24.8±0.3 6.5+0.1 3.1±0.6 
04 42.8±0.5 7.8 土 0.1 3.3 土 0.3 
05 10.6+0.7 7.3+0.7 2.9+0.2 
= I = 二 
* Water-soluble polysaccharides; ** Water-soluble alcohol-insoluble polysaccharides. 
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GT2 mycelia GT2 fruiting body 
、 — , , 一 」 L 
GLTPW mycelia GLTPW fruiting body 
L i / v I a a I ^ V 
Water extract of GT2 mycelia Water extract of GT2 fruiting body 
L a F V L j U V 
Water extract of GLTPW mycelia Water extract of GLTPW fruiting body 
Figure 3.5 Profiles of total terpenes and water-soluble terpenes from GT2 and 
GLTPW mycelia and fruiting bodies by GC-MS. 
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Figure 3.6 Putative identification of resolved peaks of terpenes from mycelia of GT2 
(magnified Figure 3.5 GT2 mycelia) and its water extract (magnified Figure 3.5 
Water extract of GT2 mycelia). Peaks were identified by similarity of mass spectra of 
the resolved compound at the authentic compound in database (Wiley 275). The 
similarity index is higher than 90%. 
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Figure 3.7 Terpene profiles of commercial Ganoderma broken spore products. 
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Figure 3.8 Putative identification of resolved peaks in commercial spore sample No.l 
(magnified Figure 3.7 No.l). Peaks were identified by similarity of mass spectra of 
the resolved compound at the authentic compound in database (Wiley 275). The 
similarity index is higher than 90%. 
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Figure 3.9 Terpene profiles of commercial Ganoderma spore oil products. 
87 
Chapter 3 Results 
1 I 
2r 1 
» I » 
» 丨 匆. 
M- I 
» n 
I — “ — “ — “ — — “ — ^ — “ — ^ — ” 1 . I ’ ’ ’�’ ’ ’ ’ � ’ ’ ’ ’�’ ’ ’ ’ T•…•’,“’ ’ * ’ ：‘ ’ ’ ’ ’ , 1 ’ ；二 
GT2 mycelia GT2 fruiting body 






I I 丄 , ‘ ,...‘ .1 . Jl � l i l . 丄 . 」 : 1 1 Z 
I r't ' ' ' IB ' ' ' iW ' ' I'i' ' ' ' 17,a' «J I “ » ^ — ^ “ ^ a-J 
GLTPW mycelia GLTPW fruiting body 





I Y ； / 
I r ••• t'i - •,“• ••.「•• 1 “’ • • ' i. J 飞 ’ 飞 
a i 7i IB «a \i 17a a J 
Water extract of GT2 mycelia Water extract of GT2 fruiting body 
» I 
： / ： I 
——:�li..一,....... • i ^ ^ ^ 
“ ‘‘.… ' ' ' . . . . ' ' ' . . . . ' ' " . . .. ' ' ' . . . . ' ' ' ' ‘ n ； h ；. 厂 … • . “ 」 
Water extract of GLTPW mycelia Water extract of GLTPW fruiting body 
Figure 3.10 Fatty acid profiles of GT2 and GLTPW samples. 
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Figure 3.11 Fatty acid profiles of commercial Ganoderma spore products. 
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3.1.4 Anti-oxidation activities 
The anti-oxidation activities are other important criteria to evaluate the Gamoderma 
samples. The anti-oxidation activities of samples were assessed by scavenging assays 
against both superoxide radicals and DPPH radicals (Tables 3.3 and 3.4). Radical 
scavenging abilities were expressed as vitamin-C-equivalent units and 
vitamin-E-equivalent units respectively. Among the cultivated samples, water extract 
of GT2 mycelia had the highest activities in both anti-oxidation assays. Most 
commercial spore products showed lower anti-oxidation activities than cultivated 
samples. However, some commercial spore products gave even higher activities in 
both assays, such as No.03 which was found to have vitamin C (> 10% dry weight) 
as an additive (manufacturer, personal communication). 
3.1.5 Anti-proliferation effect on human breast cancer cells 
The anti-proliferation activities of GT2 and GLTPW water extracts and Ganoderma 
commercial spore products were determined using MCF-7 breast cancer cells. Figure 
3.12 gives the dose effects of GT2 and GLTPW water extracts on MCF-7 
proliferation. Stimulation effects were shown at low concentrations, while 100% 
inhibition were detected at 10 mg/ml. Table 3.5 shows the inhibition ratio on MCF-7 
proliferation of commercial spore products at 10 mg/ml compared to the control. The 
inhibition effects of spore products at the concentration of 10 mg/ml ranged from (17 
土 19) % to (100 土 0) % (Table 3.5). Only four products could reach 100% inhibition, 
which is the same as GT2 and GLTPW samples (Table 3.5，Figure 3.12). 
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Table 3.3 Anti-oxidation activities of GT2 and GLTPW. 
Superoxide radical scavenging DPPH radical scavenging 
(mg Vc /ml) (mg Ve /ml) 
GT2 mycelia 6299±43 596±7 
GLTPW mycelia 5545土27 569±10 
GT2 fruiting body 3154±50 517±6 
GLTPW fruiting body 3308±45 515±7 
Table 3.4 Anti-oxidation activities of Ganoderma commercial spore products. 
� , Superoxide radical scavenging DPPH radical scavenging 
— sample (mgVc/ml ) - ( m g V e / m ) 
1 1197 土 8 496土 4 
2 627土 1 205土4 
3 727±3 217±7 — 
4 3331 土 10 1333±5 — 
5 2018±26 220土 5 — 
6 729+1 189±3 
7 3387土 17 1380±3 一 
8 2164土 17 358土 8 — 
3117 土 8 1264土 2 — 
n 2471+42 424±5 — 
n 5093±26 1620+35 一 
n 645土 1 297+3 — 
01 635±2 59+1 — 
^ 735±4 69 土 1 — 
^ 11581 土 70 24968±47 
04 640+3 188±2 
一 05 623±2 280土 2 
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Figure 3.12 Effects of GT2 and GLTPW on proliferation of MCF-7 in RPMI 1640 
medium with 10% FBS. Inhibition effect = (1-viable cell number of treatment/viable 
cell number of control) x 100. 
Table 3.5 Inhibition effects of Ganoderma commercial products on MCF-7 
proliferation tested at the concentration of 10 mg/ml. 
Spore sample Inhibition effect (%)* Spore sample Inhibition effect (%)* 
1 63±11 11 93 土 1 
2 53±12 \2 100+0 
3 ^ 13 — 65±4 
4 100±0 01 — 59+4 
5 17±19 02 一 33+2 
6 — 61 土 18 03 57土 15 
7 100±0 04 — 78土 6 
8 2 9 ^ 05 一 85 土 1 
1 0 1 0 0土 0 
* Inhibition effect = (1-viable cell number of treatment/viable cell number of control) 
xlOO. 
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3.1.6 Hormone-like bioactivities 
GT2 mycelia, which had high polysaccharide and terpene content, showed high 
anti-oxidation activities and a significant ability to stimulate MCF-7 proliferation at 
low concentrations, was selected to study its hormone-like bioactivity. The effects of 
water extract of GT2 on the proliferation of steroid hormone sensitive MCF-7 in 
steroid-depleted medium was studied. Besides, the affinity to steroid receptors and 
the influence on the steroid-responsive gene in MCF-7 were also investigated. 
3.1.6.1 E-screen test 
In steroid-depleted medium, CD-MEM, the proliferation of MCF-7 could be 
stimulated by estrogenic compounds and inhibited by androgenic compounds. Thus 
the effect of water extract of GT2 mycelia was tested in CD-MEM. MCF-7 treated 
with water extract showed a dose-dependent increase of proliferation at 
concentrations lower than 0.5 mg/ml, but it downed when concentration was higher 
than 0.5 mg/ml (Figure 3.13). 
100「 
-50 ‘ ‘ 丨 ‘ 
0 0.25 0.5 0.75 1 
Concentration (mg/ml) 
Figure 3.13 Effect of water extract of GT2 mycelia on MCF-7 proliferation in 
CD-MEM. RPE: relative proliferation effect. RPE = (NS/NN-1)/(NP/NN-1) X 100, Ns： 
number of cells in sample treatment; Np： number of cells in positive control (E2); Nn： 
number of cell in vehicle control. 
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3.1.6.2 In vitro estrogen receptors (ERs) competitor binding assays 
The affinity of water extract to ERs was investigated by in vitro estrogen receptors 
(ERs) competitor binding assays. Water extract of GT2 did not show significant 
binding to both ERa and ERp (Figure 3.14) in tested concentrations, while terpenes 
extracted from mycelia had slight affinity to ERa with an EC50 of 9.3 mg/ml (95% 
confidence limit is (3.2, 199.4) and strong affinity to ERp with an EC50 of 0.9 mg/ml 
(95% confidence limit is (0.7, 1.1) (Figure 3.15). Table 3.6 compares the EC50 of two 
samples and E2. The capacity of terpene extracts is 2.0 x 10^ less than E2 on ERa 
and 4.1 X 106 less than E2 on ERp. 
• 150 「 t 150 「 
•I 100 - + E 2 I 100 - ^ + E 2 
« ，„ J 士 GTM « / -A-GTM 
1 '' - / I - / 
^ 0 - ^ « 0 -
— I — I — I — I — I — I — I — I — I — I -50 — I — I — I I 1 I I I I I 
-9 -8 -7 -6 -5 -4 -3 - 2 - 1 0 I -9 -8 -7 -6 -5 -4 -3 - 2 - 1 0 1 
Concentration Log(ing/ml) Concentration Log(mg/inl) 
Figure 3.14 The estrogen binding assays for ERa (left) and ERp (right) with crude 
water extract from G tsugae mycelia (GTM), and E2 as the positive control. Relative 
affinity = signal from sample / the high signal from E2 x 100. 
150「 + E 2 ^ 150 厂 
I 100 ^ +GTMteipene | 100 - ^ 十 GTMteipene 
I：'. J ^ IrV J 
tf oc 
-50 ~ ‘ ~ ‘ I ~ I ‘ I ~ ~ I ~ I ~ ‘ ~ ‘ .50 ~ I ~ I ~ I 1 _ I _ _ I _ I _ _ I _ _ I _ I 
-9 -8 -7 -6 -5 -4 -3 - 2 - 1 0 1 -9 -8 -7 -6 -5 -4 -3 - 2 - 1 0 1 
Concentration Log(ing/ml) Concentration Log(mg/ml) 
Figure 3.15 The estrogen binding assays for ERa (left) and ER(3 (right) with terpene 
extract from G tsugae myclia (GTM terpene), and E2 as the positive control. 
Relative affinity = signal from sample / the high signal from E2 x 100. 
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Table 3.6 The EC50 of binding to ERa and ERp of water extracts and terpenes 
extracted from mycelia of GT2. 
_ „ … ， ，，、 95% Confidence Limits (mg/ml) 
Receptor Sample EC50 (mg/ml) ; — 
Lower Upper 
E2 4.6X10_7 — 3.9X10_7 “ 5.5x10"^ 
ERa Water extract N.A. 
Terpene extract 93 ^ 199.4 
E2 2.1X10_7 — 7.6X10_8 6.7X10'^ 
ERP Water extract N.A. 
Terpene extract O O \A 
*: N.A.: not applicable. EC50 and its 95% confidence limits were calculated by EPA 
Probit analysis program used for calculating LC/EC values version 1.5. 
3.1.6.3 Recombinant yeast cell-based ER-, AR- and PGR-responsible promoter 
assays 
Recombinant yeast cell-based ER-, AR- and PGR-responsible promoter assays were 
done to evaluate the effect of water extract of GT2 on steroid receptors. Recombinant 
yeast cells transfected with ERa, AR and PGR were treated with water extract of 
GT2 mycelia. Activities of p-galactosidase in the yeasts containing ERa and PGR in 
water extract treatments had no significant difference with vehicle control (Figures 
3.16 and 3.17). However, water extract activated AR when concentration larger than 
0.1 mg/ml (Figure 3.18). 
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Figure 3.16 Ability of water extract of GT2 mycelia to activate ERa in recombinant 
yeast cell based ER-responsible promoter assay. Positive control is E2 (1 nM). 
Ranking of treatments was by one-way ANOVA and Tukey test at 5% probability 
with "a" of lowest ranking. 
10.00 � b 
.會 8 . 0 0 r w m 
1 6.00 _ 
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Q QQ ftWH__I__^M I rofeg I 
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control control 
Figure 3.17 Ability of water extract of GT2 mycelia to activate PGR in recombinant 
yeast cell based PGR-responsible promoter assay. Positive control is progesterone (1 
nM). The concentration of water extract of GT2 mycelia is 1 mg/ml. Ranking of 
treatments was by one-way ANOVA and Tukey test at 5% probability with "a" of 
lowest ranking. 
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Figure 3.18 Ability of water extract of GT2 mycelia to activate AR in recombinant 
yeast cell based AR-responsible promoter assay. Positive control is DHT (10 nM). 
Ranking of treatments was by one-way ANOVA and Tukey test at 5% probability 
with "a" of lowest ranking. 
3.1.6.4 ER- and AR-pathway gene expression by real time PCR 
The expression of endogenous estrogen and androgen responsive genes were 
measured by real time PCR. Water extract of GT2 mycelia slightly induced the 
expression of ERa and significantly increased pS2. But ERp was not affected in all 
tested concentrations. At concentration of 0.5 mg/ml that MCF-7 proliferation got the 
largest increase, while the expression of ERa and pS2 reached the zenith. 
Surprisingly, although PGR is also an estrogen responsive gene, it was suppressed by 
water extract of GT2 in a dose-dependent manner (Figure 3.19). Figure 3.20 shows 
the expression of AR and its responsive genes under treatments with water extract of 
GT2 mycelia. It seems that GT2 could not only increase the expression of ERa and 
pS2, but also increased the expression of AR and TMEPAI. However the other 
androgen responsive gene, UDPGDH had a slight but insignificant decrease when 
the concentration of water extract increased. 
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Figure 3.19 Expression of ERs and estrogen responsive genes in treatments with 
water extract of GT2 mycelia. Ranking of the expression for each gene respectively 
was by one-way ANOVA and Tukey test at 5% probability with "a" of lowest 
ranking. Ranking was labeled in different colors for different genes. 
9 m Control 
g _ T • 0.05 mg/ml 
7 - _ • 0.25 mg/ml 
1) 6 _ b mo.5 mg/ml 
I 5 ^ J y • 0 . 7 5 mg/ml 
^ 4 b a b ^ ^ l m 1 mg/ml 
§ 3 - a i i n 
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I [ i i ^ B , m I ^ m I I 
AR TMEPAI UDPGDH 
Figure 3.20 Expression of AR and androgen responsive genes in treatments with 
water extract of GT2 mycelia. Ranking of the expression for each gene respectively 
was by one-way ANOVA and Tukey test at 5% probability with "a" of lowest 
ranking. Ranking was labeled in different colors for different genes. 
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3.2 Action mechanism of p,p'-Z)Z)£' 
The adverse effects of p,p-DDE mention in section 1,2.4 was though to be through 
the disruption of steroid hormone pathways (section 1.2.6). Thus the effects on the 
proliferation of MCF-7, steroid hormone receptors and their responsive genes were 
studied. To compare with the natural steroid hormones, E2, DHT and progesterone 
were studied in parallel. 
3.2.1 E-screen 
In steroid-depleted medium, CD-MEM, MCF-7 was treated with p,p '-DDE. 
Dose-dependent increase of RPE is shown under both E2 and p’p '-DDE treatments 
(Figure 3.21). The EC50 ofE2 is 6.2 x IQ-'^  M (95% confidence limit was (4.5 x lO^'^ 
8.4 X 10-12) M), and the EC50 of DDE is 1.0 x lO^^  M (95% confidence limit was (1.2 
X 10-7，9.8 X 10-^) M) . 
jgQ +17p-estradiol(E2) 
p,p'-DDE 
100 ^ ^ 
_5Q 1 1 1 1 1 1 1 1 I I 
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 
Concentration Log (M) 
Figure 3.21 Effect ofp，p，-DDE on MCF-7 proliferation in CD-MEM. RPE: relative 
proliferation effect. RPE = (NS/NN-1)/(NP/NN-1) X 100, Ns： number of cells in 
sample treatment; Np： number of cells in positive control (E2); Nn： number of cell in 
vehicle control. 
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When p’p '-DDE and E2 were added together to CD-MEM, synergic effect is shown 
as Figure 3.22 The large black squares give the single effect of E2 at concentrations 
of 1 pM (10-12 M), 10 pM (10-" M), and 100 pM (IQ-'^ M). The corresponding RPE 
curve with increasing concentration of p’p '-DDE are shown on the right with small 
black squares, black triangles and circles respectively. The RPE increased with the 
increase of p’p，-DDE when the concentration of E2 was low. However, with high 
concentration of E2, the effect of p’p，-DDE was insignificant, when RPE was around 
100 (Figure 3.22). 
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Figure 3.22 Synergic effect of p,p -DDE and E2 on MCF-7 proliferation in 
CD-MEM. RPE: relative proliferation effect. RPE = (NS/NN-1)/(NP/NN-1) X 100, Ns： 
number of cells in sample treatment; Np： number of cells in positive control (E2); Nn： 
number of cell in vehicle control. 
DHT suppressed MCF-7 proliferation in CD-MEM as shown in Figure 3.23; MCF-7 
proliferation decreased with increasing DHT concentration. In the present of 10 |iM 
p’p，-DDE，the decreasing curve turned and showed a rise. In the paired-sample t test, 
the difference between with and without p,p '-DDE at each DHT concentration is 
significant (P = 0.035). This indicates that p,p -DDE reversed the suppression of 
DHT. With 1 nM E2, the reversed effect was more significant (P = 0.013 when 
compared with PE under DHT treatments and P = 0.04 when compared with PE 
under combined treatments with DHT and p,p '-DDE in paired-sample T test). 
However, the slopes of two linear trend lines in the presence of p，p '-DDE and E2 are 
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different. This may suggest different mechanisms involved for reversing the 
inhibition effect of DHT. 
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Figure 3.23 Reversed effects of p,p '-DDE and E2 on the inhibition induced by DHT. 
MCF-7 was incubated in CD-MEM with different treatments. PE: proliferation effect. 
PE = NS/NN, NS： number of cells in sample treatment; NN： number of cell in vehicle 
control. * highlights the concentration of DHT, at which, compared with the control 
with vehicle, the proliferation of MCF-7 was significantly decreased by DHT only. 
3.2.2 In vitro estrogen receptors (ERs) competitor binding assays 
The affinities to ERa and P were studied with estrogen receptor competitor binding 
assays. Relative affinity refers to the percentage of the highest effect of E2. DHT 
showed little binding to ERa in the concentration less than 100 nM (10'^ M), but 
slight affinity to ER(3 with an EC50 of 3.1 |iM (Figure 3.24). p,p'-DDE had weak 
binding to ERa with an EC50 of 412.7 |iM, but surprisingly strong binding to ERp 
with a EC50 of 0.4 |xM (Figure 3.25). EC50 of binding to ERa and p was calculated by 
EPA Probit analysis program version 1.5, and the 95% confidence limits are shown 
in Table 3.7. The EC50 of p,;?'-DDE to ERa is 2.4x10^ fold of that of E2，and 5.7x10^ 
fold to ERp. The EC50 of DHT to ERp is 7.0 fold less than that of p’p '-DDE. 
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Figure 3.24 The estrogen binding assays for ERa (left) and ERp (right) with DHT, 
and E2 as the positive control. 
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Figure 3.25 The estrogen binding assays for ERa (left) and ERp (right) with 
p’p '-DDE, and E2 as the positive control. 
Table 3.7 The EC50 of binding to ERa and p of E2，DHT and p’p '-DDE. 
95% Confidence Limits (M) 
Receptor Sample EC50 (M) 
Lower Upper 
E2 1.7x10-9 1.4x10-9 2.0x10-9 
ERa DHT N.A.* N.A. N.A. 
p,p'-DDE 4.1x10-4 1.3x10-4 2.4x10"^ 
E2 7.7x10-'® 2.8X10_ig 2.5X10-9 
ERP DHT 11x10-6 2.3x10-7 5.5x10"^ 
p,p'-DDE 4.4x10-7 2.9x10-7 6.9x10-7 
*: N.A.: not applicable. EC50 and its 95% confidence limits were calculated by EPA 
Probit analysis program version 1.5. 
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3.2.3 Recombinant yeast cell based ER- and AR-responsihle promoter 
assays 
Recombinant yeast cells transfected with ERa and AR were treated with p，p，-DDE. 
E2 and DHT were used as positive controls for ERa and AR respectively. p’p -DDE 
slightly activated ERa with a EC15 of 12.7 x 10"^  M (95% confidence limit is (7.2 x 
10-6，20.2 X 10-6) M) as shown in Figure 3.26. Surprisingly p,p'-DDE also slightly 
activated AR with a EC 15 of 17.8 x lO"^  M (95% confidence limit is (7.8 x \ 0 ' \ 28.1 
X 10-6) M) as shown in Figure 3.27. However, bothp,p'-DDE (10 [iM) and E2 (1 nM) 
antagonized the effect of 10 nM DHT in reducing the activation of AR (Figure 3.28). 
Bothp’p，-DDE and E2 did not activate progesterone receptor (Figure 3.29). 
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Figure 3.26 Ability of p,p -DDE to activate ERa in recombinant yeast cell based 
ER-responsible promoter assay. Treatments by E2 were the positive control. Relative 
affinity = signal from sample / the high signal from E2 x 100. 
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Figure 3.27 Ability of p,p '-DDE to activate AR in recombinant yeast cell based 
ER-responsible promoter assay. Treatments by DHT were the positive control. 
Relative affinity = signal from sample / the high signal from E2 x 100. 
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Figure 3.28 Ability ofp,p'-DDE (10 ^iM) and E2 (1 nM) to inhibit the activation of 
AR by DHT (10 nM). Relative affinity = signal from sample / the high signal from 
E2 X 100. Treatments were compared by one-way ANOVA. ***： P < 0.001. 
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Figure 3.29 Ability of p,p -DDE (10 |iM) and E2 (1 nM) to activate progesterone 
receptor, positive control is progesterone (1 nM). Relative affinity = signal from 
sample / the high signal from E2 x 100. Treatments were compared by one-way 
ANOVA.***:P< 0.001. 
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3.2.4 ER- and AR-pathway gene expression by real time PCR 
In CD-MEM, the expression of ERs, AR and their responsive genes were examined. 
p,p '-DDE was compared with two positive controls E2 and DHT. E2 significantly 
increased the expression of two forms of ER and also dramatically increased their 
responsive genes, pS2 and PGR, when its concentration was above 10 pM (Figure 
3.30). Under DHT treatments, expression of ERa was increased too, but it did not 
affect ERP. Besides, pS2 and PGR were both slightly increased by DHT (Figure 
3.30). p,p'-DDE showed an expression pattern different from those of E2 and DHT. 
It had little effect on ERa, ERp and pS2, but dramatically increased PGR at 10 \iM 
without activating PGR receptor (Figure 3.29 and 3.30). For AR and its responsive 
genes, Figure 3.31 shows the comparison among effects of E2, DHT and p,p'-DDE. 
E2 slightly increased expression of AR at only 10 pM with the fold less than 2, 
markedly decreased TMEPAI, but increased UDPDGH (Figure 3.31). In contrast, AR, 
TMEPAI and UDPDGH were increased by DHT (Figure 3.31). p’p’-DDE slightly 
decreased AR, had little effect on TMEPAI, and slightly increased UDPDGH (Figure 
3.31). 
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Figure 3.30 Expression of ERs and estrogen responsive genes in treatments with E2, 
DHT or p,p '-DDE. Ranking of the expression for each gene respectively was by 
one-way ANOVA and Tukey test at 5% probability with "a" of lowest ranking. 
Ranking was labeled in different colors for different genes. 
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Figure 3.31 Expression of AR and androgen responsive genes in treatments with E2, 
DHT or p,p '-DDE. Ranking of the expression for each gene respectively was by 
one-way ANOVA and Tukey test at 5% probability with "a" of lowest ranking. 
Ranking was labeled in different colors for different genes. 
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3,3 G a n o d e r m a tsugae mycelia extract against p，p，-DZXE 
Compared with the effects of water extract of GT2 and p’p，-DDE，treating MCF-7 
with both tested samples together provided the evidence about how water extract 
worked at the presence of p’p，-DDE. 
3.3.1 E-screen test 
Figure 3.32 shows the RPEs curves of water extract of GT2 alone, GT2 extract with 
10 \iM p,p'-DDE and GT2 extract with 1 nM E2. Even though the water extract of 
GT2 increased the proliferation of MCF-7 when its concentrations were lower than 
0.5 mg/ml but decreased MCF-7 population at higher concentrations in 
estrogen-depleted media. It decreased the mitogenic effects of p,p'-DDE or E2 in a 
dose-dependent manner from 0.05 mg/ml to 1 mg/ml. DHT reduced the mitogenic 
effect of GT2 at low concentrations but enhanced its suppression effect at high 
concentrations (Figure 3.33). 
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Figure 3.32 Effect of water extract of GT2 on suppressing the mitogenic effects of 
p,p'-DDE and E2 on MCF-7 in CD-MEM. RPE: relative proliferation effect. RPE = 
(NS/NN-1)/(NP/NN-1) X 100，Ns： number of cells in sample treatment; Np： number of 
cells in positive control (E2); Nn： number of cell in vehicle control. 
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Figure 3.33 Effect of water extract of GT2 combined with DHT on proliferation of 
MCF-7 in CD-MEM. RPE: relative proliferation effect. RPE = (NS/NN-1)/(NP/NN-1) 
X 100，Ns： number of cells in sample treatment; Np： number of cells in positive 
control (E2); NN： number of cell in vehicle control. 
3.3.2 ER- and AR-pathway gene expression by real time PGR 
To compare the expression of estrogen or androgen responsive genes under the 
treatment by water extract of GT2 or p’p，-DDE alone, real time PCR was also done 
for the treatment by two tested samples together. Figure 3.34 shows that pS2 was 
significantly increased by water extract of GT2, and insignificant increased by 10 
jiM -DDE. Unexpectedly, pS2 was significantly suppressed when p,p'-DDE and 
water extract of GT2 were combined to treat the MCF-7 cells. In comparison, 
p,p'-DDE significantly induced PGR transcription, while water extract of GT2 
suppressed it. Combination treatment even lowered PGR expression. For AR and 
TMEPAI, p,p'-DDE and water extract of GT2 had opposite effects. And combination 
treatment decreased AR transcription and slightly but insignificantly increased 
TMEPAI transcription as with GT2 treatment. UDPGDH was slightly but 
insignificantly decreased by -DDE or water extract of GT2, whereas their 
combination caused a significant decrease. In general, p,p'-DDE and water extract of 
GT2 at the tested concentration had opposite effects on the ERs and AR-responsive 
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genes, except pS2. And the combination of p,/?'-DDE and water extract of GT2 
suppressed most gene transcription except the insignificant increase in TMEPAI. 
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Figure 3.34 Expression of ER- and AR-responsive genes in treatments with 10 ^iM 
-DDE alone, 0.5 mg/ml water extract of GT2 only and combination of them. 
Three vehicle controls with the vehicles for the three treatments, 0.1% DMSO, 1% 
ultra pure water and 0.1% DMSO combined with 1% ultra pure water are shown for 
comparison. Treatments were compared with their own control by independent 
sample T test in SPSS. *: P<0.05，**:P<0.01. 
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3.3.3 Analysis of cell cycle 
Obviously water extract of GT2 and p,p,-DDE had interaction when act on the 
proliferation of MCF-7. Thus their effects on the cell cycle were also studied and 
compared with E2 and DHT. 1 nM E2 and 100 nM DHT, which increased and 
decreased the proliferation of MCF-7 respectively, had a great effect on the cell cycle 
of MCF-7. E2 significantly shortened the G2/M phase since few cells were detected 
in this phase. It also promoted cells to enter S phase from Gl/GO phase, causing a 
great decrease of cell percentage in Gl/GO phase and a great increase in S phase. On 
the contrary, DHT arrested cells in Gl/GO phase, causing an increase of cell 
percentage in that phase and a decrease in the other two phases. However, the effect 
of -DDE was not significant in statistical analysis, even though the averages of 
three independent tests indicated a slight decrease in Gl/GO and G2/M phase and a 
slight increase in S phase，which was similar to E2. 10 jxM p,p'-DT>E was mitogenic 
for MCF-7 cells but the cell cycle was not affected. Effects of water extract of GT2 
were studied and shown in panel B. At the two doses tested, water extract of GT2 did 
not affect the cell phase of MCF-7 cells. However, when combined with p’p '-DDE, 
both concentrations of GT2 water extract accumulated cells in S phase, causing a 
decrease of cell percentage in GO/Gl phase with little change in G2/M phase (Figure 
3.35). 
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Figure 3.35 Cell cycles of MCF-7 were analyzed by flow cytometry. Effect of (A) 10 
I^ M p,p'-DDE was compared with 1 nM E2, 100 nM DHT and their vehicle control, 
and (B) 0.5 mg/ml or 1 mg/ml water extract of GT2 and (C) combined treatment with 
water extract of GT2 and 10 |iM p,p'-DDE were compared with their own vehicle 
controls. Ranking of the treatments was by one-way ANOVA and Tukey test at 5% 
probability with "a" of lowest ranking. 
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3.3.4 Analysis of DNA damage 
Besides of effect of MCF-7 proliferation, p’p '-DDE had been reported to damage the 
DNA of plant cells (Gong, 2004 and Gong et al., 2006). Thus whether p,p'-DDE is 
able to damage DNA of MCF-7 was investigated by Single Cell Gel Electrophoresis 
assay (also called comet assay). It is a sensitive technique for the detection of DNA 
damage (Fairbaim et al” 1995). When the DNA is damage, the broken DNA will 
form a tail in the electronic field, which looks like the comet tail (Figure 3.37). The 
positive control of DNA damage was set by treating MCF-7 with H2O2 at the 
concentration from 0 i^M to 100 Four common parameters, Tail DNA, tail extent 
moment, olive tail moment and tail length were measured. Tail length (jj.m) is the 
distance of DNA migration from the body of the nuclear core; the tail DNA is the 
fraction of total DNA in the tail (%); the Olive Tail Moment is calculated from the 
formula: [(Tail mean - Head mean)/Tail% DNA]/100; and the Tail Extent Moment is 
measured as (Tail length x Tail %DNA/100). Among these parameters, tail DNA, 
tail extent moment, olive tail moment but not tail length showed a significant 
dose-dependent manner (Figure 3.36). Thus, only these three parameters were 
measured in the following assays. 
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Figure 3.36 DNA damage induced by H2O2. MCF-7 was treated with H2O2 at the 
concentration from 0 |a,M to 100 |iM. Tail DNA, tail extent moment, olive tail 
moment and tail length were measured. Ranking of treatments was by one-way 
ANOVA and Tukey test at 5% probability with "a" of lowest ranking. Ranking was 
labeled in different colors for different genes. 
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MCF-7, in CD-MEM, was treated by water extract of GT2, p’p '-DDE or both of 
them together. Treatment of E2 was compared with that of p’p，-DDE. Compared with 
its vehicle control, p,p'-DT>E but not E2 increased DNA damage with higher tail 
DNA, tail extent moment and Olive tail moment (Table 3.8). Water extracts of GT2 
also increased tail DNA, but did not significantly change tail extent moment and 
Olive tail moment (Table 3.8). Interestingly, when 10 p M a n d 0.5 mg/ml G. 
tsugae extract (the mitogenic dose) were combined as treatment, reduction in Olive 
tail moment and slight but insignificant increase in Tail DNA were observed, 
indicating no DNA damage. When the combination effect was with 1 mg/ml G. 
tsugae extract (the anti-proliferative dose), increase in Tail DNA but not the other 
parameters was observed (Table 3.8). Figure 3.37 shows the image of comet cell 
from each treatment, which represents the effect of each treatment. It seemed that 
p,p -DDE increased the DNA damage, which could not be detected in treatment by 
E2, and 0.5 mg/ml water extract reduced this effect. 
Table 3.8 DNA damage analysis of treatments on MCF-7 by comet assay. 
Treatments Tail DNA Tail extent moment Olive tail moment 
DMSO 9.9±6.2' 6.4 土 62±5.T 
10| iM p,p,-DDE 18.2土9.1b 10.3±11.1^ 9.1±6.5^ 
InM E2 8.7±6.3a 5.0±6.5' 6.5±5.8' 
I W 11.5±5.2" 7.4 土 7.9ab 6.4 土 3.7' 
0.5 mg/ml GT2 5.5土6.5' 8.1±5.4' 
1 mg/ml GT2 17.0土 10.8b 8.6±9.8^ 6.9土4.9' 
DMSO+H2O 10.3±6.4" 4J±6.r 7.014.6" 
？ 二 12.6±7.3- ^ ^ 
10 [iM p’p -DDE -
二 m l G 二 ^ ^ 
10 [iM p,p -DDE 
a, b, c: Ranking of each group of treatment respectively was by one-way ANOVA 
and Tukey test at 5% probability with "a" of lowest ranking. Ranking was labeled in 
different colors for different genes. 
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Figure 3.37 Images of comet cells from different treatments. 
3.3.5 Analysis of sub-Gl peak 
One of the features of apoptotic cells is extensive degradation of the DNA at the 
linkers between the nucleosomes (Ormerod, 2002). If apoptotic cells are fixed in 
ethanol, and then resuspended in a buffer, such as PBS, the smaller fragments of 
DNA are extracted so that the apoptotic cells have a lower DNA content compared to 
the normal cells. The apoptotic cells form a peak below the G1 peak (often referred 
to as the sub-Gl peak) (Ormerod, 2002). Necrotic cells, whose DNA is degraded 
randomly, also have a reduced DNA content and will be distributed across the same 
region of the histogram (Ormerod, 2002). Fragments of broken cells containing small 
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amounts of DNA may also be present, but could be excluded by limiting the particle 
size in detection (Ormerod, 2002). Thus sub-Gl peak was measured in this study. It 
can be a indicator to estimate the degree of cell death. No significant difference was 
found among the sub-Gl peak of three vehicle controls by one-way ANOVA (Figure 
3.38). Compared with their vehicle controls, 1 nM E2, 100 nM DHT, and 10 \iM 
p,p，-DDE did not significantly change the proportion of cells with low DNA content 
(Figure 3.38). In contrast, water extract of GT2, which had been proved to induce 
apoptosis (Luk, 2004), increased sub-Gl cells in a dose-dependent manner (Figure 
3.38). However, when combined with 10 |xM p,p'-DDE, 0.5 mg/ml GT2 water 
extract did not induce it as the vehicle control, but the increasing effect by 1 mg/ml 
GT2 water extract was not inhibited by p,p '-DDE (Figure 3.38). It seem that 
p,p'-DDE itself did not increase the cell death even though it can induce the DNA 
damage as showed in the comet assay. Moreover, it can reduce the proportion of cells 
with low DNA content when low concentration of water extract triggered the cell 
death. However, when the concentration increased, the effect of water extract of GT2 
was stronger than p’p，-DDE. 
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Figure 3.38 Proportion of sub-Gl cells in treatments. Effects of 10 [iM /?,/?’-DDE , 1 
nM E2 and 100 nM DHT were compared with their vehicle control, and 0.5 mg/ml or 
1 mg/ml water extract of GT2 in single and combination with 10 jiM p,p'-DDE were 
compared with their own vehicle controls, respectively. Treatments were grouped by 
one-way ANOVA with Tukey method. 
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3.3.6 DNA damage and apoptosis relative gene expression by real time 
PCR 
Besides of the detection of DNA damage and sub-Gl peak, genes expression relative 
to DNA damage and apoptosis were also measured. Bcl-2, Bax and p53 are proteins 
reported to involve in apoptosis (Cory and Adams, 2002; Vousden and Lu, 2002). 
Ganoderma extract had been proved to increase p53 and the ratio of Bax/Bcl-2 (Tang 
et al., 2006). In this study, p,p -DDE had a dose-dependent increase on the 
expression of Bax at concentrations lower than 10 |j,M, at which there was a sudden 
decrease. At the same time, Bcl-2 slightly increased with the increase of p,p '-DDE, 
which made the Bax/Bcl-2 ratio raised at low concentrations but down to a normal 
ratio at high concentrations as control (Figure 3.39). Similar to Bax, expression of 
p53 was increased by the treatments with p,p，-DDE, but the increasing effect 
dropped under 10 [iM p,p -DDE treatment (Figure 3.40). These indicated the 
involvement of these genes in the action of p，p '-DDE on MCF-7 cells. 
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Figure 3.39 Expression of Bcl-2 and Bax under treatments with different 
concentrations of p’p，-DDE. Control was parallel with only vehicle. Ranking of the 
expression for each gene respectively was by one-way ANOVA and Tukey test at 5% 
probability with "a" of lowest ranking. Ranking was labeled in different colors for 
different genes. 
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Figure 3.40 Expression of p53 under treatments with different concentrations of 
p’p '-DDE. Control was parallel with only vehicle. Ranking of the expression for each 
gene respectively was by one-way ANOVA and Tukey test at 5% probability with 
"a" of lowest ranking. Ranking was labeled in different colors for different genes. 
3.3.7 DNA microarray 
To further understand the effects of and water extract of GT2, signal 
transduction pathways in MCF-7 were studied by DNA microarray, compared with 
two natural hormones, E2 and DHT. The Oligo GEArray® Human Signal 
Transduction in Cancer Microarray profiles the expression of 113 genes indicators or 
markers for the activation of 15 different signal transduction pathways involved in 
oncogenesis. The microarray slides and their deduced transcription profiles are 
shown in Figures 3.41 and 3.42. 56 highly expressed genes and 4 treatments were 
clustered, and the trees are shown on the top and left in Figure 3.43. These genes 
were grouped into 6 clusters as the purple lines shown on the right. The color of each 
block was determined by the fold change against the control. The log2 values of the 
fold change were scaled from green to red. A red color means up-regulation, a green 
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one means down-regulation and black is no change. Surprisingly E2 and DHT had 
similar differential profiles on many genes of the signal transduction pathways, e.g. 
cluster 3，4 and 5 that were up-regulated or down-regulated by both steroids at the 
same time, even though they promoted the cells into two opposite fates. The distance 
between these two treatments in the tree of treatments was the closest, even though 
there were also some genes, e.g. of cluster 1, with opposite changes of expression. 
The effects of p,p '-DDE were gentler and showed a profile quite different from 
either E2 or DHT (Figure 3.43). In cluster 2, 3 and 4，the profile of/?,;?-DDE was 
somehow similar to E2, but with less magnitude, while in cluster 1 and 5, p,p '-DDE 
had different profile from that of E2. Water extract of GT2, a complex mixture 
prepared from vegetative mycelia, did not show a statistical association with two 
natural hormones and nor p,p'-DDE according to the overall profiles (Figure 3.43). 
However, within each cluster, some degrees of similarity were found. Water extract 
of GT2 mycelia had similar effect to those of E2 but opposite to those of DHT on 
genes of cluster 1, while similar to DHT on cluster 6. Also, for those genes from 
cluster 3 and the upper half of cluster 5, water extract acted like both E2 and DHT, 
when for those from cluster 4 and the lower half of cluster 5, it acted opposite to E2 
and DHT. 
Figure 3.43 indicates the distribution of genes in two dimensions against the log2 fold 
change of expression in each pair of treatments. E2 and DHT seemed to be apt to 
up-regulate these signaling genes, and had a positive association with each other. 
When expressed genes of water extract and p,p '-DDE were compared, most data 
points scattered around zero point, indicating an ambiguous relationship. However, 
when we looked into individual signaling pathways (Table 3.9), water extract of GT2 
and p,p'-DDE seemed to had opposite effects on TGF(3 pathway (Figure 3.44). 
Besides, p,p '-DDE slightly up-regulated genes of Wnt and hypoxia pathway 
downstream genes, when water extract obviously promoted some genes but 
suppressed others. Also p,p '-DDE seemed to affect Cox-2 pathway and MAPK 
pathway downstream genes while water extract had little effect. Besides, water 
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extract seemed to affect hedgehog and PI3K / AKT pathway downstream genes 
while p’p -DDE had little effect. Both water extract and p，p，-DDE obviously acted 
on DNA Damage / p53 and stress / 38 JNK pathway downstream genes but the 
manner was complicated. 
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Figure 3.41 Slides of DNA microarray showing the differential regulation on 
expression profiles of the signal transduction pathways of MCF-7 treated with 
p,p '-DDE, E2 and DHT in comparison to DMSO, the vehicle control. 
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Figure 3.42 Slides of DNA microarray showing the differential regulation on 
expression profiles of the signal transduction pathways of MCF-7 treated with the 
water extract of GT2. 
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Figures 3.43 Expression profile of MCF-7 under treatments. 
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gene expression in each pair of treatment. 
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Table 3.9 List of genes regulated by different signaling pathways. 
Androgen Pathway: 
Cycl in-dependent kinase 2 
Transmembrane, prostate androgen induced RNA 
Cox-2 Pathway: 
V-fos FBJ murine osteosarcoma viral oncogene homolog 
Heat shock 70kDa protein 4 
Myeloid cell leukemia sequence 1 (BCL2-related) 
Peroxisome proliferator-activated receptor gamma 
Tumor necrosis factor receptor superfamily, member 10b 
DNA Damage / p53 Pathways: 
BCL2-associated X protein 
Growth arrest and DNA-damage-inducible, alpha 
Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
Heat shock 70kDa protein 4 
Insulin-like growth factor binding protein 3 
Tumor necrosis factor receptor superfamily, member 10b 
Tumor protein p53 inducible protein 3 
Tumor protein p53 (Li-Fraumeni syndrome) 
Estrogen Pathway: 




Bone morphogenetic protein 4 
Engrailed homeobox 1 
Hedgehog interacting protein 
Patched homolog 2 (Drosophila) 
Wingless-type MMTV integration site family, member 1 
WD repeat and SOCS box-containing 1 
Hypoxia Pathway: 
REB binding protein (Rubinstein-Taybi syndrome) 
Egl nine homolog 2 (C. elegans) 
Endothelin 1 
Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
Hexokinase 1 
Heme oxygenase (decycling) 1 
Insulin-like growth factor binding protein 3 
Metallothionein 3 
Transferrin receptor (p90, CD71) 
Inflammation / N F K B Pathways: 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (pi 05) 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
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MAPK Pathway: 
Early growth response 1 





Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
Jun oncogene 
V-myc myelocytomatosis viral oncogene homolog (avian) 
STAT Pathway: 
BCL2-like 1 
Interleukin 4 receptor 
Interferon regulatory factor 1 
Stress / p38 & JNK Pathways: 
Activating transcription factor 2 
Dual specificity phosphatase 1 
V-fos FBJ murine osteosarcoma viral oncogene homolog 
Heat shock 70kDa protein 4 
Heat shock 27kDa protein 1 
V-myc myelocytomatosis viral oncogene homolog (avian) 
Tumor protein p53 (Li-Fraumeni syndrome) 
Survival / N F K B Pathway: 
V-akt murine thymoma viral oncogene homolog 1 
BCL2-like 1 
Baculoviral lAP repeat-containing 2 
Tumor necrosis factor, alpha-induced protein 3 
TGFp Pathway: 
Cyclin-dependent kinase inhibitor IB (p27, Kipl) 
Cyclin-dependent kinase inhibitor 2B (pi5, inhibits CDK4) 
Cyclin-dependent kinase inhibitor 2C (pi8, inhibits CDK4) 
Cyclin-dependent kinase inhibitor 2D (pi9, inhibits CDK4) 
Transforming growth factor, beta-induced, 68kDa 
TIMP metallopeptidase inhibitor 1 
Wnt Pathway: 
Bone morphogenetic protein 4 
Cyclin D1 
V-fos FBJ murine osteosarcoma viral oncogene homolog 
FOS-like antigen 1 
Forkhead box N1 
Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
Jun oncogene 
V-myc myelocytomatosis viral oncogene homolog (avian) 
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Figure 3.45 Distribution of genes in 2-dimention against the log2 fold change of gene 
expression in p’p '-DDE and water extract of GT2 treatment. 
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4 Discussion 
4,1 Analysis of Ganoderma spp, 
G tsugae and G lucidum are two red lingzhi which are commonly used as 
commercial lingzhi products. Commercial products could be made up of mycelia, 
pileus, spores or their extracts. Although the fruit body of Ganoderma had been 
utilized as herbal medicine for several thousand years in China, the spores of 
Ganoderma became popular just from the late 20th century. The spores of 
Ganoderma also contain a large amount of bioactive substances like the fruit body. 
The bioactivity of the spores was reported to be even higher than that of the fruit 
body of Ganoderma (Min et al., 1998). The breaking of the spores of Ganoderma 
was proved to improve the release of activity (Zhu et al., 2000). Thus, most 
commercial spore products claim that they are sporoderm-broken. However the 
qualities of these spore products are uneven. Choice reported in January, 2008 that 
half of 16 tested spore products contain less than 90% broken spores, of which the 
lowest was only about 5%. 
In this study, these spore products, as well as four spore oil products (Table 2.1), 
were compared with laboratory cultivated G tsugae GT2 and G lucidum TPW 
samples. According to the fragment sizes of Mt-SSU-rDNAs, most of identified 
commercial spore products seem to be G. lucidum (Figure 3.4). DNA of several 
products could not be amplified probably because the sporoderm-broken process 
destroyed their DNAs seriously. The Mt-SSU-rDNAs of GT2 and GLTPW had 
different sizes (Figure 3.2), and the ITS2 regions were different (Figure 3.3). 
Chemical and biological properties also indicated some differences between these 
two species? as well as the commercial spore products. 
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Polysaccharides exist abundantly in fungi and are the major component of fungal cell 
wall. They had been recognised as effective anti-tumor substances which have drawn 
special research attention in correlation with immunomodulatory effects (Wang et al., 
1997; Peng et al., 2005; Cao and Lin, 2006). Polysaccharides extracted from mycelia 
were generally higher than fruiting bodies (Table 3.1), because polysaccharides of 
glucan was metabolized when fruiting bodies are formed (Carlile et al., 2001). 
Water-soluble polysaccharides consisted of more active components that are 
responsible for immunostimulatory and cancer therapy (Habijanic et al., 2001; 
Berovic et al., 2003). The total water-soluble polysaccharide content of mycelia of 
GT2 was highest among samples of both GT2 and GLTPW (Table 3.1). It also had 
the highest abilities to scavenge both superoxide radicals and DPPH radicals among 
GT2 and GLTPW samples (Table 3.3). However treating the MCF-7 breast cancer 
cells in RPMI medium supplement with 10% FBS, mycelia extracts showed slightly 
lower toxicity to the cells than the fruiting bodies at low concentrations (Figure 3.12). 
Interestingly, mycelia of GT2 slightly induced the growth of cells at low 
concentration (Figure 3.12). The water-soluble alcohol-insoluble polysaccharide 
content that usually had large molecular weight and the total terpene content were 
not significantly different in all samples of GT2 and GLTPW (Table 3.1). The 
qualities of commercial spore products varied in a large range. Water-soluble 
polysaccharide content was from (1.5 土 0.1) % to (42 土 0.5) % with the content of 
only one product higher than that of mycelia of GT2 (Table 3.2). However, 
water-soluble alcohol-insoluble polysaccharide content seems not to be a constant 
portion of water-soluble polysaccharide, 10 commercial spore products were higher 
than mycelia of GT2 (Table 3.2). The differences of terpene content among spore 
products were much less, between (2.5 土 0.5) % and (4.9 土 0.4) %. These values 
were only around half of GT2 and GLTPW samples (Table 3.2). Even though 
polysaccharides and terpenes were reported in a mass of literatures to contribute to 
the anti-tumor activities, the total contents of these two groups of bioactive 
molecules seems not to be significantly relative to their toxicities to the breast cancer 
cell. The inhibition effects of spore products at the concentration of 10 mg/ml ranged 
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from (17 土 19) % to (100 土 0) % (Table 3.5). Only four products could reach 100% 
inhibition, which is the same as GT2 and GLTPW samples (Table 3.5，Figure 3.12). 
Besides, the anti-oxidation abilities of most spore products were less than mycelia of 
GT2. Only one product was high, but it might be due to some unknown supplements 
in the spore powder. 
Table 4.1 Comparison of the terpene profiles of GT2 and GLTPW samples. 
" ^ e s GT2 GLTPW 
" S ^ l e M* I FB* I WM* WFB* M* | FB* | WM* WFB* 
Lanostetpl V 
9(1 l>Dehydioagosteiyl baizoate V ^ 
Etgostepl V ^ n 
Etgosta-5,8^-trien-3-ol V 
E^osta-5,7-<iiai-3-ol V V 
Etgost-5,8(14>digi-3-ol “ ~ ~ — 
Ergosta4,7^-trien-3.beta-ol V 
5,6-DihydroetgosteiDl V 
Neoeigosterol V V I I T I 
7-Etgostenol V 
g-Etgostaol V T \ 
Etgosta-7^-dier>6one V V V V V V V V 
^^nan-20-one | � | V | � | " \ / | > / | � | � V 
*M: mycelia; FB: fruiting body; WM: water extract of mycelia; WFB: water extract 
of fruiting body. 
From the chromatograms, the terpenes composition of GT2 and GLTPW samples and 
spore products were different. Similar compounds were identified in mycelia and 
fruiting body of GT2. However, terpenes in mycelia and fruiting body of GLTPW 
were quite different (Table 4.1). Some major terpenes, such as ergosterol, 
neoergosterol, ergosta-5,8,22-trien-3-ol, ergosta-5,7-dien-3.ol and ergosta-4,7,22-
trien-3.beta.-ol were absent in water extract samples. Two water-soluble terpenes, 
ergosta-7,22-6-one and pregnan-20-one were found in all GT2 and GLTPW samples. 
For the commercial spore products, the terpene profiles were quite different. Several 
major terpenes, fluocinolone acetonide, ergosta-7,22-dien-3-ol, y-ergosterol, 
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erogsta-7,22-dien-6-one and pregnan-20-one were present in most samples (Table 
4.2). Other terpenes that were found in only one or two samples are also listed in 
Table 4.2. Some of these terpenes were not found in GT2 and GLTPW samples, such 
as fluocinolone acetonide, cholesta-5,7,9(l l)-trien-3-ol, 5-cholestene-3-ol, 
ergost-7-en- 3-ol and 9,19-cyclolanost-24-en-3-ol. And some terpenes found in GT2 
and GLTPW samples were not detected in spore products, such as lanosterol, 
9(11 )-dehydroergosteryl benzoate, ergosta-5,7-dien-3-ol, 5,6- dihydroergosterol and 
neoergosterol. All of these suggest the difference of raw materials and processed 
products. 
134 
Chapter 4 Discussion 
Table 4.2 Comparison of the terpene profiles of commercial spore products. 
Sample No. I 1 I 2 I 3 I 4 I 5 I 6 I 7 I 8 I 10 I 11 I 12 
FluocinoloneAcetonide V m V m I V I � I 
Cholesta-5,7,9(ll>trien-3-ol — 
CholestCTol 
Vitamin E V V 
Ergost-4,7;22-tiien-3.ali^-ol ^ 
Bgostaol V V 
Ergosta-7^-dien-3-ol V V V V V _ _ V V V V T 
5-Cholestene-3-ol V 
V 1 m 
y-Etgostetol V V m 1 V 1 .V1 I � I � I 
9,l»€yclolanost-24-en-3-ol 
Ergosta-7^-<iien-6-one • n / V V V V V V V 
Pregnan-2(k)ne V V V V V V V V V 




Vitamin E V 
Etgost4,7^-triQi-34^-ol V 
Etgostepl V V 
Etgosta-7^-dien-3-ol V V V V V V V V 
5-Cholestene-3-ol 
Etgost-7-en-3-ol V 
Y-E^ostapl V V V V V V 
9,19-Cyclolanost-24-ai-3-ol V V 
Ergosta-7^-diai-6one V V V V V V V V V 
Pregnan-2(k)ne I � I 列 列 I ^ M 
Fatty acids are another major group of bioactive components in Ganoderma, and 
reported to be mainly unsaturated, which are relative to the stability of cell 
membrane, contributed to anti-oxidation and supplementary to essential fatty acids in 
human body (Chen et al., 2005; Wang et al., 2006). For the GT2 and GLTPW 
samples, major fatty acids, such as palmitic acid (CI6:0), linoleic acid (CI8:2 w6，9c)， 
oleic acid (CI 8:1 w9c) and stearic acid (CI 8:0) had large peaks of different areas in 
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the MIDI profiles (Figure 3.10, Table 4.3). The total contents of saturated fatty acids 
and unsaturated fatty acids were similar (Figure 3.10，Table 4.3). Some minor fatty 
acids were present in some samples but absent in others, which help to identify the 
two species and their different parts (Figure 3.10, Table 4.3). In their water extract 
samples, most fatty acids were remained, even though some minor fatty acids were 
lost in water extraction process (Figure 3.10, Table 4.3). Commercial spore products 
had much more complicated fatty acid profiles. Fatty acid profiles were depended on 
the qualities and degree that the spores were broken. Chen et al. reported that fatty 
acid content extracted from sporoderm-broken spores was 38.95% higher than that of 
non-broken spores (Chen et al., 1999). In some spores products, the contents of two 
major fatty acids, linoleic acid (CI8:2 w6，9c)，oleic acid (CI8:1 w9c), are relatively 
more than mycelia and fruiting bodies (Figure 3.11). 
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Table 4.3 Comparison of the fatty acid profiles of GT2 and GLTPW samples. 
Species GT2 GLTPW 
" S ^ l e 一 M* I FB* I WM* M* | FB* | WM* WFB* 
10:0 V V V V V V ~ V V 
11:0 20H ~ V V V V “ V ""“V 
14:0 ISO V V V V 
w5c V V V V V ~ V 
V V V V V V V V 
13:0 20H V V V V V V~~ V V 
13:0 30H/15:1 i l /H — V V ~ V V “ V V V 
15:0 ISO ~ ~ V ~ 
15:0 ANTEISO " " “ V ~ — 
14:0 30H/16:1 ISO I V — — -
15:1 w8c V V V V V V “ V V 
15:0 V _ V ~ V 
16:0 ISO V “ -
16:1 w7c/15iso 20H V V V V “ V V V V 
16:1 w5c V V 
V V " V V V V V ~ V 
17^0 ANTEISO V V " V V V ~ V V V ~ 
17:0 - “ ~ ~ 厂 V 
l ^ w 6，9 c / l 8 : 0 ANTE V V V V “ V ~ V V V 
w9c V V " V V V ~ V V "V~~ 
18:1 w7c V 一 V 
| � | > / | > / | v | > / | > / | a / | > ; 
*M: mycelia; FB: fruiting body; WM: water extract of mycelia; WFB: water extract 
of fruiting body. 
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Table 4.4. Comparison of the fatty acid profiles of commercial spore products. 
SanpleNo. 丨 1 丨 2 | 3 丨 4 丨 5 丨 6 丨 7 | 8 | 10 丨 11 | 12 
9:0 一 
10:0 - V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V ~\ / V V 
11:0 ANTEISO 
11:0 V _ _ V _ _ V V _ _ V _ _ V ~ ~ V ~ ~ V 
10:0 30H V V__V ~ ~ V ~ ~ V ~ ~ V 
11:0 IS0 30H - V V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V 
11:020H V _ _ V _ _ _ V _ _ V _ _ V _ _ V _ _ V ~ ~ V ~ ~ V 
i i :0 30H V V ~ ~ V ~ ~ V V 
12:0 ISO 一 V V ~ ~ V ~ ~ V ~ ~ T V V 
12:0 30H ~ ~ V ~ ~ V ~ ~ V ~ ~ V ~ ~ V ~ ~ V " V " T " 
12:0 ANTEISO ~ V _ _ V _ _ V _ _ V ~ ~ V ~ ~ V V 
12:0 V V T V .V " T " V V 
13:0 ISO V — 
13:0 ANTEISO V T~ 
l ^ i s o V V V V V ~ ~ T V V 
14:1 ISO E 
14:1 w5c V _ _ V V ~ ~ V V " 一 V 
14:0 V__V ~ ~ V ~ ~ V V ~ ~ V ~ ~ V V V 
13:0 ISO 30H V V 
13:0 20H V__V T 
15:1 ISO V 
13:0 30H/15:1 i l /H V__V ~ ~ V V ~ ~ V ~ ~ V ~ ~ V V V 
ISO 15:1 AT 5 V 
15:0 ANTEISO V 
15:0 ISO 20H/16:lw7c V 
15:1 w8c V__V ~ 7 ~ 
15:1 w6c V 
15:0 — V V V V V V V V T~ 
15:0 20H V 
15:0 30H V 
14:0 ISO 30H V 
14:0 20H V 
16:0 10 methyl V 
16:1 ISOG V 
16:0 ISO V 
16:0 ANTEISO V V 
16:1 w l l c V V V 
16:1 w9c V V V V V V V V 
16:1 w7c/15iso 20H V _ _ V _ _ V _ _ V _ _ V _ _ V ~ ~ V V ~ ~ V " 
w 5 c | v | v | v | v | v | v | v | v | V ~T~ 
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SanpleNo. | 1 | 2 | 3 | 4 丨 5 | 6 | 7 | 8 | 10 | 11 | 12 
16:0 V V V V V V V V V ^ 
16:1 20H V 
16:0 20H V V 
ISO 17:1 w9c - V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V V _ _ ^ 
17:1 ANTEISO B/il V ~ ~ V ~ ~ V ~ ~ V V ~ ~ V ~ ~ V V V 
17:0 ANTEISO 
17:1 w8c ~ V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V V 
17:1 w7c V 
17:1 w6c V V V 
17:1 w5c V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V _ _ V ~ ~ 
17:0 ~ V _ _ V _ _ V _ _ V _ _ V _ _ V ~ ~ V V ~ ~ T 
17:0 C Y C L O V 
18:0 ANTE/18:2 V "V V T V 
18:1 ISO H 
18:3 w6c (6,9,12) 
18:0 ISO 
18:2 w6,9c/l8:0 ANTE V V T~ 
18:1 w9c V V V 
18:1 w7c V__V ~ ~ V ~ ~ V ~ ~ V ~ ~ V ~ ~ V V ~ ~ 
18:0 V _ _ V _ _ V ~ ~ V ~ ~ V ~ ~ V ~ ~ T V 
TBSA 10Mel8:0 
19:0 ISO V V V ~ ~ V V ~ ~ T V T " 
19:1 w9c/19:l w l l c V 
19:0 V V V 
un 18.846/19:1 w6c V 
18:1 20H V V V ~ ~ V V ~ 
18:0 20H V V V 
18:0 30H V 
20:4w6，9，12，15c 
20:2 w6,9c V V 
20:1 w9c V _ _ V _ _ V ~ ~ V V 
20:0 ISO V~~V " T " 
139 
Chapter 4 Discussion 
Table 4.4 Comparison of the fatty acid profiles of commercial spore products 
(continued). 
SanpleNo. I 13 I 01 I 02 I 03 I 04 I 05 I 9 I 31 I 32 I 33~ 
9:0 V V V ^ 
10:0 " V V V V V V V V V 
11:0 ANTEISO V 
11:0 ~ T ~ 
10:0 30H ~ T " 
11:0 ISO 30H 
11:0 20H V V V V V 
11:0 BOH V 
12:0 ISO V 
12:0 30H V . 
12:0 ANTEISO V 
12:0 V 
13:0 ISO V 
13:0 ANTEISO V V 
14:0 ISO V 
14:1 ISOE 
14:1 w5c V V 
"T^o V V V V V V V V V 
13:0 ISO 30H 
1 ^ 2 0 H V V V V V V 
15:1 ISO 
13:0 30H/15:1 i l /H V V V ~ T " V ~ T " V V 
ISO 15:1 AT 5 
15:0 ANTEISO V 
15:0 ISO 20H/16:lw7c 
15:1 w8c V V V V 
15:1 w6c 
15:0 V � � V V ~ T ~ V ~ T " V 
15:0 20H 
15:0 30H V 
14:0 ISO 30H 
14:0 20H 
16:0 10 methyl V 
16:1 ISOG 
16:0 ISO 
16:0 ANTEISO V ~ T " 
16:1 w l l c 
16:1 w9c V V V 
w7c/15iso20H | V | V | V | V | V | | V | V | V | ^T" 
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" s ^ l e N o . I 13 I 01 I 02 I 03 I 04 I 05 I 9 I 31 I 32 I 33 
16:1 w5c � � a/ � � V V yl V 
16:0 " V V V V V V V V V 
16:1 2 0 H V 
16:0 2 0 H 
ISO 17:1 w9c V 
17:1 ANTEISO B/ i l V 
17:0 ANTEISO V V V 
17:1 w8c V V V V V V 
17:1 w7c V 
17:1 w6c 
17:1 w5c V V 
l 7 i b V V V V ~ V V V V 
17:0 CYCLO ~ ~ ~ V 
18:0 ANTE/18:2 
18:1 ISOH V 
18:3 w6c (6,9,12) 一~~ V 
18:0 ISO V 
l ^ w 6， 9 c / l 8 : 0 ANTE V V V ~ T " V V V V V 
w9c V V V V V V V V V 
18:1 w7c V V V V ~ T " V V T " 
T s i b V V V ~ T " V V~ V V V V 
TBSA 10Mel8:0 V V 
19:0 ISO V V ~ T " V V V 
19:1 w9c/19:l w l l c 
19:0 V V 
un 18.846/19:1 w6c 
18:1 2 0 H V V _ V "~T~ V V V 
18:0 2 0 H 
18:0 3 0 H V 
20:4 w6，9，12，15c V 
20:2 w6,9c V 
20:1 w9c V V V V V 
20:0 ISO ~ T " V 
丨 w 丨 ^ M l v | v | v | 
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In summary, mycelia of GT2 had high contents of polysaccharides and terpenes, high 
abilities to scavenge free radicals and inhibit the growth of breast cancer cells. 
Commercial spore products did not show a consistent performance in relation to their 
terpene nor polysaccharide contents; some samples that showed higher content of 
polysaccharides, or higher ability to scavenge free radicals, or completely inhibit the 
growth of breast cancer cells had poor performance in other assays. Also, mycelia is 
easy to cultivate and harvest in laboratory, low cost and less time, while spores were 
much more expensive in production and cost in processes including 
sporoderm-breaking. Taking all these into consideration, mycelia of GT2 was 
selected in further studies on hormone-like capacities. 
E-screen is a common assay to screen estrogen like compounds (Soto et al. 1995). 
The end point is the proliferation of estrogen-dependent breast cancer cells, MCF-7. 
E-screen assumes that, in estrogen-depleted medium, estrogen-like compounds could 
induce cell proliferation by activating estrogen receptors, and this pathway is specific 
(Soto et al. 1995). Luk (2005) has reported the estrogenicities of water extracts of 
both G. lucidum and G. tsugae, and the active compounds were proved to be terpenes 
but not polysaccharides. In this study, the water extract of GT2 mycelia induced the 
proliferation of MCF-7 in E-screen assay at low concentrations, but inhibited it at 
high concentrations (Figure 3.13)，which is in accordance with the result in 
anti-proliferation assay (Figure 3.12) This indicates the presence of estrogen-like 
compounds in the water extract. In the in vitro estrogen receptors competitor binding 
assays, terpenes were proved again to contribute to the estrogenicity of water extract 
of GT2. It showed significant affinities to both ERa and p (Figure 3.15); even though 
the water extract did not have significant effect in ERs binding (Figure 3.14) and 
yeast-based ER-responsible promoter assay (Figure 3.16). The latter result may 
probably be because of the low sensitivity of these two assays. Endogenous 
ER-pathway relative genes were much more sensitive to the water extract. The 
expression of pS2, which has been widely used as a marker of estrogen 
responsiveness in ER-containing breast cancer cells, acts like an indicator of disease 
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progression and a predictor of success of anti-estrogen therapy in breast cancer 
patients (Soubeyran et al., 1996; Elledge et a l , 2000; Crosier et al., 2001). pS2 
transcription was increased by more than 12 folds, while ERa was only slightly 
increased (Figure 3.19). However, interestingly, another estrogen-responsive gene， 
PGR, which is up-regulated by estrogen through ERs (Nardulli et al., 1988; Wei et 
al., 1988; Hewitt and Korach, 2000; Vienonen et al., 2002), was significantly 
down-regulated by water extract of GT2 in a dose-dependent manner. Multiple 
receptors might be affected by the tested samples, estrogen receptor mediates 
multiple pathways, and these pathways might have crosstalk to others. Beside ERs, 
MCF-7 cells also express AR and PGR. Water extract of GT2 activated AR in 
yeast-based AR-responsive promoter assay, but had no effect on PGR. It also 
significantly increased one of the AR-responsive genes, TMEPAI, in MCF-7, but had 
no effect on the other, UDPGDH (Figure 3.20), which should have been up-regulated 
by androgens in breast cancer cells (Lapointe and Labrie, 1999). It seems that water 
extract of GT2 could act on both estrogen and androgen receptor and affect their 
regulated gene. However, as showed in microarray, GT2 had a quite different 
differential expression profile from those of E2 and DHT. 
义 i T ^ 
O COOH 
T 冬 R« 
A 
[ I 1=1 A r A ft 
B C D 
Figure 4.1 Structure of ganoderic acids (A), 17p-estradiol (B), DHT (C) and 
progesterone (D). R1-4 may be -H, -OH, = 0 or -OAC. 
143 
Chapter 4 Discussion 
Compared with the most common estrogen, androgen and progesterone in human, 
the general structure of ganoderic acids, a group of triterpenes found in Ganoderma 
spp., have a similar skeleton (Figure 4.1), which make them the candidates that are 
responsible to the hormone-like effects of water extract of GT2. Since the first 
isolation of two triterpenes, ganoderic acids A and B, from the dried epidermis of G. 
lucidum in 1982 by Kubota et al. (1982)，more than 130 oxygenated triterpenes 
(mostly lanostane-type triterpenes) have been isolated from the fruiting bodies, 
spores, mycelia and culture media of Ganoderma spp. (Chaiml and Hayashi, 1994; 
Kim and Kim, 1999). Different structures of triterpenes might have different 
affinities to steroid receptors, although so far there are few studies on the interaction 
of triterpenes from Ganoderma spp. with steroid receptors. Anyway, containing 
terpenes with similar structures to that of steroids and showing the effects on both 
ERs and AR and their responsive genes make the water extract of GT2 a potential 
and safe modulator in hormone therapy. 
4,2 Effects ofp，p，-DDE 
Breast cancer is a steroid hormone-responsive disease (Friedman, 2007). The breast 
tumors frequently express steroid receptors, such as ER, PGR and AR, and the 
growth and development of the tumor are intensively regulated by them (Lea et al., 
1989; Hall et al” 1996; Kuenen-Boumeester et al., 1996; Ando et al., 2002; Honma 
et al., 2003; Moinfar et al, 2003; Riva et a l , 2005). The presence of ER has been 
well-known as a risk factor of the breast cancer development for decades. ER 
positive phenotype was statistically associated with breast cancer for both pre- and 
postmenopausal women (Khan et al., 1994). Two isoforms of ER, ERa and ERp，are 
distinguished from each other in term of structure, expression and function. Dotzlaw 
showed that both ERs expressed in either normal or neoplastic breast tissue or cells, 
and their expression had no correlation in different samples (Dotzlaw et al.，1997). 
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However at the promoters of some genes, particularly those involved in proliferation 
like cyclin Dl , ERa and ERp could have opposite actions (Liu et al., 2002a). This 
suggested that the overall proliferative response to E2 of ERa- and ER|3-positive 
breast cancer cells is the result of a balance between ERa and ER(3 signaling. And 
PGR, which is another good diagnostic maker for breast cancer, is also required for 
the normal cell proliferation and differentiation of the mammary epithelium 
(Mulac-Jericevic et al., 2000; Conneely et al., 2001). It had a significant positive 
relationship with the expression of ER in breast tumors (Khan et al., 1994), since it is 
a downstream gene regulated by ERa (Hewitt and Korach, 2000). Ablation of PGR 
expression in mice resulted in a significantly reduced incidence of mammary tumor 
growth in response to carcinogen challenge (Lydon et al., 1999). This demonstrates a 
crucial role of PGR as obligate mediators of the intracellular signaling pathways for 
the initiation of mammary tumors induced by the carcinogen (Lydon et a l , 1999). 
Moreover, AR expression was also frequently detected in both primary breast 
tumours (70-90%) (Lea et al.l989, Soreide et al. 1992, Kimura et al. 1993) and 
breast tumour metastases (75%) (Lea et al. 1989)，which suggests that androgens are 
also important regulators of breast cancer. 
In this study, MCF-7 was used as the breast cancer cell model in the investigation of 
the action mechanism of p,p '-DDE. MCF-7 is sensitive to E2, which promotes the 
proliferation through ER (Darbre and Daly, 1990). Thus this model is widely used in 
the studies on ER-positive breast cancer and endocrine disruptors (Soto et al., 1995; 
Rasmussen et al., 2003). p,p'-DDE significantly increased the RPE of MCF-7 in 
steroid-depleted media (Figure 3.21). And this effect could be synergic to that of E2 
when the concentration of E2 was not reaching a saturation effect (Figure 3.22). 
Even though this assay is commonly accepted as a screening assay for estrogen-like 
compounds, the presence of multiple steroid pathways may complicate the result 
because of the similarity between p,p '-DDE and these steroids (Figure 1.4). And it 
seems that ER, PGR and AR are contributed to the regulation of proliferation and 
survival of the MCF-7 cells. Thus the effects of p,p'-DDE on ER, AR and PGR 
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pathways altogether have been taken into consideration. 
MCF-7 cytosol was reported to contain approximately 100 fm/mg protein ER, more 
than 300 fm/mg protein PGR, and about 40 fm/mg protein AR (Horwitz et a l , 1975). 
Both ER a and p were proved to be present in cytosolic, nuclear and mitochondrial 
fractions (Chen et al., 1998). Interestingly, although the affinity of p,p -DDE to ERa 
was reported to be low (Kelce et al., 1995; Kuiper et al., 1998)，the highest affinity of 
p,p'-DDE to ERP was impressively high up to 80% of that of E2 (Figure 3.25), and 
the ECso，4.4x10-7 m (139.9 ^g/i), was 571 fold higher than the EC50 of E2 (Table 
3.7). This EC50 of p,p -DDE to ERp was much lower than the average serum 
concentration of p,p '-DDE, 862+0.154 |ag/l, in a group of breast cancer patients in 
India (Mathur et al., 2002), while the serum concentration of E2 was only reported to 
be at the level of tens of pM in both breast cancer and control groups (Dorgan et al., 
1996). The estimated EC50 of/?,/?-DDE to ERa was 4.1x10"^ M, almost 1000 fold 
higher than ERP (Table 3.7). Also the effect of p,p -DDE was low on ERE-promoter 
activation in recombinant yeast cells transfected with ERa. These were consistent 
with previous studies on ERa (Kelce et al., 1995; Chen et al., 1997; Kuiper et a l , 
1998). 
The transcription of PGR could be increased by ERa through the binding on the ERE 
half-site on the promoter A of PGR gene (Kastner et al, 1990). Also, 
Boonyaratanakomkit and colleagues (2008) had reported that PGR could activate 
MAPK (Erk-l/-2) through interaction with the SH3 domain of Src and rapid 
activation of c-Src. Selected target genes such as cyclin D1 (CCNDl) that plays a 
key role in Gl-S cell cycle progression were regulated by activated MAPK 
(Boonyaratanakomkit et al., 2008). Thus PGR was thought to contribute to the 
substantial (70%) increase in the percentage of cells in G2/M+S phase induced by 
progestin through progesterone receptor in T47D breast cancer cells 
(Boonyaratanakomkit et al., 2008). Besides, PGR activated by medroxyprogesterone 
acetate (MPA) protected T47-D and MCF-7, both of which were PGR-positive breast 
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cancer cells, from apoptosis induced under serum starvation (Ory et al., 2001). 
However, the protective effect of MP A against apoptosis was not related to the status 
of tumor suppressor gene p53 and pro-apoptotic protein Bax (Ory et a l , 2001). 
Actually the anti-apoptotic protein Bcl-2 was down-regulated by MP A (Ory et al., 
2001). In this study, the expression of PGR was obviously increased by p,p '-DDE in 
a dose-dependent manner (Figure 3.30). Thus the increase of RPE in E-screen 
induced by p,p -DDE may be due to the functions of PGR in both cell cycle 
progression and anti-apoptosis. However, p,p -DDE itself did not activate this 
receptor, since it had no effect on the PRE-promoter activation in recombinant yeast 
cells transfected with PGR. So the action of PGR was probably independent on its 
ligand activation. In addition, the ability of p，p，-DDE to activate ERa was as low as 
only 30% of that of E2 (Figure 3.26), and pS2 that has a full site of ERE was also 
rarely affected by p,p '-DDE (Figure 3.30). Therefore, the increase of PGR seems not 
to be due to the activation of ERa. This up-regulation mechanism of PGR might not 
follow the classical ERa-PGR pathway. Furthermore, unlike the MPA-promoted 
anti-apoptotic effects in T47-D cells, Bax in MCF-7 was obviously increased by 
p,p -DDE at low concentrations (Figure 3.39). On the other hand, Bcl-2 was also 
increased by p,p '-DDE in a dose-dependent manner, which kept the change of ratio 
between Bax and Bcl-2 at an almost constant level between 3.5 and 3.9 fold of that in 
control cells (Figure 3.39). Under 10 \iM of p,p'-DDE, the ratio between Bcl-2 and 
Bax returned to the basal level while a sudden drop of Bax expression appeared with 
the increase of Bcl-2 (Figure 3.39), indicating suppression of the apoptosis pathway. 
Besides, the expression of p53 under p，p '-DDE treatments was consistent to that of 
Bax (Figure 3.40). It was an upstream regulator of Bax that could be induced by 
genotoxic stresses particularly DNA damage (MacDonald and Ford, 1997). From 
these, it could be seen that p’p '-DDE might activate apoptosis pathway, which was 
probably due to the genotoxicity of p,p '-DDE (Binelli et al., 2008; Ennaceur et al.， 
2008), but with the increase of p’p '-DDE, apoptosis was inhibited accompanying the 
up-regulation of PGR and Bcl-2, and finally p’p '-DDE increased the RPE of MCF-7. 
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For AR pathway, p,p '-DDE has been already well accepted as an anti-androgen 
(Kelce et al., 1995). Activated AR was shown to inhibit MCF-7 cell proliferation and 
induce moderate increases in the proportion of G1 phase cells (Greeve et al., 2004). 
In this study, p,p，-DDE significantly inhibited the activity of AR activated by DHT 
in recombinant yeast (Figure 3.28), and it rescued the MCF-7 when DHT was 
inhibiting its proliferation (Figure 3.23). At the same time, E2 also showed a stronger 
inhibition on the transcription of AR activated by DHT in recombinant yeast (Figure 
3.28), a higher ability to suppress the anti-proliferation of DHT on MCF-7 (Figure 
3.23), and also decrease the expression of androgen responsive gene, TMEPAI 
(Figure 3.31). The result shows the natural anti-androgenic property of E2. Thus, the 
proliferative effect of E2 might be a combination of suppression of AR pathway and 
promotion of ER pathwa. Aube et al. (2008) also suggested that the anti-androgen 
property of p,p，-DDE may contribute to its estrogen-like effect in breast cancer cell 
model in the presence of physiological concentrations of estrogens and androgens. 
However, in this study steroids in medium were deprived. p，p '-DDE regulated genes 
of the AR and ER pathways similarly with E2 (Figures 3.30 and 3.31). The 
proliferative effect of p’p '-DDE did not diminish even though DHT was absent. Also, 
the expression of genes responsive to AR was not significantly changed by p’p '-DDE 
when DHT was not added into the medium (Figure 3.31). These all indicate that the 
inhibition of AR pathway was not the only or even main cause for p,p -DDE to 
enhance the proliferation of MCF-7. Rather, p’p '-DDE should have a direct effect on 
proliferation. p,p -DDE up-regulated PGR and ERa transcription but not ERp 
(Figure 3.30). 
Whether binding to ER|3 and the remarkable increase of PGR are involved in the 
proliferation promoted by p’p ’-DDE needs to be further investigated. The 
relationship between activation of ERp and up-regulation of PGR was controversial 
in several studies. In HeLa cells transfected with PGR-B, PGR-B promoter activity 
was enhanced by ERa, but not by ER(3 in 24 or 48 h (Flototto et al., 2004). Similar 
results were also obtained in BT20 and Ishikawa cells (Flototto et al., 2004). Inability 
148 
Chapter 4 Discussion 
of ERp to mediate the up-regulation of the PGR-B promoter was probably due to the 
difference between the AFl domains at NH2 terminus of ERa and ER(3 (Flototto et 
al., 2004), which was probably important to the recruitment of coactivators (Hawse 
et al., 2008). In contrast, in human fetal osteoblast (hFOB) cells transfected with ERp 
(hFOB/ERp cells), PGR-A and PGR-B mRNAs were induced progressively by E2 
after 48 h of treatment. Yet human fetal osteoblast (hFOB) cells transfected with 
ERa (hFOB/ERa cells) required 12 days posttreatment to achieve the maximum 
induction. Further, i?-tetrahydrochrysene (THC), an ERp selective antagonist, 
abolished the up-regulation of PGR mRNAs in hFOB/ERp but not in hFOB/ERa 
cells (Rickard et al., 2002). Thus, the response of PGR may vary in different cell 
lines or different treatment time. Also, ERp probably has a separate pathway to 
activate PGR promoter, not as that of ERa through binding to Spl and Spl sites 
(Petz and Nardulli, 2000; Schultz et al., 2003; Schultz et a l , 2003), since ERp needs 
much more time than ERa. In this study, PGR was up-regulated by p，p，-DDE after 4 
day treatment. The role of ERp on the effects of p,p，-DDE could be studied by 
blocking its effects on the downstream events. 
In addition, comparing the ER- and AR-responsive gene expression profiles under 
the treatment of E2, DHT and p’p -DDE, p,p '-DDE had a distinguished pattern from 
those of E2 or DHT. As expected, E2 dramatically increased the expression of ERa 
and p, ER responsive genes, pS2 and PGR and suppressed the AR responsive gene, 
TMEPAI in a dose-dependent manner (Figures 3.30 and 3.31). Also DHT 
significantly enhanced the expression of AR, TMEPAI and UDPGDH (Figures 3.31). 
However, surprisingly, E2 also increased the expression of UDPGDH (Figures 3.31), 
even though it was reported to be enhanced by DHT and directly regulated by AR in 
breast cancer cell, ZR-75-1 (Lapointe and Labrie, 1999). That may be because 
UDPGDH is a key enzyme in the control of sex steroid inactivation via 
glucuronidation in breast cancer cells (Taniguchi et al., 2002). E2 exerted a 
stimulatory effect on the glucuronidation of androgens and their metabolites in 
MCF-7 (Roy et al., 1992). Thus the increase of UDPGDH promoted by E2 may be 
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related to the glucuronidation of other steroids. This pathway was considered as a 
possible regulation of breast cancer cell growth by hormones. Unlike either E2 or 
DHT, all the tested doses ofp,p'-DDE did not affect the expression of UDPGDH. It 
seems that although p,p '-DDE can bind to steroid receptors, it may be resistant to 
inactivation pathways for natural steroids by glucuronidation. Thus p,p '-DDE can 
stay long and show prolonged effects. 
Another harmful effect of 10 |a.M p,p -DDE was DNA damage detected by comet 
assay (Table 3.8) as reported in wheat Triticum aestivum (Gong et al., 2004). 
Increased p53 and Bax expression was observed with p,p '-DDE at low-medium 
concentrations (< 1 |iM) mentioned in chapter 3 (Figures 3.39 and 3.40). Yet the 
increase of Bcl2 leaded to lower Bax/Bcl2 ratio at 10 [iM. At 10 jiM which was the 
dose used in the combination experiment with water extract of GT2, p’p '-DDE did 
not affect Bax/Bcl2 ratio and only slightly increased p53 expression (Figures 3.39 
and 3.40). Similar effect of 10 p,p'-DDE on sub-Gl cells was observed with 
flow cytometry experiment (Figure 3.38). In a word, 10 |xM p,p '-DDE increased 
DNA breakage without increasing of cell death including apoptosis which plays a 
important role to clear abnormal cells (Figure 3.38 and Table 3.8). These may 
increase mutation burden and explain the increased breast cancer risk. 
In summary, p,p '-DDE increased the proliferation of MCF-7, when it had high 
affinity to ER(3 and induced the expression of PGR which may be related to the 
regulation of apoptosis. Inhibition of AR pathway by p’p '-DDE had been proved by 
previous study (Aube et al. 2008)，which plays a role on rescuing the breast cancer 
cell when androgen try to inhibit its proliferation. Besides, p,p '-DDE induced DNA 
damage without increasing the apoptosis. With these effects of p，p '-DDE, hypothesis 
to explain the relationship between the concentration of p，p '-DDE in human body 
and the increase of breast cancer risk could be that p’p '-DDE induces DNA mutation 
by DNA damage effect, DNA mutation is preserved by inhibiting apoptosis, and 
these mutation were further amplified by increasing the proliferation of mutated cells 
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(Figure 4.2). 
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Figure 4.2 Schema of the hypothesis that p’p '-DDE increases breast cancer risk. “+，’ 
means the previous node increases the effect of next node; means the previous 
node decrease the effect of next node; ‘‘?，, means the effect is not prove yet. ‘‘丄，，and 
" t " means decrease and increase induced by p’p，-DDE respectively. p,p '-DDE had 
high affinity to ER(3 and induced the expression of PGR which may be related to the 
decrease of apoptosis and increase of proliferation of MCF-7. Inhibition of AR 
pathway by p’p '-DDE plays a role on rescuing the breast cancer cell when androgen 
try to inhibit its proliferation. p,p '-DDE also induced DNA damage which may 
increase DNA mutation. Mutation could be preserved by inhibiting apoptosis, and 
amplified by increasing the proliferation of mutated cells. Finally, cancer risk 
increases. 
4J Protective effects of GT2 against 
Selective estrogen receptor modulators (SERMs) were commonly used in the 
hormone therapy of breast cancer, as well as the chemoprevention. Tamoxifen, the 
first selective estrogen receptor modulator, has saved the lives of estimated 500,000 
patients with ER-positive breast tumor (Cuzick and Baum, 1985). The value of 
tamoxifen in preventing breast cancer was also proved in rats in 1970s (Jordan et al., 
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1976). And much later, a large-scale breast cancer prevention trial by Bernard Fisher 
and his colleagues found that tamoxifen caused a 50% reduction in the incidence of 
breast cancer at a daily dose of 20 mg for 5 years (Fisher et al., 1998). However, the 
anti-estrogenic property of tamoxifen causes the side effects, such as osteoporosis 
and coronary heart diseases, since estrogen was essential to maintain bone density 
and could possibly protect women from coronary heart disease. Moreover, the 
increase of endometrial cancer risk by tamoxifen was reported in mouse as well as 
clinical cases (Gottardis et al., 1988; Fomander et al., 1989; Fisher et a l , 1994)，and 
there were the increased risks of deep-vein thrombosis and pulmonary emboli 
(Cuzick et al., 2002; 2003). To simultaneously prevent those site effects and reduce 
the incidence of breast cancer, raloxifene, which was approved by the FDA for the 
treatment and prevention of osteoporosis in 1998，was used for treatment of breast 
cancer in high-risk postmenopausal women. Clinical trials demonstrated that 
raloxifene treatment maintained bone density and reduced spinal fractures in women 
at risk for osteoporosis (Delmas et al., 1997; Ettinger et al., 1999) while it reduced 
the risk of breast cancer by 75% without measurable increases in endometrial cancer 
(Cummings et al., 1999; Cauley et al., 2001). However, the prevention strategy 
required not only the multiple functions in high risk postmenopausal women but also 
long term benefits and low side effects in high-risk premenopausal women. 
Raloxifene has not been tested in premenopausal women. Therefore, tamoxifen 
remains the only proven intervention in premenopausal women, although its side 
effects have drawn lots of health care concerns. 
Even though the high achievement in hormone therapy has been proved for these 
synthetic hormones, long term treatment for both premenopausal and 
postmenopausal women was reported to be associated with more or less increased 
risk of deep-vein thrombosis, pulmonary emboli, coronary heart disease, stroke, 
breast cancer or gallbladder disease (Farquhar et al., 2009). Compared with 
bioidentical hormones, synthetic counterparts were found to be associated with 
higher risks of breast cancer and cardiovascular disease (Holtorf et al., 2009). 
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Patients reported greater satisfaction with hormone replacement therapies that 
contain bioidentical hormones than those that contain synthetic counterparts (Holtorf 
et al., 2009). Thus, with the concern about the safety of synthetic hormones, 
hormone-mimicking compounds from plants, such as phytoestrogens, are considered 
as an alternative to prevent breast cancer and alleviate menopausal symptoms. 
Isoflavones, a group of phytoestrogens from soybean, have drawn lots of attention 
when epidemiological studies suggested that the incidence of breast cancer was 
lower in countries where the intake of soybean was high (Shu et al., 2001). However, 
short-term intervention studies suggested a stimulatory effect of phytoestrogens on 
the proliferation of breast tissue and breast cancer cells, and the role of 
phytoestrogens remains unclear (McMichael-Phillips et al., 1998; Oseni et al., 2008). 
With the mass of evidence on anti-cancer activities in vivo and in vitro, the clinical 
value of Ganoderma extracts against cancers has drawn lots of attention (Sliva, 2003; 
Yuen and Gohel, 2005). Ganoderma extracts have been used as adjunct therapy in 
some cancer treatments (Pfeifer et al., 2000; Meyer and Gillatt, 2002; Yuen and 
Gohel, 2005; Mahajna et al., 2009). These benefits are thought to be mainly due to its 
anti-oxidation and immuno-modulation abilities (Yuen and Gohel, 2005; Mahajna et 
al., 2009), both of which are not achieved by synthetic hormones but particularly 
good for women with age and high risk of cancers. Also, Ganoderma extracts have 
the potential to prevent osteoporosis (Shimizu et al., 2006a, b; Miyamoto et al., 
2009)，which is one of the important concerned side effects in breast cancer 
treatment. Thus cancer prevention probably could be obtained by daily consumption 
of Ganoderma extracts. In this study, it was shown that not only the anti-oxidation 
and immuno-modulation abilities of Ganoderma extracts contributed to their 
potential to prevent cancer, but also their endocrine regulation activities do. In 
section 4.1 the hormone-like effects of Ganoderma extract have been discussed. The 
water extract of GT2 affected ER and AR pathways, both of which regulated the 
proliferation of MCF-7 in opposite effects. In the absence of hormones and endocrine 
disruptors, the water extract of GT2 increased the proliferation of MCF-7 at low 
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concentrations. However, in the presence of E2 or p,p '-DDE with a highest effect on 
promoting proliferation, the water extract suppressed their effect from low to high 
concentrations showing a dose-dependent curve (Figure 3.32). This effect was in a 
dose-dependent manner (Figure 3.32). Interestingly when the proliferation was 
suppressed by DHT, low concentration of water extract reversed this suppression 
(Figure 3.33). It seems that the water extract of GT2 can act as a buffer that kept the 
hormonal action on proliferation of MCF-7 in balance. pS2 expression was 
consistent with this observation. 0.5 mg/ml water extract of GT2 increased 
transcription pS2 reproducibly whereas 1 mg/ml water extract of GT2 increased pS2 
expression to less extent in the absence of p,p'-DDE (Figures 3.19 and 3.34). 
However, 0.5 mg/ml of water extract of GT2 suppressed the expression of pS2 in the 
presence of 10 |xM p,p '-DDE (Figures 3.34). For the mitogenic effect o f p , p '-DDE in 
E-screen (steroid-depleted) media, cell cycle progress was less affected (Figure 3.35), 
but PGR expression was reproducibly enhanced (Figures 3.30 and 3.34). Both 0.5 
mg/ml and 1 mg/ml water extract of GT2 suppressed the PGR expression (Figures 
3.19 and 3.34). Thus, it is no surprise that in the combination treatment o f p , p -DDE 
and water extract of GT2, PGR transcription was suppressed (Figure 3.34). Besides, 
10 [iM p，p’-DDE down-regulated TMEPAI but had less effect on UDPGDH in the 
steroid-deprived media (Figures 3.31 and 3.34). In contrast, 0.5 mg/ml water extract 
of GT2 up-regulated TMEPAI and down-regulated UDPGDH (Figures 3.20 and 
3.34). The combination treatment showed up-regulated TMEPAI and downregulated 
UDPGDH (Figure 3.34). Thus, water extract of GT2 exerted greater influence on the 
AR-related genes than p’p '-DDE even though it is a strong anti-androgen (Kelce et 
al., 1995 & 1997). All of these indicates the potential of water extract of GT2 to 
reverse the endocrine disruption effects of p,p -DDE. Besides, 0.5 mg/ml (the 
mitogenic dose) water extract of GT2 seemed to alleviate the DNA damage caused 
by p’p '-DDE (Table 3.8). Yet at the anti-proliferative dose (1 mg/ml) of water extract 
of GT2 (Figure 3.13), DNA damage (Table 3.8) caused by DNA fragmentation in the 
apoptosis process was observed (Luk, 2005). Thus, 0.5 mg/ml water extract of GT2 
was more effective in anti-DDE action on DNA damage. In a word, 0.5 mg/ml water 
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extract of GT2 can reduce multiple effects of p,p'-DDE as showed in Figure 4.3. 
j r 从 Apoptosis \ ^ 
” ——~\ 
ERp — PGR / ？产 ^ DNA damage 
\ ^ ^ J ^ Proliferation ^ 
\ GT2 
Figure 4.3 Schema of the effects of p,p，-DDE and water extract of GT2 on MCF-7. 
‘‘+，，means the previous node increases the effect of next node; ‘‘-，，means the 
previous node decrease the effect of next node; ‘‘?,，means the effect is not prove yet. 
p’p '-DDE had high affinity to ERp and induced the expression of PGR which may be 
related to the decrease of apoptosis and increase of proliferation of MCF-7. 
Inhibition of AR pathway by p，p '-DDE plays a role on rescuing the breast cancer cell 
when androgen try to inhibit its proliferation. p’p '-DDE also induced DNA damage. 
Water extract of GT2 also had high affinity to ERp but decrease the expression of 
PGR. Even though 0.5 mg/ml water extract of GT2 itself induced the proliferation, it 
suppressed it at the presence of p，p，-DDE. Activation of AR and down-regulation of 
PGR expression may contribute to the suppression of proliferation. Water extract of 
GT2 had been proved to induce apoptosis. It also showed the ability to reduce the 
DNA damage induced by p,p '-DDE. All of these indicated the potential of water 
extract of GT2 to alleviate the adverse effects of p’p '-DDE. 
155 
Chapter 4 Discussion 
However, the complexity of water extract of GT2 components made the final 
outcomes complicated. The experiment was no longer a straight line from input to 
output. We needed to investigate more than only one or two genes or pathways. 
Microarray allows high throughput of gene expression profiles. In this study, 
multiple signal transduction pathways were found to be regulated by p’p '-DDE and 
water extract. Interestingly, significant negative association (R^=0.97) was found 
between p,p '-DDE and water extract treatments on the genes regulated by TGFp 
pathway (Figure 3.45). The functions of TGFp pathway include cell proliferation, 
differentiation, motility, adhesion, organization, and programmed cell death (Chang 
et al., 2007). It was reported to play a critical role in breast cancer development and 
metastasis (Zheng, 2009; Padua and Massague, 2009). Besides, abrogation of TGFp 
signaling induces apoptosis in breast cancer cells (Bierie et al., 2009), which explain 
the opposite effect of p,p -DDE and water extract on apoptosis. Another group of 
genes that is regulated by stress / p38 & JNK pathway was influenced by p,p'-DDE 
and water extract. p38 & JNK pathway which predominantly regulates inflammatory 
and stress response has recently been found to function as a tumor suppressor 
through regulating proliferation, transformation, invasion and cell death (Loesch and 
Chen, 2008). Regulation of this pathway could be a strategy to suppress 
tumorigenesis. Hypoxia pathway was also relative to the adverse effect of p’p '-DDE, 
since eight of night genes regulated by hypoxia pathway was up-regulated by 
p’p '-DDE, while five of them were down-regulated by water extract. This probably 
was relative to the anit-oxidative ability of water extract. For DNA damage / p53 
pathway, six of eight genes were up-regulated by p，p '-DDE. This is consistent to the 
results from comet assay and the effect of p’p，-DDE on apoptosis that is discussed 
above. But the situation for water extract was complicated probably because it 
promoted apoptosis and reduce DNA damage at the same time. Also, p,p '-DDE 
seemed to up-regulate Wnt pathway regulated genes, but the effect of water extract 
was ambiguous. In general, 27 of 56 high expressed genes had been regulated 
oppositely by p，p -DDE and water extract of GT2 (Figure 4.4). These genes could be 
regulated by multiple signaling pathways (Table 4.5). 
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The multiple functions of water extract of GT2 which is a mixture of different 
compounds showed the potential to prevent the adverse effects induced by p’p '-DDE, 
an organopollutant. Furthermore some additional benefits are suggested for 
Ganoderma spp. in breast cancer prevention for women with age, such as to 
supplement weak estrogen in menopause women, prevent osteoporosis, enhance 
immune system, anti-oxidation, and even reduce risk of heart disease. Thus, water 
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Figure 4.4 Cluster of genes that had opposite regulation in p,p -DDE and water 
extract of GT2 treatments. 
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Table 4.5 List of genes that had opposite regulation in p，p，-DDE and water extract of 
GT2 treatments. 
Androgen Pathway: 
Transmembrane, prostate androgen induced RNA 
Cox-2 Pathway: 
Myeloid cell leukemia sequence 1 (BCL2-related) 
DNA Damage / p53 Pathways: 
Insulin-like growth factor binding protein 3 
Tumor protein p53 (Li-Fraumeni syndrome) 





Engrailed homeobox 1 
Patched homolog 2 (Drosophila) 
Wingless-type MMTV integration site family, member 1 
Hypoxia Pathway: 
CREB binding protein (Rubinstein-Taybi syndrome) 
Hexokinase 1 
Insulin-like growth factor binding protein 3 
Inflammation / NFKB Pathways: 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (pi 05) 
MAPK Pathway: 
Early growth response 1 
Jun oncogene 





Interleukin 4 receptor 
Interferon regulatory factor 1 
Stress / p38 & JNK Pathways: 
Tumor protein p53 (Li-Fraumeni syndrome) 
Survival / NFKB Pathway: 
BCL2-like 1 
Baculoviral lAP repeat-containing 2 
TGFp Pathway: 
Cyclin-dependent kinase inhibitor IB (p27, Kipl) 
Cyclin-dependent kinase inhibitor 2C (pi8, inhibits CDK4) 
Transforming growth factor, beta-induced, 68kDa 
TIMP metallopeptidase inhibitor 1 
Wnt Pathway: 
Forkhead box N1 
Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
Jun oncogene 
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4.4 Further investigation 
The present study is the first investigation on the possibility that food therapy 
reverses the adverse effects induced by a persistent endocrine dismptor, p’p，-DDE. In 
the breast cancer cell model, MCF-7, multiple end points supported the excellent 
performance of Ganoderma tsugae water extract. Several pathways are involved in 
these processes. However whether this protection by G. tsugae extract was triggered 
by a common upstream signaling or a collaboration of several pathways was still 
unknown. Further study is needed to reveal the early events under the treatment of 
either p,p '-DDE or water extract of GT2. A series of studies on different time points 
may unfold how the signaling plays out. And a systematical signal transduction and 
transcriptional regulation network can be drawn to help find out the candidate targets 
for preventing endocrine disruption induced by persistent pollutants. Beside 
endocrine network, p’p '-DDE and water extract of GT2 might act in other systems. 
Further detailed dissection is needed. It was found in this study that ERp may be one 
of the targets, since that both p’p -DDE and water extract of GT2 got high affinities 
to this receptor, and it probably had a link to the regulation of the downstream genes 
which are relative to proliferation and apoptosis. However, the complexity of the 
steroid receptor system in this cell model made it difficult to identity the function of 
ERp. Thus another model with high and stable expression of ERp but without other 
steroid receptor will be useful and preferable to figure out how ER|3 work in the 
interaction between p，p '-DDE and water extract of GT2. 
On the other hand, in vivo experiments are also very important to verify the benefits 
of water extract of GT2 in animals. Ovariectomized female mice can be used as an 
animal model to simulate the physiological environment of menopause women. The 
health, hormone status and breast cancer risk should be investigated under the 
treatment of p’p，-DDE or water extract. The availability of bioactive components of 
GT2 can be measured within blood and tissue samples. Combination effects can also 
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be studied with the comparison of the physiological parameters in the single and 
combination treatment of both tested samples. Hormone target genes and cancer 
related signals are useful end points to estimate the action mechanisms. Furthermore, 
clinical studies can also be carried out in people with high serum concentrations of 
；7，/?，-DDE. 
4,5 Conclusion 
This study demonstrated the potential of G. tsugae that ‘ protects human against 
persistent organopollutant, p,p '-DDE. Multiple adverse effects of p,p -DDE were 
proved in several experiments, including those on cell proliferation, DNA damage 
and cell death of MCF-7. Water extract of G. tsugae GT2 mycelia had excellent 
performance in eliminating these effects. Change of several upstream events were 
also supported these observations. Both water extract of GT2 and p’p '-DDE had high 
affinity to ERP in vitro, but had opposite effect on the expression of PGR. This 
leaded to their final effects on cell proliferation and apoptosis. The expression of pS2 
could be up-regulated by both water extract and p,p '-DDE. However it was 
suppressed under combination treatment. This was consistent to the effect of water 
extract on MCF-7 proliferation that was induced at the absence of p’p，-DDE but was 
decreased at the presence of p,p -DDE. Increase of three parameters in comet assay 
and dual regulation on Bax and p53 verified that p,p -DDE induced DNA damage 
but prevented it from going to cell death. In contrast, water extract decreased DNA 
damage and was proved, in previous studies, to induce apoptosis. DNA microarray 
was applied to study the human signal transduction pathways in cancer, the 
expression profile in MCF-7 that treated with p,p -DDE was different from that 
treated with E2 or DHT. Several pathways, beyond ER and AR pathways, were 
affected by p,p -DDE, indicating its multiple functions. These pathways further 
proved the adverse effects of p’p '-DDE. However, water extract of GT2 had opposite 
regulative effects to that of p,p，-DDE on almost half of tested highly expressed genes 
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regulated by multiple signal transduction pathways. These genes were regulated by 
different signal transduction pathways including those related to hormone actions, 
tumorigenesis and DNA damage. 
In another word, the adverse effects of p’p '-DDE on cell proliferation, DNA damage 
and cell death were partially eliminated by water extract of G. tsugae mycelia, 
demonstrating the potential of G. tsugae as a value functional food that protects 
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